EULAR 2018 Congress Amsterdam - Preliminary Scientific Programme - PLEASE OBSERVE THE EMBARGO

Please note that this is a Preliminary Version of the Scientific Programme for the EULAR Congress 2018 in Amsterdam. The programme is subject to change at any time.
THE EULAR ABSTRACT EMBARGO IS IN PLACE UNTIL 13 JUNE 2018 00:01 CET. See the EULAR Congress Website
Details on Oral Abstract Presentations and Poster Tours will be published approximately one month prior to the congress. Until then, you will see the lecture slot, but without presenter name and without abstract title.
To select single time slots, please use the drop down selection option (Standard: Overview all days and sessions).
To print, please use the 'File - Print' option of your browser. Best results are achieved using landscape and scaling down to 75 percent in the printer preferences.

 


Wednesday 13.06.2018 14:15 - 15:45


 
WIN & HOT Session - Hall 7.1
  
WIN & HOT Session 2
   SpeakerTincani Angela (Italy)SP0001WIN Session: Systemic lupus: Issues about pregnancy
   SpeakerDörner Thomas (Germany) WIN Session: Recent advances in the treatment of lupus

 
Challenges in Clinical Practice Session - Hall 3
  
Little arthritis in PsA and axSpA with newly onset arthritis - does it matter?
   ChairMarzo-Ortega Helena (United Kingdom)  
   ChairCoates Laura (United Kingdom)  
   PresenterNikiphorou Elena (United Kingdom)SP0002Case 1 presentation: PsA beyond the typical poly-articular phenotype: how to deal with this in clinical practice?
   DiscussantVeale Douglas (Ireland) Case 1 discussion: How to use RCT data to guide treatment decisions in real life?
   PresenterSepriano Alexandre (Portugal)SP0003Case 2 presentation: axSpA patient with peripheral manifestations
   DiscussantDougados Maxime (France)SP0004Case 2 discussion: Extra-spinal manifestations in axSpA, are they forgotten?

 
Clinical Science Session - Auditorium / Balcony
  
Cancer and inflammation
   ChairBaecklund Eva (Sweden)  
   ChairVisser Karen (Netherlands)  
   SpeakerSuarez-Almazor Maria (United States) RMD as comorbidity in cancer patients
   SpeakerMariette Xavier (France) The role of TNF in cancer
   SpeakerRoxburgh Campbell (United Kingdom)SP0005Inflammation in cancer: friend or foe
   AbstractHorne AnnaCarin (Sweden)OP0001RISK OF MALIGNANCY IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS: A REGISTER-BASED COHORT STUDY
   AbstractKim Seoyoung (United States)OP0002NO DIFFERENCE IN THE RISK OF MALIGNANCY IN TOCILIZUMAB VERSUS TNF INHIBITOR INITIATORS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A MULTI-DATABASE COHORT STUDY

 
From Bench to Bedside - Elicium 2
  
Psychological distress and pain; not all in the mind
   ChairCavanagh Jonathan (United Kingdom)  
   ChairSo Alexander (Switzerland)  
   SpeakerWoodhams Stephen (United Kingdom) What do preclinical models tell us about why psychological distress is so bad for arthritis pain?
   SpeakerSundermann Benedikt (Germany)SP0006Distress and pain; integrated brain pathways
   SpeakerSmeets Rob (Netherlands)SP0007Dealing with psychological distress to optimise outcomes for arthritis pain
   AbstractRathbun Alan (United States)OP0003ASSOCIATION BETWEEN DISEASE SEVERITY AND ONSET OF DEPRESSION IN KNEE OSTEOARTHRITIS
   AbstractNascimento Bruno (Brazil)OP0004COGNITIVE IMPAIRMENT IN RHEUMATOID ARTHRITIS PATIENTS: A CASE-CONTROL STUDY.

 
Challenges in Clinical Practice Session - Hall 7.2
  
Inflammation in the shadow of fibromyalgia
   ChairWalsh David (United Kingdom)  
   Chairvan der Helm - van Mil Annette (Netherlands)  
   PresenterTrouvin Anne-Priscille (France)SP0008Case 1 presenter: It's in the brain but it's not psychologic: when nociceptive turns to nociplastic
   DiscussantPerrot Serge (France) Case 1 discussant: Clinical case with RA in whom apparent high disease activity is confounded by FM; how does changing diagnosis change management and outcome?
   PresenterHassan Neelam (United Kingdom)SP0009Case 2 presenter: FIBROMYALGIA ONSET OF SYSTEMIC LUPUS ERYTHEMATOSUS?
   DiscussantChoy Ernest (United Kingdom) Case 2 discussant: Clincal case with FM later diagnosied with CTD; how does changing diagnosis change management and outcome?

 
From Bench to Bedside - Forum
  
Shaping the future In systemic sclerosis
   ChairOspelt Caroline (Switzerland)  
   ChairPauling John (United Kingdom)  
   SpeakerDenton Christopher (United Kingdom)SP0010Fibroblast-Matrix-Vessel: The unhappy triad
   SpeakerDistler Jörg (Germany)SP0011Is there an universal translator? Which (animal) models tell us most?
   SpeakerFurst Daniel (United States)SP0012Novel SSc drugs that really will make it to clinics!
   AbstractBittern Hannah (Germany)OP0005PATTERNS OF 31 NEW AUTOANTIBODIES AGAINST G PROTEIN-COUPLED RECEPTORS AND GROWTH FACTORS IN SYSTEMIC SCLEROSIS CAN BE DESCRIBED BY LATENT FACTORS
   AbstractSpiera Robert (United States)OP0006SAFETY AND EFFICACY OF LENABASUM (JBT-101) IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS SUBJECTS TREATED FOR ONE YEAR IN AN OPEN-LABEL EXTENSION OF TRIAL JBT101-SSC-001

 
Basic and Translational Science Session - Elicium 1
  
Basic mechanisms of inflammation
   ChairGattorno Marco (Italy)  
   ChairAvcin Tadej (Slovenia)  
   SpeakerLamkanfi Mohamed (Belgium) Inflammasome biology matters
   AbstractZhao Yunpeng (China)OP0007GROWTH DIFFERENTIATION FACTOR 11 ATTENUATES INFLAMATORY ARTHRITIS THROUGH ANTAGONIZING NF-ΚB SIGNALING PATHWAY
   SpeakerKastner Daniel (United States) New insights into monogenic autoinflammatory diseases
   AbstractSaito Megumu (Japan)OP0008MODELING AN AUTOINFLAMMATORY IMMUNOPROTEASOME DISEASE NAKAJO-NISHIMURA SYNDROME WITH HUMAN PLURIPOTENT STEM CELL-DERIVED MYELOID CELL LINES
   SpeakerRoth Johannes (Germany)SP0013S100-alarmins: potential therapeutic targets for arthritis

 
Health Professionals Session - Amtrium
  
Health Professionals Welcome Session
   ChairStamm Tanja (Austria)  
   ChairPeter Wilfred F. (Netherlands)  
   SpeakerMoe Rikke Helene (Norway)SP0014Welcome to Amsterdam by the new chair of ESCHPR
   SpeakerNdosi Mwidimi (United Kingdom) What is a EULAR study group. Example from the study group on Patient Education (STOPE)
   SpeakerBetteridge Kate (United Kingdom)SP0015What’s new? Presentation of the HPR Newsletter
   Speakerde Thurah Annette (Denmark) Places to go and things to see during Congress
   Speakernot confimed yet Q&A

 
The Young Rheumatologist - Emerald
  
Statistics made simple: a practical approach to complex concepts
   ChairCarpenter Lewis (United Kingdom)  
   ChairRamiro Sofia (Netherlands)  
   SpeakerMachado Pedro (United Kingdom) How to report statistics in rheumatology journals: reaching out to the clinical reader.
   SpeakerCarpenter Lewis (United Kingdom) Confounders, effect modifiers and mediators: Is it all the same?
   SpeakerLydersen Stian (Norway)SP0016Stepwise or not to stepwise? The do’s and dont's of multivariable modelling
   AbstractMyasoedova Elena (United States)OP0009RISING PREVALENCE OF FUNCTIONAL DISABILITY IN PATIENTS WITH RHEUMATOID ARTHRITIS OVER 20 YEARS
   AbstractSolomon D (United States)OP0010USE OF CLAIMS AND ELECTRONIC MEDICAL RECORD DATA TO PREDICT RA DISEASE ACTIVITY

 
PARE Session - PARE Room
  
E-health for better care
   ChairMazuras Kristijonas (Lithuania)  
   ChairBendzuck Gerlinde (Germany)  
   SpeakerRichter Jutta (Germany)SP0017Bits and bytes: fitting medical information - PICASO the platform for improved personal, coordinated care
   SpeakerRomero Pazos Victoria (Spain) Ésaude - A digital platform that unites tools to provide personalised health
   SpeakerSilva Mitchell (Belgium)SP0018Smart wearables – The right tool for health monitoring and improving quality of health?
   AbstractStones Simon (United Kingdom)OP0011-PAREA WEEK TO TWEET: FINDINGS FROM YOUNG PARE'S ONLINE COURSE FOR TWITTER NOVICES
   AbstractTrope Sonia (France)OP0012-HPRCREATION OF THE FIRST DIGITAL TRAINING DESIGNED FOR PATIENTS WITH RHEUMATOID ARTHRITIS BY PATIENT ORGANISATION IN RHEUMATOLOGY

 
EULAR Projects in Paediatric Rheumatology - E106 / E107
  
EULAR Projects in Paediatric Rheumatology and UCAN
   ChairWulffraat Nico (Netherlands)  
   ChairArmbrust Wineke (Netherlands)  
   SpeakerYeung Rae (Canada) UCAN as a tool for personlised medicine in pediatric Rheumatology
   SpeakerRuperto Nicola (Italy) UCAN and PRINTO aligned to link bed and bedside: perspective from the bed
   SpeakerVastert Sebastian (Netherlands)SP0019UCAN and PRINTO aligned to link bed and bedside: perspective from the benchside
   SpeakerSeyfert-Margolis Vicki (United States)SP0020How digital tools can help to cross borders in international collaborations
   AbstractDrechsel Paula (Germany)OP0013PREGNANCY OUTCOMES IN DMARD EXPOSED PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS – RESULTS OF THE BIOLOGIC REGISTER JUMBO

 
Practical Skills Session - D201 / D202
  
Crystal I
   ChairTausche Anne Kathrin (Germany)  
   ChairPascual Eliseo (Spain)  
   TutorSivera Francisca (Spain)  
   TutorPimentao José (Portugal)  
   TutorOliviero Francesca (Italy)  
   TutorNorkuviene Eleonora (Lithuania)  

 
Practical Skills Session - D203 / D204
  
Ultrasound Basic I
   ChairBruyn George A. W. (Netherlands)  
   ChairSchmidt Wolfgang A. (Germany)  
   SpeakerNaredo Esperanza (Spain)SP0021How to assess dactylitis + demo
   SpeakerSzkudlarek Marcin (Denmark)SP0022How to assess bone erosions – indications, pitfalls and new techniques + demo
   SpeakerFredberg Ulrich (Denmark)SP0023How to assess mechanical and inflammatory tendinitis + demo
   Speakerd'Agostino Maria-Antonietta (France) How to assess and score enthesitis in clinical practice + demo
   TutorNysom Sara (Denmark)  

Wednesday 13.06.2018 16:15 - 17:45


 
Abstract Session - Hall 7.1
  
Opening Plenary Abstract Session
   ChairDörner Thomas (Germany)  
   ChairLandewé Robert B.M. (Netherlands)  
   AbstractSolomon Daniel (United States)OP0014SERUM URATE, GOUT, AND CARDIOVASCULAR DISEASE IN A RANDOMIZED CONTROLLED TRIAL OF CANAKINUMAB: A CANTOS SECONDARY ANALYSIS
   AbstractPoppelaars Pomme (Netherlands)OP0015MORTALITY OF THE COBRA EARLY RHEUMATOID ARTHRITIS TRIAL COHORT AFTER 23 YEARS FOLLOW UP
   AbstractCai Guoqi (Australia)OP0016A MULTICENTRE RANDOMISED CONTROLLED TRIAL OF ZOLEDRONIC ACID FOR OSTEOARTHRITIS OF THE KNEE WITH BONE MARROW LESIONS
   AbstractCurtis Jeffrey (United States)OP0017THE IMPACT OF THE DURATION OF BISPHOSPHONATE DRUG HOLIDAYS ON HIP FRACTURE RATES
   AbstractMøller-Bisgaard Signe (Denmark)OP0018THE VALUE OF ADDING MRI TO A CLINICAL TREAT-TO-TARGET STRATEGY IN RHEUMATOID ARTHRITIS PATIENTS IN CLINICAL REMISSION: CLINICAL AND RADIOGRAPHIC OUTCOMES FROM THE IMAGINE-RA RANDOMISED CONTROLLED TRIAL
   AbstractWallace Daniel (United States)OP0019BARICITINIB IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
   AbstractAringer Martin (Germany)OP0020VALIDATION OF NEW SYSTEMIC LUPUS ERYTHEMATOSUS CLASSIFICATION CRITERIA
   AbstractRobson Joanna (United Kingdom)OP0021DRAFT CLASSIFICATION CRITERIA FOR THE ANCA ASSOCIATED VASCULITIDES

 
Abstract Session - Hall 3
  
Abstract Session: From NSAIDs to bDMARDs in SpA: what is new?
   ChairMoltó Anna (France)  
   ChairCiurea Adrian (Switzerland)  
   AbstractCouvaras Loukianos (France)OP0022IS A PRIMARY GOOD RESPONSE TO NSAIDS PREDICTIVE OF THE SUBSEQUENT RESPONSE TO THE FIRST TNF INHIBITOR IN PATIENTS WITH RECENT AXIAL SPONDYLOARTHRITIS?
   AbstractLindström Ulf (Sweden)OP0023EFFECT OF ANTERIOR UVEITIS, PSORIASIS AND INFLAMMATORY BOWEL DISEASE ON DRUG-SURVIVAL FOR TNF-INHIBITORS IN ANKYLOSING SPONDYLITIS.
   AbstractLindström Ulf (Sweden)OP0024WHAT HAPPENS TO PATIENTS WITH ANKYLOSING SPONDYLITIS WHO START A FIRST BIOLOGIC? A SWEDISH STUDY OF TREATMENT TRAJECTORIES IN CLINICAL PRACTICE.
   AbstractRios Rodriguez Valeria (Germany)OP0025IDENTIFICATION OF PREDICTORS OF STRUCTURAL DAMAGE PROGRESSION IN THE SACROILIAC JOINTS IN PATIENTS WITH EARLY AXIAL SPONDYLOARTHRITIS ON A LONG-TERM ANTI-TNF TREATMENT
   AbstractKwatra Nisha (United States)OP0026ADALIMUMAB SERUM CONCENTRATION FAILS TO PREDICT ACHIEVEMENT OF SUSTAINED REMISSION OR ABSENCE OF FLARE FOR PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS IN THE ABILITY-3 STUDY
   AbstractKoo Bon San (Korea, Republic Of)OP0027CHARACTERISTICS OF CYTOKINES AND CHANGES IN INTERLEUKIN-17 LEVELS IN THE SYNOVIAL FLUID OF PATIENTS WITH ANKYLOSING SPONDYLITIS ON TREATMENT WITH BIOLOGICS
   AbstractDubinina Tatyana (Russian Federation)OP0028EFFICACY AND SAFETY OF BCD-085, A NOVEL IL-17 INHIBITOR, IN ANKYLOSING SPONDYLITIS. RESULTS OF PHASE 2 CLINICAL STUDY.
   AbstractPaccou Julien (France)OP0029CLINICAL EFFECT OF VEDOLIZUMAB ON ARTICULAR MANIFESTATIONS IN PATIENTS WITH SPONDYLOARTHRITIS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE
   Abstractvan der Heijde Désirée (Netherlands)LB0001DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS): 12-WEEK RESULTS FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY

 
Abstract Session - Auditorium / Balcony
  
Abstract Session: RA therapy - new molecules and new strategies
   ChairHugle Thomas (Switzerland)  
   ChairSeror Raphaele (France)  
   AbstractBrilman Elisabeth (Netherlands)OP0030CORTICOSTEROID BRIDGING STRATEGIES WITH METHOTREXATE MONOTHERAPY IN EARLY RHEUMATOID AND UNDIFFERENTIATED ARTHRITIS; A COMPARISON OF EFFICACY AND TOXICITY IN THE TREACH AND IMPROVED STUDIES
   AbstractCostello Ruth (United Kingdom)OP0031THE IMPORTANCE OF ASSESSING MULTIPLICATIVE AND ADDITIVE INTERACTION: EXAMINING THE EFFECT OF GLUCOCORTICOID THERAPY ON MORTALITY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND CONCOMITANT TYPE II DIABETES.
   AbstractLopez-Olivo Maria A. (United States)OP0032MALIGNANCIES AND SERIOUS INFECTIONS IN RANDOMIZED CONTROLLED TRIALS OF JANUS KINASE INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
   AbstractMueller Ruediger (Switzerland)OP0033EFFECT OF A STEP-UP OR STEP-DOWN IN TOFACITINIB DOSE ON EFFICACY AND SAFETY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN LONG-TERM EXTENSION STUDIES
   AbstractStouten Veerle (Belgium)OP0034LONG-TERM EFFECTIVENESS OF THE COBRA SLIM REMISSION INDUCTION AND TREAT TO TARGET STRATEGY IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS LACKING CLASSICAL MARKERS OF POOR PROGNOSIS: 2 YEAR RESULTS OF THE CARERA TRIAL
   AbstractSmolen JS (Austria)OP0035UPADACITINIB AS MONOTHERAPY: A PHASE 3 RANDOMIZED CONTROLLED DOUBLE-BLIND STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE
   AbstractBurmester G.R. (Germany)OP0036A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF UPADACITINIB (ABT-494), A SELECTIVE JAK-1 INHIBITOR, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DMARDS
   AbstractKaine Jeffrey (United States)OP0037EFFICACY OF TOFACITINIB AFTER TEMPORARY DISCONTINUATION IN PATIENTS WITH RHEUMATOID ARTHRITIS: ANALYSIS OF DATA FROM OPEN-LABEL LONG-TERM EXTENSION STUDIES

 
Abstract Session - Elicium 2
  
Abstract Session: Doctor, how bad will my rheumatoid become? : RA - Prognosis, Predictors and Outcomes
   ChairAllaart Cornelia (Netherlands)  
   ChairPratt Arthur (United Kingdom)  
   AbstractBrahe Cecilie Heegaard (Denmark)OP0038DOSE TAPERING AND DISCONTINUATION OF BIOLOGICAL THERAPY IN RHEUMATOID ARTHRITIS PATIENTS IN REMISSION IN ROUTINE CARE – 2-YEAR OUTCOMES AND IDENTIFICATION OF PREDICTORS
   AbstractGwinnutt James (United Kingdom)OP0039HIGH DISEASE ACTIVITY AND DISABILITY AT ONE YEAR IN TWO CLUSTERS OF PATIENTS WITH RHEUMATOID ARTHRITIS DEFINING THEMSELVES AS IN AN ACCEPTABLE STATE AT TREATMENT INITIATION
   AbstractLliso-Ribera Gloria (United Kingdom)OP0040SYNOVIAL CELL INFILTRATION IN ACPA-VE PATIENTS DISPLAYS SIMILAR SIGNATURES TO OTHER SERONEGATIVE INFLAMMATORY ARTHRITIS. RESULTS FROM THE PATHOBIOLOGY OF EARLY ARTHRITIS COHORT (PEAC).
   AbstractBurgers Leonie (Netherlands)OP0041DOES TREATMENT STRATEGY INFLUENCE THE ABILITY TO ACHIEVE AND SUSTAIN DMARD-FREE REMISSION IN RA?; RESULTS OF A LONGITUDINAL STUDY COMPARING AN INTENSIVE DAS-STEERED TREATMENT STRATEGY WITH TREAT-TO-TARGET IN ROUTINE CARE
   AbstractHunt Laura (United Kingdom)OP0042IN ACPA POSITIVE AT-RISK INDIVIDUALS, WHICH MRI AND US FINDINGS BEST PREDICT DEVELOPMENT OF CLINICAL SYNOVITIS?
   AbstractBaker Kenneth (United Kingdom)OP0043PREDICTORS OF DRUG-FREE REMISSION IN RHEUMATOID ARTHRITIS: RESULTS FROM THE PROSPECTIVE BIOMARKERS OF REMISSION IN RHEUMATOID ARTHRITIS (BIORRA) STUDY.
   AbstractWiddifield Jessica (Canada)OP0044AFTER HOW LONG OF DISEASE DURATION DOES THE INCREASED MORTALITY RISK APPEAR IN RECENT ONSET RHEUMATOID ARTHRITIS?
   AbstractKeebler Daniel (United States)OP0045ADVERSE EVENT REPORTING RATES AND PLACEBO/STANDARD-OF-CARE-ARM ACR RESPONSES VARY BY REGION IN RHEUMATOID ARTHRITIS TRIALS

 
Abstract Session - Hall 7.2
  
Abstract Session: Immunobiology of vasculitis
   ChairMolloy Eamonn S. (Ireland)  
   ChairCid Maria C (Spain)  
   AbstractBunch Donna (United States)OP0046EFFECT OF A SELECTIVE C5AR ANTAGONIST, AVACOPAN (CCX168), ON PLASMA COMPLEMENT LEVELS IN ANCA ASSOCIATED VASCULITIS (AAV)
   Abstractvon Borstel Anouk (Netherlands)OP0047CIRCULATING CD24HICD38HI REGULATORY B CELLS INFLUENCE TH17 CELL RESPONSES IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIDES
   AbstractWada Yoko (Japan)OP0048THE UTILITY OF SERUM ANGIOPOIETIN-1 AND ANGIOPOIETIN-2 IN PATIENTS WITH ANTI-NEUTROPHIL CYTOPLASMIC AUTOANTIBODY-ASSOCIATED VASCULITIS.
   AbstractHid Cadena Rebeca (Netherlands)OP0049ABERRANT VISTA EXPRESSION ON CD45RA+CD25DIM TH-CELLS IN GIANT CELL ARTERITIS.
   AbstractHessels Arno (Netherlands)OP0050GENE POLYMORPHISMS OF THE GLUCOCORTICOID RECEPTOR AND 11Β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 AFFECT RELEVANT CLINICAL OUTCOMES IN ANCA ASSOCIATED VASCULITIS
   AbstractPrieto-Peña Diana (Spain)OP0051EVOLUTION OF THE VASCULAR INVOLVEMENT OBJECTIFIED BY PET/TAC IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB
   AbstractAntovic Aleksandra (Sweden)OP0052MICROPARTICLES AS POTENTIAL BIOMARKERS OF DISEASE ACTIVITY IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY – ASSOCIATED VASCULITIS
   AbstractMekinian Arsène (France)OP0053INFLAMMATORY DISORDERS ASSOCIATED WITH TRISOMY 8 MYELODYSPLASTIC SYNDROMES : FRENCH RETROSPECTIVE CASE CONTROL STUDY

 
Abstract Session - Forum
  
Abstract Session: Envisioning new horizons for people with osteoarthritis
   ChairRamonda Roberta (Italy)  
   ChairSellam Jeremie (France)  
   AbstractMulrooney Elisabeth (Norway)OP0054PAIN IN HAND OSTEOARTHRITIS AND THE ASSOCIATIONS WITH RADIOGRAPHIC OSTEOARTHRITIS SEVERITY AND PSYCHOLOGICAL FACTORS.
   AbstractZhu Zhaohua (China)OP0055A NOVEL METHOD FOR ASSESSING PROXIMAL TIBIOFIBULAR JOINT ON MR IMAGES IN PATIENTS WITH KNEE OSTEOARTHRITIS
   AbstractRoemer Frank (Germany)OP0056MOLECULAR AND STRUCTURAL BIOMARKERS OF INFLAMMATION AT 2 YEARS AFTER ACUTE ACL INJURY DO NOT PREDICT STRUCTURAL KNEE OSTEOARTHRITIS AT 5 YEARS
   AbstractDiaz Armonie (France)OP0057EFFICACY AND SAFETY OF A DISTRACTION-ROTATION KNEE BRACE (ODRA) IN MEDIAL KNEE OSTEOARTHRITIS - A PHASE III RANDOMIZED CONTROLLED TRIAL (ERGONOMIE STUDY)
   AbstractMinten Michiel (Netherlands)OP0058LOW-DOSE RADIATION THERAPY AS TREATMENT FOR HAND AND KNEE OSTEOARTHRITIS: TWO DOUBLE-BLINDED RCT'S
   AbstractEckstein Felix (Austria)OP0059EFFICACY AND SAFETY OF INTRA-ARTICULAR SPRIFERMIN IN SYMPTOMATIC RADIOGRAPHIC KNEE OSTEOARTHRITIS: PRE-SPECIFIED ANALYSIS OF 3-YEAR DATA FROM A 5-YEAR RANDOMIZED, PLACEBO-CONTROLLED, PHASE II STUDY
   AbstractJansen Mylène (Netherlands)OP0060KNEE JOINT DISTRACTION COMPARED WITH HIGH TIBIAL OSTEOTOMY AND TOTAL KNEE ARTHROPLASTY: TWO-YEAR CLINICAL, STRUCTURAL, AND BIOMARKER OUTCOMES
   AbstractKennedy Sarah (United States)OP0061TREATMENT OF KNEE OSTEOARTHRITIS WITH SM04690 IMPROVED WOMAC A1 “PAIN ON WALKING” – RESULTS FROM A 52 WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF A NOVEL, INTRA-ARTICULAR, WNT PATHWAY INHIBITOR
   AbstractReichenbach Stephan (Switzerland)LB0002BIOMECHANICAL THERAPY FOR OSTEOARTHRITIS OF THE KNEE: A RANDOMIZED CONTROLLED TRIAL (BIOTOK)

 
Abstract Session - Elicium 1
  
Abstract Session: Fracture risk and consequences
   ChairPrieto-Alhambra Daniel (United Kingdom)  
   ChairLems Willem F. (Netherlands)  
   AbstractSehgal Maanek (United States)OP0062OSTEOPOROTIC HIP FRACTURES IN MEN: A RISING CONCERN
   AbstractUngprasert Patompong (Thailand)OP0063PERIPHERAL ARTERIAL DISEASE AND RISK OF OSTEOPOROTIC HIP FRACTURE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF COHORT STUDIES
   AbstractSenolt Ladislav (Czech Republic)OP0064GENERAL BONE LOSS IN PATIENTS WITH EROSIVE AND NON-EROSIVE HAND OSTEOARTHRITIS DURING THREE YEARS.
   AbstractRomera-Lopez Cintia (Spain)OP0065OSTEOPOROSIS AND VERTEBRAL FRACTURES ARE ASSOCIATED WITH DISEASE ACTIVITY AND RADIOGRAPHIC DAMAGE IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS.
   AbstractSzafors Paulina (France)OP0066RISK OF FRACTURE AND LOW MINERAL DENSITY IN ADULTS WITH INFLAMMATORY BOWEL DISEASES. A SYSTEMATIC LITERATURE REVIEW WITH META-ANALYSIS.
   AbstractCasabella Andrea (Italy)OP0067DICKKOPF-1 (DKK1) SERUM LEVELS AND BONE QUALITY (TBS EVALUATION) IN PATIENTS WITH SYSTEMIC SCLEROSIS AND RHEUMATOID ARTHRITIS.
   AbstractMazzucchelli Ramon (Spain)OP0068SHORT TERM EFFECTS OF AMBIENT AIR POLLUTION ON OSTEOPOROTIC HIP FRACTURE. AN ECOLOGICAL STUDY IN A PERIOD OF 16 YEARS
   AbstractAlvarenga Jackeline (Brazil)OP0069THE RELATIONSHIP BETWEEN ESTIMATED BONE STRENGTH BY FINITE ELEMENT ANALYSIS AT THE PERIPHERAL SKELETON TO AREAL BMD AND TBS AT LUMBAR SPINE IN ADULTS

 
Joint Session HPR / PARE - Amtrium
  
New drugs - new perspectives: clinical and regulatory issues concerning biosimilars
   Chairvan Eijk-Hustings Yvonne (Netherlands)  
   ChairWiek Dieter (Germany)  
   SpeakerKvien Tore K. (Norway)SP0024An up-date on biosimilars
   SpeakerFrench Tracy (United Kingdom)SP0025Shared decision making in switching to biosimilars
   SpeakerKönig Franz (Austria) Statistical and regulatory aspects of biosimilars
   SpeakerWiek Dieter (Germany)SP0026Biosimilars - The changing views of EULAR'S member organisations of PARE
   AbstractCvancarova Småstuen Milada (Norway)OP0070-HPRIS PATIENTS’ SATISFACTION WITH BEING SWITCHED TO A BIOSIMILAR MEDICATION ASSOCIATED WITH THEIR LEVEL OF HEALTH LITERACY? RESULTS FROM A NORWEGIAN USER SURVEY.

 
Abstract Session - Emerald
  
Abstract Session: Movement in musculoskeletal pain; from risk to management
   ChairWalsh David (United Kingdom)  
   ChairGossec Laure (France)  
   AbstractBeukenhorst Anna (United Kingdom)OP0071THE PREVALENCE OF PAIN FLARES: IMPACT OF DEFINITION
   AbstractAili Katarina (Sweden)OP0072SLEEP PROBLEMS AND FATIGUE AS A PREDICTOR FOR THE ONSET OF CHRONIC WIDESPREAD PAIN OVER A 5- AND 18-YEAR PERSPECTIVE. A 20-YEAR PROSPECTIVE STUDY.
   AbstractDruce Katie (United Kingdom)OP0073CENTRAL SENSITISATION PREDICTS FATIGUE INDEPENDENTLY OF MUSCULOSKELETAL PAIN.
   AbstractKang Ji-Hyoun (Korea, Republic Of)OP0074ASSOCIATION BETWEEN BRAIN-DERIVED NEUROTROPHIC FACTOR GENE POLYMORPHISMS AND FIBROMYALGIA IN A KOREAN POPULATION: A MULTI-CENTER STUDY
   AbstractTran Gui (United Kingdom)OP0075ULTRASOUND-DETECTED SHOULDER PATHOLOGIES CLUSTER INTO GROUPS WITH DIFFERENT CLINICAL ASSOCIATIONS: DATA FROM A PROSPECTIVE STUDY OF 500 COMMUNITY REFERRALS FOR SHOULDER PAIN
   AbstractGavilán-Carrera Blanca (Spain)OP0076ISOTEMPORAL SUBSTITUTION OF SEDENTARY TIME WITH PHYSICAL ACTIVITY IN FIBROMYALGIA: ASSOCIATION WITH QUALITY OF LIFE AND DISEASE IMPACT. THE AL-ÁNDALUS PROJECT
   AbstractOzyasar Aykut (Turkey)OP0077EFFECTIVENESS OF 8-WEEKS SUPERVISED AND NON-SUPERVISED AEROBIC EXERCISE PROGRAMSON CLINIC FINDINGS,FUNCTIONAL STATUS AND QALITY OF LIFE IN THE PATIENTS WITH FIBROMYALGIA SYNDROME
   AbstractCaliskan Uckun Aslı (Turkey)OP0078IS THE EFFICACY OF PHYSICAL THERAPY RELATED TO THE PAIN IN THE PATIENT'S MIND?

 
PARE Session - PARE Room
  
Don’t Delay, Connect Today!
   ChairCanhão Helena (Portugal)  
   ChairBoteva Boryana (Bulgaria)  
   SpeakerBurmester Gerd Rüdiger (Germany) Why we need the Don’t Delay Connect Today campaign
   SpeakerStamm Tanja (Austria) How HPRs can support the campaign
   SpeakerIonescu Ruxandra (Romania)SP0027Don`t Delay, Connect Today - implementation of the EULAR campaign in Romania
   AbstractBANKOVA HRISTINA (Bulgaria)OP0079-PARE"AWARENESS WEEK FOR RHEUMATIC DISEASES- 8-14 MAY 2017"
   AbstractKoutsogianni Katerina (Greece)OP0080-PAREPHOTO ALBUM OF PEOPLE WITH RHEUMATIC DISEASES UNDER THE TITLE: “THERE ARE SOME PEOPLE… OUR PEOPLE!!!”

 
Abstract Session - E106 / E107
  
Abstract Session: Lets improve Diagnosis and treatment of Orphan Diseases
   ChairBruyn George A. W. (Netherlands)  
   ChairRadunovic Goran (Serbia)  
   AbstractStone John (United States)OP0081PHENOTYPIC SUBGROUPS IN IGG4-RELATED DISEASE – A CLUSTER ANALYSIS
   AbstractHatemi Gulen (Turkey)OP0082APREMILAST FOR BEHÇET’S SYNDROME: A PHASE III RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY (RELIEF)
   AbstractKoga Tomohiro (Japan)OP0084SERUM FIBROBLAST GROWTH FACTOR 2 IS A USEFUL BIOMARKER TO DISTINGUISH ADULT ONSET STILL DISEASE FROM SEPSIS
   AbstractKuemmerle-Deschner Jasmin (Germany)OP0085SAFETY OF LONG-TERM (UP TO 6 YEARS) CANAKINUMAB THERAPY (<2, 2−<4 AND 4−<8MG/KG) IN PATIENTS AGED <4 TO 65 YEARS FROM BETA-CONFIDENT REGISTRY
   AbstractGuex-Crosier Yan (Switzerland)OP0086LONG-TERM EFFICACY AND SAFETY OF ADALIMUMAB BY IMMUNOSUPPRESSANT USE IN PATIENTS WITH NON-INFECTIOUS UVEITIS IN THE VISUAL III TRIAL
   AbstractTiosano Shmuel (Israel)OP0087INCREASED RISK OF ISCHEMIC HEART DISEASE AND MORTALITY AMONG FMF PATIENTS – PERSPECTIVE FROM A BIG DATABASE
   AbstractKostine Marie (France)OP0088IMMUNE-RELATED ADVERSE EVENTS OF CANCER IMMUNOTHERAPY - WHEN INFLAMMATORY SIDE EFFECTS ARE ASSOCIATED WITH SURVIVAL: A SINGLE-CENTRE PROSPECTIVE COHORT STUDY.
   AbstractMehta Bella (United States)OP0083TEMPORAL TRENDS AND MORTALITY OF HOSPITALIZED PATIENTS WITH ADULT ONSET STILLS DISEASE: A NATIONWIDE ESTIMATE.

 
Abstract Session - D201 / D202
  
Abstract Session: New driving molecules in systemic sclerosis
   ChairValentini Gabriele (Italy)  
   ChairBecker Mike O. (Switzerland)  
   AbstractBoleto Gonçalo (France)OP0089ABATACEPT IS EFFECTIVE IN EXPERIMENTAL DIGESTIVE AND LUNG TISSUE FIBROSIS
   AbstractWalker Ulrich (Switzerland)OP0090MITOCHONDRIAL DNA MUTATIONS AND RESPIRATORY CHAIN DYSFUNCTION IN LUNG FIBROSIS OF SYSTEMIC SCLEROSIS.
   AbstractAntinozzi Cristina (Italy)OP0091CXCL10/CXCL11 SERUM MEASUREMENT AS POTENTIAL PREDICTOR OF SYSTEMIC SCLEROSIS.
   AbstractAntonopoulos Ioannis (Greece)OP0092DECREASED DICKKOPF-1 EXPRESSION IN CLINICALLY UNINVOLVED SKIN FROM PATIENTS WITH SYSTEMIC SCLEROSIS
   AbstractMarut Wioleta (Netherlands)OP0093LOW RUNX3 EXPRESSION ALTERS DENDRITIC CELL FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS AND CONTRIBUTES TO ENHANCED FIBROSIS
   AbstractRomano Eloisa (Italy)OP0094SLIT2/ROBO4 AXIS MAY CONTRIBUTE TO ANGIOGENESIS DISTURBANCE IN SYSTEMIC SCLEROSIS (SSC)
   AbstractFrantz Camelia (France)OP0095SOLUBLE CD163 AS A POTENTIAL BIOMARKER IN SYSTEMIC SCLEROSIS

 
Abstract Session - D203 / D204
  
Abstract Session: A rollercoaster from bench to bedside and back again: Pediatric Rheumatology in the 21st century
   ChairLamot Lovro (Croatia)  
   ChairSmith Eve (United Kingdom)  
   AbstractNakamura Jun (Japan)OP0096ADENO-ASSOCIATED VIRUS VECTOR-MEDIATED INTERLEUKIN-10 INDUCTION PREVENTS VASCULAR INFLAMMATION IN A MURINE MODEL OF KAWASAKI DISEASE
   AbstractFisher Corinne (United Kingdom)OP0097STIMULATED MONOCYTE-DERIVED MACROPHAGES FROM PATIENTS WITH ENTHESITIS RELATED ARTHRITIS SECRETE HIGHER LEVELS OF IL23 AND LOWER LEVELS OF INTERFERON GAMMA COMPARED TO HEALTHY CONTROLS
   AbstractKostik Mikhail (Russian Federation)OP0098CLINICAL PICTURE AND SPECTRUM OF CONDITIONS ASSOCIATED WITH NLRP12 GENE MUTATIONS.
   AbstractShoop-Worrall Stephanie (United Kingdom)OP0099REMISSION IN JIA CAN BE PREDICTED FROM ONE YEAR FOLLOWING DIAGNOSIS IN A UK MULTICENTRE INCEPTION COHORT
   AbstractRedeker Imke (Germany)OP0100INCREASE IN DIRECT HEALTHCARE COSTS IN JUVENILE IDIOPATHIC ARTHRITIS OVER THE PAST 10 YEARS – RESULTS OF A HEALTH INSURANCE CLAIMS DATA ANALYSIS
   AbstractChaplin Hema (United Kingdom)OP0101EXPLORING PAIN AND THE IMPACT OF JIA ON ADOLESCENTS AND YOUNG ADULTS: A MIXED-METHODS STUDY
   AbstractBarendregt Anouk (Netherlands)OP0102PROLONGED IMAGE ACQUISITION TIME AFTER CONTRAST AGENT ADMINISTRATION RESULTS IN INCREASED SYNOVIAL THICKNESS ON POST-CONTRAST MRI OF JIA PATIENTS: STANDARDISATION IS KEY
   AbstractDe Benedetti Fabrizio (Italy)OP0103IDENTIFICATION OF OPTIMAL SUBCUTANEOUS DOSES OF TOCILIZUMAB IN CHILDREN WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS

Wednesday 13.06.2018 18:15 - 19:45


 
Basic and Translational Science Session - Elicium 1
  
Burning bones
   ChairDistler Jörg (Germany)  
   ChairLories Rik (Belgium)  
   SpeakerGravallese Ellen M. (United States)SP0028Bone inflammation in arthritis
   AbstractSpinelli Francesca Romana (Italy)OP0104ANTIBODIES AGAINST CARBAMYLATED PROTEINS ARE INVOLVED IN OSTEOCLASTOGENESIS BY INDUCING RANKL EXPRESSION IN OSTEOBLASTS IN VITRO
   SpeakerSchett Georg (Germany) Monitoring and treatment of bone inflammation
   AbstractAnsari Mohammad (United States)OP0105ZCCHC6 DELETION DOWNREGULATES IL-6 AND REDUCES THE SEVERITY OF EXPERIMENTAL OSTEOARTHRITIS IN MICE
   SpeakerGunzer Matthias (Germany)SP0029Fine structure analysis to detect bone pores

 
Health Professionals Session - Amtrium
  
Delay in treatment and the role of health professionals
   ChairPrimdahl Jette (Denmark)  
   ChairMosor Erika (Austria)  
   SpeakerStack Rebecca (United Kingdom)SP0030Reasons for delay in help seeking at the onset of symptoms
   SpeakerVan der Elst Kristien (Belgium)SP0031Are illness perception and coping style associated with patient delay?
   SpeakerMakri Souzi (Belgium)SP0032The patients perspective on delay in treatment
   SpeakerFautrel Bruno (France)SP0033Delay in treatment from the GP perspective
   AbstractBartlett Susan (Canada)OP0106WHO IS NOT REACHING REMISSION IN EARLY RA AND WHY? PREDICTORS FOR PERSISTENT DISEASE ACTIVITY IN THE FIRST YEAR DIFFER IN MEN AND WOMEN AND ARE RELATED TO LIFESTYLE AND TREATMENT

Thursday 14.06.2018 08:15 - 09:45


 
Basic and Translational Science Session - Elicium 1
  
Fat and fatty acids: targets for therapy?
   ChairSenolt Ladislav (Czech Republic)  
   ChairBokarewa Maria (Sweden)  
   SpeakerSchipper Henk (Netherlands)SP0034Adipose tissue and inflammation
   AbstractBosello Silvia (Italy)OP0107ADIPOCYTOKINES IMBALANCE IS ASSOCIATED WITH VASCULAR DAMAGE IN SYSTEMIC SCLEROSIS
   SpeakerCaamano Jorge (United Kingdom)SP0035Lymphoid cluster formation in adipose tissue
   AbstractHülser Marie-Lisa (Germany)OP0108DIET INDUCED METABOLIC CHANGES IN AN OSTEOARTHRITIS MOUSE MODEL
   SpeakerJoosten Leo (Netherlands)SP0036Free fatty acids: Good or bad in rheumatology?

Thursday 14.06.2018 10:15 - 11:45


 
WIN & HOT Session - Hall 7.1
  
WIN & HOT Session 5
   SpeakerSchulze-Koops Hendrik (Germany) WIN Session: Advances in the diagnosis and monitoring of vasculitis
   SpeakerStone John H. (United States) HOT Session: Recent advances in the treatment of systemic vasculitides

 
Abstract Session - Hall 3
  
Abstract Session: Biologics in RA. Improving and maintaining the response
   ChairFerraccioli Gianfranco (Italy)  
   ChairNajm Aurelie (France)  
   AbstractGarcia Montoya Leticia (United Kingdom)OP0109IN RA PATIENTS WITH INITIAL RESPONSE TO RITUXIMAB, EARLY DEPTH OF B CELL DEPLETION IS ASSOCIATED WITH LONG TERM MAINTENANCE OF THERAPY
   AbstractArad Uri (Israel)OP0110SERUM TOCILIZUMAB TROUGH CONCENTRATIONS ARE ASSOCIATED WITH CLINICAL DISEASE ACTIVITY INDEX SCORES IN ADULT RHEUMATOID ARTHRITIS PATIENTS
   AbstractKaneko Yuko (Japan)OP0111TOCILIZUMAB DISCONTINUATION AFTER ATTAINING REMISSION IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO WERE TREATED WITH TOCILIZUMAB ALONE OR IN COMBINATION WITH METHOTREXATE: RESULTS FROM A PROSPECTIVE, RANDOMISED, CONTROLLED STUDY (THE SECOND YEAR OF THE SURPRISE STUDY)
   Abstractl'Ami Merel (Netherlands)OP0112THERAPEUTIC DRUG MONITORING TO OPTIMIZE SWITCHING BETWEEN BIOLOGIC AGENTS IN RHEUMATOID ARTHRITIS
   AbstractVan Mulligen Elise (Netherlands)OP0113GRADUAL TAPERING TNF BLOCKERS VERSUS CONVENTIONAL SYNTHETIC DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN SUSTAINED REMISSION: FIRST YEAR RESULTS OF THE RANDOMISED CONTROLLED TARA-STUDY
   AbstractIshikawa Yuki (United States)OP0114ANA DEVELOPMENT IS ASSOCIATED WITH POOR RESPONSE TO BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS
   AbstractDankers Wendy (Netherlands)OP0115IMPROVED RESPONSE TO ETANERCEPT IS ASSOCIATED WITH SERUM VITAMIN D LEVELS IN RHEUMATOID ARTHRITIS
   AbstractHawley Samuel (United Kingdom)OP0116IMPACT OF TNF INHIBITORS ON NEED FOR JOINT REPLACEMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS: A MATCHED COHORT ANALYSIS OF UK BIOLOGICS REGISTRY DATA

 
Abstract Session - Auditorium / Balcony
  
Abstract Session: SLE, Sjogren’s and APS- new criteria, novel diagnostic tools and co-morbidities
   ChairTam Lai-Shan (China, People's Republic of)  
   ChairBruce Ian (United Kingdom)  
   AbstractMok Chi Chiu (Hong Kong)OP0117SAFETY AND IMMUNE RESPONSE OF A LIVE ATTENUATED HERPES ZOSTER VACCINE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A RANDOMIZED PLACEBO-CONTROLLED TRIAL
   AbstractParker Benjamin (United Kingdom)OP0118DEVELOPMENT OF METABOLIC SYNDROME IN PATIENTS WITH SLE: RESULTS FROM AN INCEPTION COHORT
   AbstractTektonidou Maria (Greece)OP0119PROGRESSION OF SUBCLINICAL ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS OF LOW DISEASE ACTIVITY: THREE-YEAR FOLLOW-UP AND COMPARISON TO RHEUMATOID ΑRTHRITIS
   AbstractRetamozo Soledad (Spain)OP0120INFLUENCE OF EPIDEMIOLOGY AND ETHNICITY ON SYSTEMIC EXPRESSION OF PRIMARY SJÖGREN SYNDROME IN 9974 PATIENTS
   AbstractCeccarelli Fulvia (Italy)OP0121LUPUS ANTICOAGULANT IS ASSOCIATED WITH THROMBOTIC EVENTS IN HEALTHY CARRIERS: RESULTS FROM A PROSPECTIVE LONGITUDINAL STUDY
   AbstractPetri Michelle (United States)OP0122VALIDATION OF REMISSION AND LUPUS LOW DISEASE ACTIVITY STATE AS PREDICTORS OF ORGAN DAMAGE IN SLE
   AbstractConigliaro Paola (Italy)OP0123EVALUATION OF RETINAL MICROVASCULATURE BY OPTICAL COHERENCE TOMOGRAPHIC ANGIOGRAPHY IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS MIRRORS SYSTEMIC INVOLVEMENT
   AbstractDutton Katherine (United Kingdom)OP0124IN SLE PATIENTS IN SUSTAINED LOW DISEASE ACTIVITY, NOVEL INTERFERON ASSAYS PREDICT FLARES AND GLUCOCORTICOID REQUIREMENTS

 
Abstract Session - Elicium 2
  
Abstract Session: The ‘A-B-C’ of PsA (Assessment, Biologicals, Co-Morbidities)
   ChairCoates Laura (United Kingdom)  
   ChairMcGonagle Dennis (United Kingdom)  
   AbstractPuksic Silva (Norway)OP0125DAPSA AND ULTRASOUND SHOW DIFFERENT PERSPECTIVES OF PSORIATIC ARTHRITIS ACTIVITY: RESULTS FROM A LONGITUDINAL OBSERVATIONAL STUDY OF PATIENTS STARTING TREATMENT WITH BIOLOGIC DMARDS
   AbstractBosch Philipp (Austria)OP0126EVALUATING LOW DISEASE ACTIVITY DEFINITIONS IN PSORIATIC ARTHRITIS USING ULTRASOUND
   AbstractCheng Tsz Ho (Hong Kong)OP0127CAN ACHIEVING MINIMAL DISEASE ACTIVITY (MDA) PREVENT PROGRESSION OF SUBCLINICAL ATHEROSCLEROSIS AND ARTERIAL STIFFNESS? A TWO-YEAR PROSPECTIVE COHORT STUDY IN PSORIATIC ARTHRITIS
   AbstractCoates Laura (United Kingdom)OP0128THE PHENOTYPE OF AXIAL PSORIATIC ARTHRITIS: IS IT DEPENDENT ON HLA-B27 STATUS?
   AbstractLopriore Simona (Italy)OP0129DRUG SURVIVAL ON ANTI-TNF-ALPHA IN PSORIATIC ARTHRITIS PATIENTS WITH AXIAL INVOLVEMENT AND ANALYSIS OF PREDICTORS
   AbstractAvina-Zubieta Juan Antonio (Canada)OP0130RISK OF CANCER IN PATIENTS WITH PSORIASIS/PSORIATIC ARTHRITIS: A POPULATION-BASED STUDY IN THE PROVINCE OF BRITISH COLUMBIA
   AbstractRamming Andreas (Germany)OP0131INNATE LYMPHOID CELLS CORRELATE WITH DISEASE ACTIVITY AND BONE REMODELING IN PSORIATIC ARTHRITIS
   AbstractWu Dongze (China)OP0132STRUCTURAL AND MICROSTRUCTURAL INTRA-ARTICULAR BONE CHANGES AT THE METACARPAL HEADS IN PATIENTS WITH PSORIATIC ARTHRITIS COMPARED TO CONTROLS: A HR-PQCT STUDY

 
Abstract Session - Hall 7.2
  
Abstract Session: RA: such a pain, and beyond
   ChairBykerk Vivian (United States)  
   ChairNikiphorou Elena (United Kingdom)  
   AbstractLampa Jon (Sweden)OP0133UNACCEPTABLE, REFRACTORY PAIN DESPITE INFLAMMATION CONTROL IN EARLY RHEUMATOID ARTHRITIS AND ITS RELATION TO TREATMENT STRATEGY: RESULTS FROM THE RANDOMISED CONTROLLED SWEFOT TRIAL
   AbstractSilva Cristiana (Portugal)OP0134MULTIFACTORIAL EXPLANATORY MODEL OF FATIGUE IN PATIENTS WITH RHEUMATOID ARTHRITIS: A PATH ANALYSIS
   AbstractTsai Yun-Chen (Taiwan, Province of China)OP0135FOETAL-NEONATAL AND MATERNAL OUTCOMES IN WOMEN WITH RHEUMATOID ARTHRITIS
   AbstractWesterlind Helga (Sweden)OP0136SIBLINGS OF PATIENTS WITH RHEUMATOID ARTHRITIS ARE AT INCREASED RISK OF ACUTE CORONARY SYNDROME
   AbstractKrueger Klaus (Germany)OP0137ASSESSING THE RISK OF RA PATIENTS FOR COMORBID CONDITIONS THROUGH A STRUCTURED NURSE-LED INTERVIEW – THE ERIKO STUDY
   AbstractKaraca Nur Banu (Turkey)OP0138INVESTIGATION OF BIOPSYCHOSOCIAL ASSESSMENTS IN PATIENTS WITH RHEUMATIC DISEASE
   AbstractRoodenrijs N. (Netherlands)OP0139CHARACTERISTICS OF DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS: RESULTS OF AN INTERNATIONAL SURVEY
   AbstractMu Rong (China)OP0140PATTERN AND INFLUENTIAL FACTORS IN PROMOTING TREAT-TO-TARGET (T2T) FOR FOLLOW-UP RA PATIENTS WITH A RHEUMATOLOGIST-PATIENT INTERACTIVE SMART SYSTEM OF DISEASE MANAGEMENT (SSDM): A COHORT STUDY FROM CHINA

 
Abstract Session - Forum
  
Abstract Session: Quickly Emerging: Science in SSc, Myositis and related Syndromes
   ChairCutolo Maurizio (Italy)  
   ChairMachado Pedro (United Kingdom)  
   AbstractGutiérrez Jessica (Mexico)OP0141ULTRASOUND DIAGNOSTIC AND PREDICTIVE VALUE OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS.DIAGNOSTIC AND PREDICTIVE VALUE OF ULTRASOUND IN THE ASSESSMENT OF INTERSTITIAL LUNG DISEASE
   AbstractAllanore Yannick (France)OP0142RITUXIMAB IN SYSTEMIC SCLEROSIS : SAFETY AND EFFICACY DATA FROM THE EUSTAR NETWORK
   AbstractDel Papa Nicoletta (Italy)OP0143REGIONAL GRAFTING OF AUTOLOGOUS ADIPOSE TISSUE IS EFFECTIVE IN INDUCING PROMPT HEALING OF INDOLENT DIGITAL ULCERS IN PATIENTS WITH SYSTEMIC SCLEROSIS: RESULTS OF A MONOCENTRIC RANDOMIZED CONTROLLED STUDY
   AbstractBruni Cosimo (Italy)OP0144INTRAVENOUS VERSUS ORAL CYCLOPHOSPHAMIDE (CYC) FOR THE TREATMENT OF INTERSTITIAL LUNG INVOLVEMENT (ILD) AND SKIN INVOLVEMENT IN SYSTEMIC SCLEROSIS (SSC): SAFETY AND EFFICACY EVALUATION IN A LARGE MULTI-CENTRE SCLERODERMA COHORT.
   AbstractJanardana Ramya (India)OP0145SCLERODERMA RELATED INTERSTITIAL LUNG DISEASE AND MYCOPHENOLATE : LONG TERM OUTCOMES
   AbstractCiang Natalia (Hong Kong)OP0146IDIOPATHIC INFLAMMATORY MYOPATHIES & INTERSTITIAL LUNG DISEASE
   AbstractZhang Suhan (China)OP0147ABERRANT ACTIVATION OF TYPE I INTERFERON SYSTEM IN ANTI-MDA5 DERMATOMYOSITIS PATIENTS
   AbstractParker Matthew (United Kingdom)OP0148A VALIDATION OF THE 2017 EULAR/ACR IDIOPATHIC INFLAMMATORY MYOPATHIES CLASSIFICATION CRITERIA IN AN EXPERT-DEFINED SINGLE-CENTRE TEN YEAR INCIDENT COHORT

 
Abstract Session - Elicium 1
  
Abstract Session: Can imaging improve diagnosis and outcome in rheumatic diseases
   ChairConaghan Philip (United Kingdom)  
   ChairOstergaard Mikkel (Denmark)  
   AbstractMøller-Bisgaard Signe (Denmark)OP0149AN MRI GUIDED TREAT-TO-TARGET STRATEGY IN RHEUMATOID ARTHRITIS PATIENTS IN CLINICAL REMISSION IMPROVED MRI INFLAMMATION BUT NOT DAMAGE PROGRESSION - RESULTS FROM THE IMAGINE-RA RANDOMISED CONTROLLED TRIAL
   AbstractNordberg Lena (Norway)OP0150ULTRASOUND POWER DOPPLER ACTIVITY PREDICTS CLINICAL JOINT SWELLING IN EARLY RHEUMATOID ARTHRITIS PATIENTS: SECONDARY ANALYSES FROM THE ARCTIC TRIAL
   AbstractPratt Arthur (United Kingdom)OP0151ROUTINELY RECORDED MUSCULOSKELETAL ULTRASOUND FINDINGS IMPACT CLINICIANS’ DIAGNOSTIC BEHAVIOUR MAXIMALLY IN AUTOANTIBODY-SERONEGATIVE PATIENTS ATTENDING AN EARLY ARTHRITIS CLINIC.
   AbstractSingh Ruchir (United Kingdom)OP0152IS SONOGRAPHIC PHENOTYPE OF LATE-ONSET RHEUMATOID ARTHRITIS DIFFERENT FROM YOUNG-ONSET RHEUMATOID ARTHRITIS? RESULTS FROM THE BIRMINGHAM EARLY ARTHRITIS COHORT
   AbstractTen Brinck Robin (Netherlands)OP0153RESOLUTION OF SYMPTOMS OF PATIENTS WITH CLINICALLY SUSPECT ARTHRALGIA IS PARALLELED BY DISAPPEARANCE OF MRI-DETECTED SUBCLINICAL INFLAMMATION; A LONGITUDINAL STUDY
   AbstractStein Michael (Canada)OP0154PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE THE USE OF MUSCULOSKELETAL ULTRASONOGRAPHY TO IMPROVE RHEUMATOID ARTHRITIS MANAGEMENT: INTERIM ANALYSIS OF THE ECHO STUDY
   AbstractChristiansen Sara (Denmark)OP0155ULTRASOUND AS AN OUTCOME MEASUREMENT TOOL FOR OPTIMIZED MONITORING OF GOUT. VALIDATION OF THE OMERACT ULTRASOUND DEFINITIONS OF GOUT ELEMENTARY LESIONS.
   AbstractNielsen Berit Dalsgaard (Denmark)OP0156SIMPLE ASSESSMENT OF CONVENTIONAL 18F-FDG PET/CT ACCURATELY DIAGNOSES CRANIAL ARTERITIS IN GLUCOCORTICOID-NAÏVE GCA PATIENTS: A CASE-CONTROL STUDY

 
Abstract Session - Amtrium
  
HPR Abstract Session: Singing power to the people
   ChairVliet Vlieland Thea (Netherlands)  
   ChairKocher Agnes (Switzerland)  
   AbstractRøisland Mona (Norway)OP0157-HPRAGREEMENT BETWEEN JIA PATIENTS AND PARENTS ON DISEASE PERCEPTION ANALYZED BY THE NORWEGIAN VERSION OF THE JAMAR QUESTIONNAIRE
   AbstractZuidema Rixt (Netherlands)OP0158-HPREFFECTIVENESS OF AN E-HEALTH TAILORED SELF-MANAGEMENT PROGRAM FOR PATIENTS WITH RHEUMATOID ARTHRITIS: AN EXPLORATIVE RCT
   AbstractRongen- Van Dartel SAA (Netherlands)OP0159-HPRREUMANET BERNHOVEN: INTRODUCTION AND EVALUATION OF AN ONLINE SELF-MANAGEMENT TOOL AND PERSONAL HEALTH ENVIRONMENT FOR PATIENTS WITH RHEUMATOID ARTHRITIS (RA).
   AbstractSantos Eduardo (Portugal)OP0160-HPRDETERMINANTS OF HAPPINESS AND QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS: A STRUCTURAL EQUATION MODELING APPROACH
   AbstractHalls Serena (United Kingdom)OP0161-HPRTHE DEVELOPMENT OF SELF-MANAGEMENT TRAINING FOR INNOVATIVE DEPARTMENTS (STRIDE): A SKILLS-TRAINING PROGRAMME FOR RHEUMATOLOGY TEAMS TO ENHANCE SUPPORT FOR SELF-MANAGEMENT
   AbstractPérez-Ruiz Fernando (Spain)OP0162-HPRESTIMATING HEALTH-RELATED QUALITY OF LIFE FOR GOUT PATIENTS: A POST-HOC ANALYSIS OF UTILITIES FROM THE CLEAR TRIALS
   AbstractPrior Yeliz (United Kingdom)OP0163-HPRDEVELOPMENT OF AN ONLINE SELF-MANAGEMENT PLATFORM FOR PEOPLE WITH RHEUMATIC AND MUSCULOSKELETAL CONDITIONS (MSKHUB.COM)
   AbstractMoltó Anna (France)OP0164-HPRIMPACT OF A NURSE-LED PROGRAM OF PATIENT SELF-ASSESSMENT AND SELF-MANAGEMENT AXIAL SPONDYLOARTHRITIS: RESULTS OF A PROSPECTIVE, MULTICENTRE, RANDOMIZED, CONTROLLED TRIAL (COMEDSPA)

 
Abstract Session - Emerald
  
Abstract Session: Fires and firefighters: switching the immune system on and off
   ChairRönnblom Lars (Sweden)  
   Chairvan Wijk Femke (Netherlands)  
   AbstractFrank Bertoncelj Mojca (Switzerland)OP0165JOINT-SPECIFIC DIFFERENCES IN THE ACTIVATION OF THE JAK-STAT PATHWAY IN RHEUMATOID ARTHRITIS
   AbstractLi Katherine (United States)OP0166COMPARATIVE EVALUATION OF CELLULAR AND MOLECULAR CHANGES ASSOCIATED WITH RESPONSE TO SELECTIVE IL-23 BLOCKADE VS DUAL IL-12/23 BLOCKADE IN PSORIASIS SKIN
   AbstractYoshimoto Keiko (Japan)OP0167A LOW MOLECULAR WEIGHT BAFF SIGNALING INHIBITOR, BIK-13, AMELIORATES B CELL ACTIVATION IN VITRO AND IN VIVO AUTOIMMUNE MODELS AND CONSEQUENTLY SUPPRESSES PRODUCTION OF IGG AND CYTOKINES.
   AbstractJeucken Kim (Netherlands)OP0168NIK-IKK COMPLEX INTERACTION CONTROLS NF-ΚB-DEPENDENT INFLAMMATORY ACTIVATION OF THE ENDOTHELIUM IN RESPONSE TO LTΒR LIGATION
   AbstractBoeters Debbie (Netherlands)OP0169A COMBINATION OF PROTEINS AS MEASURED WITHIN THE MULTI-BIOMARKER DISEASE ACTIVITY SCORE AT PRESENTATION OF RA IDENTIFIES A GROUP OF ACPA-NEGATIVE RA PATIENTS WITH HIGH LIKELIHOOD OF DEVELOPING DMARD-FREE SUSTAINED REMISSION
   AbstractDe Graaf Dennis (Netherlands)OP0170HUMAN IL-38 REDUCES JOINT INFLAMMATION IN A MOUSE MODEL OF GOUTY ARTHRITIS
   AbstractRomero-Sanchez Consuelo (Colombia)OP0171LEPTIN LEVELS, OVERWEIGHT AND P GINGIVALIS PRESENCE CONTRIBUTE TO THE MECHANISM OF SYSTEMIC INFLAMMATION IN FIRST-DEGREE RELATIVES OF RHEUMATOID ARTHRITIS INDIVIDUALS
   AbstractScanu Anna (Italy)OP0172LPS-INDUCED PERIODONTITIS PROMOTES ARTHRITIS DEVELOPMENT IN MICE

 
PARE Session - PARE Room
  
Inclusive school environment for young people with RMDs
   ChairBoyd Peter (Ireland)  
   ChairAlunno Alessia (Italy)  
   SpeakerJanssens Els (Belgium)SP0037Bednet: Learning opportunities for bedridden children
   SpeakerAinsworth Sophie (United Kingdom)SP0038Raising awareness of invisible illnesses in schools and education
   SpeakerWilhelmer Tanita (Austria)SP0039I graduated! Education for children and adolescents with RMDs
   SpeakerKepic Mirjam (Slovenia)SP0040Parents support for children with RMDs in education
   Abstractvan Nieuwkoop Linda (Netherlands)OP0173-PAREYOUTH-R-COACH, A PROGRAM FOR YOUTH WITH A CHRONIC DISEASE

 
Abstract Session - E106 / E107
  
Abstract Session: The building blocks of systemic inflammation
   ChairZhao Yi (China, People's Republic of)  
   ChairSjowall Christopher (Sweden)  
   AbstractPsarras Antonios (United Kingdom)OP0180TYPE I INTERFERON IS PRODUCED BY NON-HAEMATOPOIETIC TISSUE RESIDENT CELLS BUT NOT PDCS IN PRE-CLINICAL AUTOIMMUNITY AND SLE
   AbstractWhite Wendy (United States)OP0174ALTERATION OF MEDIATORS OF VASCULAR INFLAMMATION BY ANIFROLUMAB IN THE PHASE IIB MUSE STUDY IN SLE
   AbstractLambers Wietske (Netherlands)OP0175INTERFERON SIGNATURE MIGHT SERVE AS EARLY BIOMARKER FOR DEVELOPMENT OF LUPUS AND CORRELATES STRONGLY WITH MYXOVIRUS-RESISTANCE PROTEIN A
   AbstractRivière Elodie (France)OP0176RNA SEQUENCING DETECTION OF GENE DYSREGULATION IN B CELLS SORTED FROM SALIVARY GLAND TISSUE AND PERIPHERAL BLOOD REVEALS NEW PATHWAYS INVOLVED IN SJÖGREN’S SYNDROME PATHOPHYSIOLOGY
   AbstractNakshbandi Uzma (Netherlands)OP0177BCL6 IDENTIFIES ECTOPIC GERMINAL CENTERS IN SALIVARY GLAND BIOPSIES IN PRIMARY SJÖGREN'S SYNDROME PATIENTS
   AbstractRuiz Roman Alberto (Spain)OP0178ANALYSIS OF B-CELLS SUBSETS IN FIRST DEGREE RELATIVES OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
   AbstractBende Richard (Netherlands)OP0179MOLECULAR DOCUMENTATION OF THE CLONAL EVOLUTION OF A DIFFUSE LARGE B-CELL LYMPHOMA OUT OF CLONALLY EXPANDED RHEUMATOID FACTOR-EXPRESSING B CELLS IN A SJÖGREN’S SYNDROME PATIENT
   AbstractUnger Julia (Austria)OP0181PATIENT PERSPECTIVES OF PEOPLE WITH PRIMARY SJÖGREN'S SYNDROME: A MULTICENTRE QUALITATIVE EUROPEAN STUDY

 
Abstract Session - D201 / D202
  
Abstract Session: The Crystal Maze - etiology and management
   ChairChoi Hyon K. (United States)  
   ChairLioté Frederic (France)  
   AbstractSingh Jasvinder (United States)OP0182GOUT AND DEMENTIA IN THE ELDERLY: A MEDICARE CLAIMS STUDY
   AbstractPerez-Ruiz Fernando (Spain)OP0183ASSOCIATION BETWEEN HFE GENOTYPES AND CLINICAL SEVERITY CHARACTERISTICS OF CALCIUM PYROPHOSPHATE CRYSTAL ARTHRITIS
   AbstractCalabrese Leonard (United States)OP0184THE FREQUENCY OF FLARES IN SUBJECTS WITH CHRONIC REFRACTORY GOUT TREATED WITH PEGLOTICASE IS RELATED TO VARIATION IN THE LEVEL OF PLASMA URATE
   AbstractSingh Gurkirpal (United States)OP0185EMERGENCY DEPARTMENT VISITS FOR GOUT: A DRAMATIC INCREASE IN THE PAST DECADE
   AbstractRamos Fernanda (Brazil)OP0186NEPHROLITHIASIS AS A COMPLICATION OF GOUT: A CROSS-SECTIONAL STUDY WITH HELICAL COMPUTED TOMOGRAPHY
   AbstractDai Lie (China)OP0187FRUCTOSE-CONTAINING BEVERAGES IS AN INDEPENDENT RISK FACTOR FOR GOUT EARLY-ONSET IN SOUTH CHINA
   AbstractKang Eun Ha (Korea, Republic Of)OP0188EFFECTS OF ALLOPURINOL VERSUS FEBUXOSTAT ON CARDIOVASCULAR RISK IN KOREAN PATIENTS WITH GOUT: A NATION-WIDE COHORT STUDY
   AbstractEa Hang Korng (France)OP0189IDENTIFICATION OF NEW AND RARE VARIANTS IN ABCG2, SLC22A1 AND ALDH16A1 GENES IN CRYSTAL-PROVEN EARLY-ONSET GOUT

 
Abstract Session - D203 / D204
  
Abstract Session: Treatments: friend or foe?
   ChairAletaha Daniel (Austria)  
   ChairJani Meghna (United Kingdom)  
   AbstractAnis Aslam (Canada)OP0190THE ROLE OF NSAIDS IN THE ASSOCIATION BETWEEN OSTEOARTHRITIS AND CARDIOVASCULAR DISEASES: A POPULATION-BASED COHORT STUDY
   AbstractSoeltoft Kasper (Denmark)OP0191ALL-CAUSE MORTALITY AND CARDIOVASCULAR DEATH IN HYDROXYCHLOROQUINE USERS IN RHEUMATOID ARTHRITIS PATIENTS - A POPULATION BASED DANISH COHORT STUDY
   AbstractCurtis Jeffrey (United States)OP0192METHOTREXATE USE AND THE RISK FOR CARDIOVASCULAR DISEASE AMONG RHEUMATOID PATIENTS INITIATING BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
   AbstractCurtis Jeffrey (United States)OP0193TOCILIZUMAB AND THE RISK FOR CARDIOVASCULAR DISEASE EVENTS AMONG RHEUMATOID ARTHRITIS PATIENTS: A DIRECT COMPARISON IN REAL WORLD SETTING
   AbstractHwang Jiwon (Korea, Republic Of)OP0194THE ASSOCIATION BETWEEN SERUM URIC ACID AND ARTERIAL STIFFNESS IN A LOW-RISK, LARGE POPULATION OF MIDDLE-AGED KOREAN
   AbstractAlemao E (United States)OP0195ROLE OF SEROPOSITIVITY ON MORTALITY IN RA AND THE IMPACT OF TREATMENT WITH DMARDS
   AbstractTison Alice (France)OP0196SAFETY AND EFFICACY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH CANCER AND PREEXISTING AUTOIMMUNE DISEASES: A NATIONWIDE MULTICENTER RETROSPECTIVE STUDY
   AbstractPundole Xerxes (United States)OP0197RHEUMATIC AND MUSCULOSKELETAL ADVERSE EVENTS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS: DATA MINING OF THE US FOOD AND DRUG ADMINISTRATION ADVERSE EVENT REPORTING SYSTEM

Thursday 14.06.2018 11:45 - 13:30


 
Poster Tour - Poster Area
  
Poster Tour T10: New data on osteoporosis and fracture prevention
   ChairGeusens Piet (Netherlands)  
   ChairBours Sandrine (Netherlands)  
   AbstractWiebe Edgar (Germany)THU0469QUANTIFYING THE TREATMENT WITH GLUCOCORTICOIDS AS A RISK FACTOR FOR THE OCCURRENCE OF OSTEOPOROSIS AND FRACTURES IN PATIENTS WITH RA
   AbstractAmin Shreyasee (United States)THU0470NON-CLONAL ELEVATION OF SERUM IMMUNOGLOBULIN FREE LIGHT CHAINS IS PREDICTIVE OF HIP FRACTURE IN BOTH WOMEN AND MEN
   AbstractMonov Simeon (Bulgaria)THU0471RISK FACTORS OF LOW BONE MINERAL DENSITY IN PATIENTS WITH SYSTEMIC SCLEROSIS
   AbstractDanila Maria Ioana (United States)THU0472FACTORS ASSOCIATED WITH READINESS FOR ADOPTING OSTEOPOROSIS TREATMENT CHANGE
   AbstractMazzucchelli Ramon (Spain)THU0473TREND OF MORTALITY AFTER OSTEOPOROTIC HIP FRACTURE IN A PERIOD OF 17 YEARS.
   AbstractMenditto Enrica (Italy)THU0474UTILIZATION OF ANTI-OSTEOPOROTIC DRUGS IN REAL-WORLD DATA: AN ANALYSIS OF PERSISTENCE TO THERAPY AND RISK OF FRACTURE
   AbstractEl Hadiyen Fatma (Netherlands)THU0475INCIDENCE AND DETERMINANTS OF VERTEBRAL AND PERIPHERAL FRACTURES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A PROSPECTIVE LONGITUDINAL COHORT STUDY
   AbstractFlorez Helena (Spain)THU0476SPONTANEOUS VERTEBRAL FRACTURES AFTER DENOSUMAB DISCONTINUATION: A REPORT OF 6 CASES.
   AbstractSaavedra Aida (Spain)THU0477FACTORS ASSOCIATED WITH THE INITIATION OF TREATMENT AFTER FRAGILITY FRACTURE IN A FRACTURE LIAISON SERVICE.
   AbstractChen Jia-Feng (Taiwan, Province of China)THU0478BEFORE AND AFTER MENOPAUSE, OSTEOPOROSIS RISK FACTORS ARE DIFFERENT IN WOMEN WITH RHEUMATOID ARTHRITIS
  
Poster Tour T11: Pain in the joint; managing a widespread problem
   ChairWalsh David (United Kingdom)  
   ChairCarubbi Francesco (Italy)  
   AbstractLozano Plata Luis Iván (Mexico)THU0516EFFICACY AND SAFETY OF VITAMIN D3 IN PATIENTS WITH FIBROMYALGIA. RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL.
   AbstractEstevez-Lopez Fernando (Spain)THU0517IDENTIFICATION OF CANDIDATE GENES ASSOCIATED WITH FIBROMYALGIA SUSCEPTIBILITY IN SOUTHERN SPANISH WOMEN: THE AL-ÁNDALUS PROJECT
   AbstractGhib Linda (Romania)THU0518THE DIAGNOSTIC VALUE OF SELECTED MICRORNAS IN PATIENTS WITH FIBROMYALGIA ASSOCIATED WITH RHEUMATOID ARTHRITIS: A PILOT STUDY
   AbstractWalsh David (United Kingdom)THU0519PREDICTION OF PERSISTENT KNEE PAIN BY PRESSURE PAIN DETECTION THRESHOLDS: RESULTS FROM THE KNEE PAIN IN THE COMMUNITY COHORT (KPIC)
   AbstractTriantafyllias Konstantinos (Germany)THU0520ASSESSMENT OF CARDIOVASCULAR RISK IN PATIENTS WITH FIBROMYALGIA BY CAROTID-FEMORAL PULSE WAVE VELOCITY - RESULTS OF A PROSPECTIVE STUDY.
   AbstractPincus Thedore (United States)THU0521A SIMPLE INDEX BASED ON SCORES ON A MULTIDIMENSIONAL HEALTH ASSESSMENT QUESTIONNAIRE (MDHAQ) PROVIDES INFORMATION QUITE SIMILAR TO ACR CRITERIA FOR FIBROMYALGIA IN ROUTINE CARE
   AbstractDeshmukh Vishal (United States)THU0522EXPERIMENTAL TENDINOPATHY TREATMENT WITH SM04755, A TOPICAL SMALL MOLECULE INHIBITOR OF THE WNT PATHWAY
   AbstractDarrieutort-Laffite Christelle (France)THU0523DO WE NEED STEROID INJECTION AFTER ULTRASOUND GUIDED PERCUTANEOUS LAVAGE OF A ROTATOR CUFF CALCIFICATION ? RESULTS AT 3 MONTHS OF A DOUBLE BLINDED RANDOMIZED CONTROLLED STUDY
   AbstractMansiz-Kaplan Basak (Turkey)THU0524IS THERE ANY EFFECT OF KINESIOTAPING ON RADIAL NERVE IN PATIENTS WITH UNILATERAL LATERAL EPICONDYLITIS? A RANDOMIZED-SINGLE BLIND STUDY.
   AbstractIsmail Ahmed (Egypt)THU0525EFFECT OF LOCAL INSULIN INJECTION IN THE TREATMENT OF MILD TO MODERATE CARPAL TUNNEL SYNDROME IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
  
Poster Tour T12: A colourful journey through the landscape of paediatric rheumatology
   ChairPrakken Berent J. (Netherlands)  
   ChairGiancane Gabriella (Italy)  
   AbstractMeneghetti Thais (Brazil)THU0546CHILDREN WITH PSORIASIS ALSO SHOW ENTHESOPATHY SIGNS RELATED TO SKIN DISEASE ACTIVITY
   AbstractHuang Bin (United States)THU0547REAL-WORLD EFFECTIVENESS OF EARLY AGGRESSIVE TREATMENT WITH BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS FOR THE TREATMENT OF NEWLY DIAGNOSED POLYARTICULAR FORM OF JUVENILE IDIOPATHIC ARTHRITIS
   AbstractVojinovic Jelena (Serbia)THU0548STANDARDIZED PROCEDURES FOR ULTRASOUND IMAGING IN PAEDIATRIC RHEUMATOLOGY: PROGRESS OF EULAR/PRES TASK FORCE
   AbstractRuperto N (Italy)THU0549ABSENCE OF ASSOCIATION BETWEEN DRUG EXPOSURE AND INFECTION IN PATIENTS WITH POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC OR NON-BIOLOGIC DMARDS TREATED WITH SC AND IV ABATACEPT
   AbstractDagher Rawane (Lebanon)THU0550NEW IL10 RECEPTOR GENE MUTATION ASSOCIATED TO A SPECTRUM OF INFLAMMATORY APHTHOSIS AND CROHN'S DISEASE
   AbstractHissink Muller Petra (Netherlands)THU0551TREATMENT STRATEGY STUDY IN NEW ONSET DMARD NAIVE JUVENILE IDIOPATHIC ARTHRITIS FIRST RESULTS ON 24 MONTHS CLINICAL OUTCOME
   AbstractKlotsche Jens (Germany)THU0552ARTICULAR AND EXTRA-ARTICULAR DAMAGE IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS – RESULTS FROM THE INCEPTION COHORT OF NEWLY DIAGNOSED PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS (ICON)
   AbstractHorneff Gerd (Germany)THU0553TNF-INHIBITOR AND LEFLUNOMIDE COMBINATION THERAPY IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS IN CLINICAL PRACTICE – LESSONS FROM THE GERMAN BIOLOGICS JIA REGISTRY (BIKER)
   AbstractNassar-Sheikh Rashid Amara (Netherlands)THU0554RITUXIMAB (RTX) IN PEDIATRIC DISEASES: DESCRIBING ITS PHARMACODYNAMICS WITH A FOCUS ON B-CELL DEPLETION AND REPOPULATION, INFECTIONS AND ANTI-DRUG ANTIBODIES
   AbstractEl Miedany Yasser (United Kingdom)THU0555GUIDELINES FOR JUVENILE IDIOPATHIC ARTHRITIS MANAGEMENT: IS THERE A ROOM FOR COMBINED METHOTREXATE AND LEFLUNOMIDE THERAPY IN THE TREATMENT RECOMMENDATIONS.
  
Poster Tour T13: Life is not a smooth trip - how pregnancy and life events interfere in rheumatic disease management
   ChairGossec Laure (France)  
   ChairRodrigues-Manica Santiago (Portugal)  
   AbstractRaymond Warren (Australia)THU0671STANDARDISED MORTALITY RATES FOR SYSTEMIC LUPUS ERYTHEMATOSUS IN WESTERN AUSTRALIA FROM 1980 TO 2015
   AbstractUrsin Kristin (Norway)THU0672IMPACT OF PREGNANCY ON PHYSICAL FUNCTION AND HEALTH-RELATED QUALITY OF LIFE IN WOMEN WITH AXIAL SPONDYLOARTHRITIS
   AbstractUrsin Kristin (Norway)THU0673DISEASE ACTIVITY DURING AND AFTER PREGNANCY IN WOMEN WITH PSORIATIC ARTHRITIS
   AbstractMotta Francesca (Italy)THU0674RHEUMATIC DISEASES AND PREGNANCY: A SINGLE CENTRE DEDICATED CLINIC EXPERIENCE.
   AbstractSingh Namrata (United States)THU0675THE IMPACT OF AUTOIMMUNE RHEUMATIC DISEASES ON BIRTH OUTCOMES IN AN ETHNICALLY DIVERSE COHORT OF WOMEN IN THE UNITED STATES
   AbstractKudaeva Fatima (Canada)THU0676A SYSTEMATIC REVIEW AND META-ANALYSIS OF VIRAL EXPOSURES AS A RISK FACTOR FOR RHEUMATOID ARTHRITIS
   AbstractRasmussen Sofie (Denmark)THU0677PNEUMOCOCCAL ANTIBODY PROTECTION IN RHEUMATOLOGICAL PATIENTS RECEIVING BDMARD THERAPY – A CROSS-SECTIONAL STUDY
   AbstractPoudel Dilli (United States)THU0678TREND OF VENOUS THROMBOEMBOLISM AMONG SELECT RHEUMTOLOGIC DISEASES: AN AUDIT OF LARGE NATIONAL US DATABASE
   AbstractMyasoedova Elena (United States)THU0679INCREASED HOSPITALIZATION RATES FOLLOWING HEART FAILURE DIAGNOSIS IN RHEUMATOID ARTHRITIS
   AbstractXu Ting (China)THU0680SURVIVAL ANALYSIS OF PATIENTS WITH CONNECTIVE TISSUE DISEASE ASSOCIATED INTERSTITIAL LUNG DISEASE
  
Poster Tour T14: Winds of change
   Chairde Thurah Annette (Denmark)  
   ChairRausch Osthoff Anne-Kathrin (Switzerland)  
   AbstractSverker Annette (Sweden)THU0710-HPRQUALITIES OF PARTICIPATION AS DESCRIBED BY PEOPLE WITH EARLY RA IN WORKING AGE
   AbstractSwinnen Thijs (Belgium)THU0711-HPRWIDESPREAD PAIN IN AXIAL SPONDYLOARTHRITIS: CLINICAL IMPORTANCE AND GENDER DIFFERENCES
   AbstractRat Anne-Christine (France)THU0712-HPRTRAJECTORIES OF PAIN AND PHYSICAL FUNCTION IN PATIENTS WITH SYMPTOMATIC KNEE AND HIP OSTEOARTHRITIS: RESULTS FROM THE FRENCH POPULATION-BASED KHOALA COHORT
   AbstractO'Dwyer Tom (Ireland)THU0713-HPRBEHAVIOUR CHANGE INTERVENTIONS TARGETING PHYSICAL ACTIVITY IN ADULTS WITH FIBROMYALGIA SYNDROME: A SYSTEMATIC REVIEW
   AbstractKristiansen Tine (Denmark)THU0714-HPRINTERPROFESSIONAL COLLABORATION IN RHEUMATOLOGY REHABILITATION - THE CLASH BETWEEN IDEOLOGY AND PRACTICE
   AbstractKnoop Jesper (Netherlands)THU0715-HPRSTRATIFIED EXERCISE THERAPY BY PHYSICAL THERAPISTS IN PRIMARY CARE IS FEASIBLE IN PATIENTS WITH KNEE OSTEOARTHRITIS
   AbstractMckenna Sean (Ireland)THU0716-HPRTHE IMPACT OF EXERCISE ON SLEEP IN PEOPLE WITH RHEUMATOID ARTHRITIS: A PILOT RANDOMISED CONTROLLED TRIAL
   AbstractPettersson Henrik (Sweden)THU0717-HPRIMPAIRED MUSCLE FUNCTION AND SHOULDER-ARM MOVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS
   AbstractBennett Sarah (United Kingdom)THU0718-HPRTHE PSYCHOSOCIAL IMPACT OF JOINT HYPERMOBILITY SYNDROME AND EHLERS-DANLOS SYNDROME (HYPERMOBILITY TYPE): A QUALITATIVE INTERVIEW STUDY.
   AbstractStöcker Juliane (Netherlands)THU0719-HPRNON-PHARMACOLOGICAL CARE IN SYSTEMIC SCLEROSIS: ROOM FOR IMPROVEMENT?
  
Poster Tour T1: Genetics – from Cause to Cure
   ChairOspelt Caroline (Switzerland)  
   ChairKnevel Rachel (Netherlands)  
   AbstractNair Nisha (United Kingdom)THU0001DIFFERENTIAL METHYLATION AS A PREDICTOR OF METHOTREXATE RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS
   AbstractAdeeb Fahd (Ireland)THU0002NOVEL PATHOGENIC STOP CODON MUTATION IN THE NF-ΚB P65 SUBUNIT (RELA) ASSOCIATED WITH BOTH BEHÇET’S DISEASE LIKE SYNDROME AND NEUROMYELITIS OPTICA IN AN IRISH FAMILY
   AbstractHigashino Toshihide (Japan)THU0003COMPREHENSIVE EVALUATION OF THE EFFECTS OF RARE AND COMMON EXONIC ABCG2 VARIANTS ON GOUT SUSCEPTIBILITY
   AbstractPadula Maria Carmela (Italy)THU0004A DE NOVO NON-SENSE ERAP1 POLYMORPHISM IN TWO HLA-B*27-NEGATIVE TWINS WITH AXIAL SPONDYLOARTHRITIS
   AbstractSeyahi Emire (Turkey)THU0005WHOLE GENOME LINKAGE AND EXOME SEQUENCING ANALYSES IN TAKAYASU ARTERITIS FAMILIES
   AbstractJalali-najafabadi Farideh (United Kingdom)THU0006APPLICATION OF MACHINE LEARNING METHODS FOR PREDICTION MODELLING OF PSORIATIC ARTHRITIS IN PATIENTS WITH PSORIASIS
   AbstractJoo Young Bin (Korea, Republic Of)THU0007GENETIC VARIANTS IN SLE SUSCEPTIBILITY LOCI, XKR6 AND GLT1D1, ARE ASSOCIATED WITH CHILDHOOD-ONSET SLE IN A KOREAN COHORT
   AbstractYarwood Annie (United Kingdom)THU0008LINKING GENETICS TO T-CELL PHENOTYPE IN JIA: RATIONAL FOR IL-2 THERAPY
   AbstractBriggs Tracy (United Kingdom)THU0009TOWARDS PRECISION MEDICINE IN CONNECTIVE TISSUE DISEASES: GENOMIC AND TRANSCRIPTOMIC STUDIES
   AbstractSainz Juan (Spain)THU0010POLYMORPHISMS IN PHASE I-METABOLIZING ENZYME AND HORMONE RECEPTOR GENES INFLUENCE THE RESPONSE TO ANTI-TNF THERAPY
  
Poster Tour T2: Adapting the adaptive immune system in health and disease
   ChairTaams Leonie (United Kingdom)  
   ChairScherer Hans-Ulrich (Netherlands)  
   AbstractCiurtin Coziana (United Kingdom)THU0023COMPLEX IMMUNOPHENOTYPING STRATIFIES PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME, SYSTEMIC LUPUS ERYTHEMATOSUS AND SECONDARY SJÖGREN’S SYNDROME ASSOCIATED WITH SYSTEMIC LUPUS ERYTHEMATOSUS INTO DISTINCT CLINICALLY RELEVANT GROUPS WITH POTENTIAL THERAPEUTIC IMPLICATIONS
   Abstractde Moel Emma (Netherlands)THU0024TREATMENT WITH IMMUNE CHECKPOINT INHIBITORS AND THE BREAK OF B-CELL TOLERANCE TO AUTOANTIGENS
   AbstractMurray-Brown William (Australia)THU0025FLORID SYNOVITIS AFTER PD1 ANTAGONIST THERAPY IS CHARACTERISED BY A MARKED ABSENCE OF PD1+ INFILTRATING T CELLS
   AbstractGraver Jacoba (Netherlands)THU0026ORGANIZED B CELLS AND PLASMA CELLS IN THE AORTA OF GIANT CELL ARTERITIS PATIENTS
   AbstractPollastro Sabrina (Netherlands)THU0027NON-RESPONSE TO RITUXIMAB THERAPY IN REUMATOID ARTHRITIS ASSOCIATES WITH INCOMPLETE DISRUPTION OF THE B-CELL RECEPTOR REPERTOIRE IN THE PERIPHERAL BLOOD
   AbstractAlivernini Stefano (Italy)THU0028INTERLEUKIN-6 RECEPTOR INHIBITION, AS FIRST-LINE B-DMARD, AFFECTS B CELL SUBPOPULATIONS DISTRIBUTION THROUGH EPIGENETIC MODIFICATIONS IN RHEUMATOID ARTHRITIS PATIENTS.
   AbstractThiel Jens (Germany)THU0029CTLA-4-IG TREATMENT INDUCES MODULATION OF B-CELL FUNCTION AND DIFFERENTIATION
   AbstractKumar Pavanish (Singapore)THU0030MOLECULAR MECHANISMS OF AUTOPHAGIC MEMORY IN PATHOGENIC T CELLS IN HUMAN RHEUMATOID ARTHRITIS
   AbstractGorski Kevin (United States)THU0031PHENOTYPE OF FOXP3+ REGULATORY T-CELLS EXPANDED BY THE IL-2 MUTEIN, AMG 592 IN HEALTHY SUBJECTS IN PHASE 1, FIRST-IN-HUMAN STUDY
   AbstractRazawy Wida (Netherlands)THU0032CCR6+CD4+ T CELLS DRIVE ANTIGEN-INDUCED ARTHRITIS VIA THE IL-23R PATHWAY
  
Poster Tour T3: Seeking the origins of Rheumatoid Arthritis
   ChairFonseca Joao Eurico (Portugal)  
   ChairRivellese Felice (United Kingdom)  
   AbstractYu Ruohan (China)THU0050HYPOXIA INDUCES PRODUCTION OF CITRULLINATED PROTEINS IN HUMAN FIBROBLAST-LIKE SYNOVIOCYTES THROUGH REGULATING HIF1Α
   AbstractTseng Wen-Yi (United Kingdom)THU0051TNF RECEPTOR 2 PLAYS AN IMMUNOREGULATORY AND ANTI-INFLAMMATORY ROLE IN ARTHRITIS
   AbstractRuiz-Romero Cristina (Spain)THU0052A CIRCULATING PROTEIN SIGNATURE CORRELATES WITH SYNOVIAL PATHOTYPES IN RHEUMATOID ARTHRITIS PATIENTS
   AbstractKuboi Yoshikazu (Japan)THU0053ANTI-FRACTALKINE MONOCLONAL ANTIBODY AMELIORATES JOINT DESTRUCTION IN COLLAGEN-INDUCED ARTHRITIS MODEL BY INHIBITION OF OSTEOCLAST PRECURSOR CELL SURVIVAL AND MIGRATION
   AbstractMo Bi Yao (China)THU0054LONG NON-CODING RNA GAPLINC PROMOTES PROLIFERATION AND INVASION OF FIBROBLAST-LIKE SYNOVIOCYTES AS MICRORNA SPONGING IN RA PATIENTS
   AbstractCroft Adam (United Kingdom)THU0055AN ANATOMICALLY DISTINCT PATHOGENIC FIBROBLAST SUBSET DRIVES INFLAMMATION IN ARTHRITIS
   AbstractFu Wenyu (United States)THU005614-3-3 IS A MOLECULAR SWITCH REGULATING MACROPHAGE POLARIZATION IN INFLAMMATORY ARTHRITIS
   AbstractCambré Isabelle (Belgium)THU0057MECHANICAL STRAIN DETERMINES THE SITE-SPECIFIC DIRECTION OF INFLAMMATION AND TISSUE DAMAGE IN ARTHRITIS
   AbstractHayashi Hiroaki (Japan)THU0058TAS8274, A HIGHLY SELECTIVE JANUS KINASE 3 INHIBITOR, SHOWS POTENT EFFICACY, BUT DOES NOT AFFECT HOST DEFENSE, IN PRECLINICAL MOUSE MODELS
   AbstractGu Zhifeng (China)THU0059PLASMA EXOSOMAL MIR-92A ARE INVOLVED IN THE OCCURRENCE AND DEVELOPMENT OF BONE DESTRUCTION IN RA PATIENTS BY INHIBITING APOPTOSIS OF FIBROBLAST-LIKE SYNOVIOCYTES
  
Poster Tour T4: RA: not just about the joints!
   ChairNikiphorou Elena (United Kingdom)  
   Chairvan Laar Jacob M. (Netherlands)  
   AbstractNikitinskaya Oxana (Russian Federation)THU0135USING FRAX® AND PERIPHERAL BONE MINERAL DENSITY FOR IDENTIFYING POTENTIAL CANDIDATES FOR OSTEOPOROSIS THERAPY AMONG RHEUMATOID ARTHRITIS PATIENTS
   AbstractGiollo Alessandro (United Kingdom)THU0136MAJOR CARDIOVASCULAR EVENTS IN 434 RHEUMATOID ARTHRITIS PATIENTS TREATED WITH RITUXIMAB FROM A SINGLE-CENTRE.
   AbstractBergström Miriam (Sweden)THU0137RHEUMATOID ARTHRITIS AS AN EMERGENCY DEPARTMENT RISK FACTOR FOR ACUTE CORONARY SYNDROME
   AbstractKwon Oh Chan (Korea, Republic Of)THU0138OCCURRENCE OF IN-STENT RESTENOSIS AFTER CORONARY DRUG-ELUTING STENT IMPLANTATION IN PATIENTS WITH RHEUMATOID ARTHRITIS
   AbstractInui Kentaro (Japan)THU0139INCREASED HOMOCYSTEINE LEVEL FOR 7 YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS: TOMORROW STUDY.
   AbstractSvanteson Mona (Norway)THU0140EFFECTS OF STATIN-TREATMENT ON CORONARY PLAQUES IN PATIENTS WITH INFLAMMATORY JOINT DISEASES
   AbstractLucassen Merel (Netherlands)THU0141LONG-TERM EFFECTS ON BONE MINERAL DENSITY AFTER FOUR YEARS OF TREATMENT WITH TWO INTENSIVE COMBINATION STRATEGIES, INCLUDING INITIALLY HIGH DOSE PREDNISOLONE, IN EARLY RHEUMATOID ARTHRITIS PATIENTS: THE COBRA-LIGHT TRIAL.
   AbstractMeissner Yvette (Germany)THU0142THE PROGNOSIS OF HEART FAILURE IN PATIENTS WITH RHEUMATOID ARTHRITIS
   AbstractBlanken Annelies (Netherlands)THU0143VASCULAR WALL INFLAMATION IN RHEUMATOID ARTHRITIS PATIENTS DECREASES AFTER 6 MONTHS OF ANTI-INFLAMMATORY THERAPY WITH METHOTREXATE OR ADALIMUMAB AS MEASURED BY 18F-FDG-PET/CT
   AbstractLjung Lotta (Sweden)THU0144PERFORMANCE OF THE ERS-RA CARDIOVASCULAR RISK PREDICTION TOOL: EXTERNAL VALIDATION IN A LARGE SWEDISH COHORT WITH RA
  
Poster Tour T5: Anti-TNF: old drugs now but still full of promises
   ChairMariette Xavier (France)  
   Chairvan der Woude Diane (Netherlands)  
   AbstractAlten Rieke (Germany)THU0182A COMPARATIVE CLINICAL STUDY OF PF-06410293, A CANDIDATE ADALIMUMAB BIOSIMILAR, AND REFERENCE ADALIMUMAB FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS
   AbstractLampa Jon (Sweden)THU0183LESS PAIN OVER 2 YEARS WITH BIOLOGICAL COMPARED TO CONVENTIONAL COMBINATION THERAPY IN EARLY RHEUMATOID ARTHRITIS: RESULTS FROM THE RANDOMISED CONTROLLED SWEFOT TRIAL
   AbstractEmery Paul (United Kingdom)THU0184IMPACT OF IMMUNOGENICITY ON CLINICAL EFFICACY AND ADMINISTRATION RELATED REACTION IN TNF INHIBITORS: A POOLED-ANALYSIS FROM THREE BIOSIMILAR STUDIES IN PATIENTS WITH RHEUMATOID ARTHRITIS
   AbstractSmolen J.S. (Austria)THU0185THE VALUE OF ADALIMUMAB TROUGH LEVELS AND CLINICAL ASSESSMENTS IN PREDICTING CLINICAL RESPONSE IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO METHOTREXATE
   AbstractFernández-Díaz Carlos (Spain)THU0186RHEUMATOID ARTHRITIS AND INTERSTITIAL LUNG DISEASE. MULTICENTRIC RETROSPECTIVE STUDY OF 118 PATIENTS TREATED WITH BIOLOGICAL NO ANTI TNF
   AbstractLourido Lucía (Spain)THU0187CIRCULATING AUTOANTIBODIES AS INDICATORS TO PREDICT THE CLINICAL RESPONSE TO INFLIXIMAB IN RHEUMATOID ARTHRITIS
   AbstractKanayama Yasuhide (Japan)THU0188EFFICACY OF INFLIXIMAB FOR SUPPRESSING RADIOGRAPHIC PROGRESSION OF CERVICAL LESIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS COMPARISON WITH METHOTREXATE ; THREE YEARS OF FOLLOW-UP ~A MULTICENTER REGISTRY STUDY ~
   AbstractGlintborg Bente (Denmark)THU0189ONE-YEAR TREATMENT RETENTION AFTER A NATIONWIDE NON-MEDICAL SWITCH FROM ORIGINATOR TO BIOSIMILAR ETANERCEPT IN 2,061 PATIENTS WITH INFLAMMATORY ARTHRITIS FOLLOWED IN THE DANBIO REGISTRY
   AbstractOstor Andrew (Australia)THU0190CLINICAL OUTCOMES AMONG RHEUMATOID ARTHRITIS PATIENTS RECEIVING ADALIMUMAB WHO DID OR DID NOT PARTICIPATE IN THE PATIENT SUPPORT PROGRAM: A SUBANALYSIS OF THE PASSION STUDY
   AbstractWesthovens Rene (Belgium)THU0191NOVEL FORMULATION OF CT-P13 FOR SUBCUTANEOUS ADMINISTRATION IN PATIENTS WITH RHEUMATOID ARTHRITIS: INITIAL RESULTS FROM A PHASE I/III RANDOMIZED CONTROLLED TRIAL
  
Poster Tour T6: Spondyloarthritis: causes, questions and consequences
   ChairLandewé Robert B.M. (Netherlands)  
   Chairvan Onna Marloes (Netherlands)  
   AbstractOgnjenovic Milica (Australia)THU0227SPINAL FRACTURE RISK IN ANKYLOSING SPONDYLITIS IN WESTERN AUSTRALIA.
   AbstractWITHDRAWN (Sweden)THU0228GUT DYSBIOSIS IN ANKYLOSING SPONDYLITIS IS ASSOCIATED WITH INCREASED FECAL CALPROTECTIN
   AbstractLiu Xiaoqing (China)THU0229ABSOLUTE REDUCTION OF PERIPHERAL CD4+CD25+FOXP3+T REGULATORY CELLS IN PATIENTS WITH SPONDYLOARTHROPATHY-RELATED OCULOPATHY
   AbstractProft Fabian (Germany)THU0230PERFORMANCE OF AN ONLINE SELF-REFERRAL QUESTIONNAIRE COMPARED TO A PHYSICIAN-BASED REFERRAL APPROACH TO IDENTIFY PATIENTS WITH A HIGH PROBABILITY OF AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE OPTIREF STUDY
   Abstractvan Lunteren Miranda (Netherlands)THU0231DO DEGREE OF FAMILY RELATIONSHIP AND ETHNICITY IMPACT THE ASSOCIATION BETWEEN A POSITIVE FAMILY HISTORY FOR SPONDYLOARTHRITIS AND PRESENCE OF HLA-B27? RESULTS FROM THE WORLDWIDE ASAS COHORT
   Abstractvan Lunteren Miranda (Netherlands)THU0232IS A POSITIVE FAMILY HISTORY OF SPONDYLOARTHRITIS RELEVANT FOR DIAGNOSING AXIAL SPONDYLOARTHRITIS ONCE HLA-B27 STATUS IS KNOWN? DATA FROM THE ASAS, DESIR AND SPACE COHORTS
   AbstractWebers Casper (Netherlands)THU0233SICK LEAVE AND ITS PREDICTORS IN ANKYLOSING SPONDYLITIS: LONG-TERM RESULTS FROM THE OUTCOME IN ANKYLOSING SPONDYLITIS INTERNATIONAL STUDY
   AbstractBirra Domenico (Italy)THU0234BMI DOES NOT AFFECT CLINICAL OUTCOME IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH TIGHT CONTROL STRATEGY
   AbstractPoudel Dilli (United States)THU0235ANKYLOSING SPONDYLITIS AND RHEUMATOID ARTHRITIS HOSPITALIZATION TRENDS IN THE US: DATA FROM NATIONAL INPATIENT SAMPLE
   AbstractBengtsson Karin (Sweden)THU0236ANKYLOSING SPONDYLITIS RELATED FACTORS PREDICT THE PRESENCE OF CARDIAC CONDUCTION DISTURBANCES – A SWEDISH LONGITUDINAL COHORT STUDY
  
Poster Tour T7: The impact of treatment on the burden of psoriatic disease
   Chairvan den Bosch Filip (Belgium)  
   ChairCoates Laura (United Kingdom)  
   AbstractBehrens Frank (Germany)THU0280EARLY AND LONG-TERM TREATMENT RESPONSE AS WELL AS HIGH TOLERABILITY LEAD TO HIGH TREATMENT SATISFACTION OF A THERAPY WITH USTEKINUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS – RESULTS OF THE NON-INTERVENTIONAL STUDY SUSTAIN
   AbstractMichelsen Brigitte (Norway)THU0281DO IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE DURING DMARD TREATMENT DIFFER BETWEEN PSORIATIC AND RHEUMATOID ARTHRITIS PATIENTS? DATA FROM THE PROSPECTIVE OBSERVATIONAL NOR-DMARD STUDY, INCLUDING BASELINE COMPARISONS WITH NORWEGIAN GENERAL POPULATION CONTROLS
   AbstractFernández-Carballido C (Spain)THU0282THE IMPACT OF COMORBIDITIES ON PHYSICAL FUNCTION IN PATIENTS WITH ANKYLOSING SPONDYLITIS (AS) AND PSORIATIC ARTHRITIS (PSA) ATTENDING RHEUMATOLOGY CLINICS
   AbstractPalsson Olafur (Iceland)THU0283PATIENTS WITH PSORIATIC ARTHRITIS WHO ARE NOT ELIGIBLE FOR RANDOMIZED CLINICAL TRIALS FOR TNF INHIBITORS HAVE SIMILAR TREATMENT RESPONSE AND DRUG SURVIVAL. RESULTS FROM THE ICEBIO REGISTRY.
   AbstractKristensen Lars Erik (Denmark)THU0284HAQ IN PSORIATIC ARTHRITIS IS DRIVEN BY GENDER, INFLAMMATION AND AGEING: OBSERVATIONAL DATA FROM COHORT STUDIES IN UK, DENMARK, ICELAND AND SWEDEN
   AbstractAydin Sibel (Canada)THU0285THE EFFECT OF FAMILY HISTORY ON DISEASE PHENOTYPES IN 1393 PSORIATIC ARTHRITIS PATIENTS
   AbstractNystad Tone (Norway)THU0286PREDICTORS FOR ORTHOPAEDIC SURGERY IN PATIENTS WITH PSORIATIC ARTHRITIS. RESULTS FROM A RETROSPECTIVE COHORT STUDY OF 590 PATIENTS DIAGNOSED 1954-2011, AND FOLLOWED UP UNTIL 2017
   AbstractFavalli Ennio (Italy)THU0287THE PREVALENCE OF REMISSION IN A REAL-LIFE COHORT OF PSORIATIC ARTHRITIS PATIENTS TREATED WITH SYNTHETIC OR BIOLOGIC DISEASE MODIFYING DRUGS
   AbstractAbu Elhija Muhanad (Israel)THU0288IMPLEMENTATION OF THE TREAT TO TARGET CONCEPT IN EVALUATION OF PSORIATIC ARTHRITIS PATIENTS
   AbstractWervers Kim (Netherlands)THU0289BURDEN OF PSORIATIC ARTHRITIS IN DIFFERENT DEFINITIONS OF DISEASE ACTIVITY: COMPARING MINIMAL DISEASE ACTIVITY AND DISEASE ACTIVITY INDEX FOR PSORIATIC ARTHRITIS
  
Poster Tour T8: Cardiovascular co-morbidites in SLE
   ChairMorand Eric F. (Australia)  
   ChairFanouriakis Antonis (Greece)  
   AbstractMendel Arielle (Canada)THU0334PATTERNS OF ASPIRIN USE IN SLE PREGNANCIES WITHIN A MULTINATIONAL INCEPTION COHORT AND RELATIONSHIP TO PREECLAMPSIA RISK FACTORS
   AbstractKim Ji Soong (Korea, Republic Of)THU0335FACTORS ASSOCIATED WITH DEVELOPMENT AND MORTALITY OF PULMONARY HYPERTENSION IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
   AbstractSánchez Hiurma (Spain)THU0336PREDICTORS OF SUBCLINICAL CAROTID ATHEROMATOSIS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RELEVANCE OF ACTIVITY, DAMAGE AND SEVERITY INDEXES.
   AbstractTanna Dhaval (India)THU0337NONBACTERIAL THROMBOTIC ENDOCARDITIS (NBTE) IN SLE: PREVALENCE, CLINICAL CHARACTERISTICS AND SEROLOGICAL PROFILE
   AbstractMok Chi Chiu (Hong Kong)THU0338OUTCOME OF STROKE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A NESTED CASE-CONTROL STUDY
   AbstractSánchez Hiurma (Spain)THU0339IMPACT OF CAROTID ULTRASOUND ON THE CARDIOVASCULAR RISK STRATIFICATION OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS.
   AbstractFasano Serena (Italy)THU0340PROLONGED REMISSION IS ASSOCIATED WITH A REDUCED RISK OF CARDIOVASCULAR DISEASE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
   AbstractPetri Michelle (United States)THU0341LOW VITAMIN D IS ASSOCIATED WITH THROMBOSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS
  
Poster Tour T9: SSc, Myositis, Related Syndromes – A Bouquet of Surprises
   ChairMüller-Ladner Ulf (Germany)  
   ChairKorsten Peter (Germany)  
   AbstractCorreia Chase (United States)THU0387HIGH-THROUGHPUT QUANTITATIVE HISTOLOGY IN SYSTEMIC SCLEROSIS SKIN DISEASE USING COMPUTER VISION
   AbstractAkashi Kengo (Japan)THU0388DIFFERENCES IN CLINICAL COURSES AND SERUM MARKERS OF INTERSTITIAL LUNG DISEASE ASSOCIATED WITH ANTI-AMINOACYL-TRANSFER RNA SYNTHETASE ANTIBODY AND ANTI-MELANOMA DIFFERENTIATION-ASSOCIATED GENE 5 ANTIBODY-POSITIVE POLYMYOSITIS/DERMATOMYOSITIS
   AbstractXanthouli Panagiota (Germany)THU0389BORDERLINE PULMONARY HYPERTENSION WAS ASSOCIATED WITH REDUCED CARDIAC OUTPUT DURING EXERCISE IN PATIENTS WITH CONNECTIVE TISSUE DISEASES
   AbstractDumitru Raluca (United Kingdom)THU0390PATIENTS WITH SYSTEMIC SCLEROSIS DEVELOP FOCAL FIBROSIS OVER TIME, AND INCREASED ECV DIFFUSE FIBROSIS SEEN IN POOR PROGNOSTIC GROUP - A FIRST LONGITUDINAL CARDIAC MRI STUDY
   AbstractSobrino Grande Cristina (Spain)THU0391CLINICAL VALUE OF COMPUTED TOMOGRAPHY FOR THE DIAGNOSIS OF ESOPHAGEAL DYSMOTILITY IN SYSTEMIC SCLEROSIS
   AbstractLepri Gemma (Italy)THU0392SYSTEMIC SCLEROSIS AND PRIMARY BILIARY CHOLANGITIS: AN OVERLAP SYNDROME? PRELIMINARY DATA FROM A MULTICENTRE EUSTAR STUDY
   AbstractBagnato Gianluca (United Kingdom)THU0393THE PREDICTOR OF MALNUTRITION IN SYSTEMIC SCLEROSIS (PREMASS) SCORE: A VALIDATED COMBINED INDEX PREDICTIVE OF FUTURE WEIGHT LOSS IN SYSTEMIC SCLEROSIS.
   AbstractTerenzi Riccardo (Italy)THU0394ENTHESITIS IN SYSTEMIC SCLEROSIS (SSC): AN ULTRASOUND (US) PILOT STUDY
   AbstractMihai Carina (Switzerland)THU0395INFLUENCE OF SETTING AN UPPER LIMIT OF THE MRSS AS AN INCLUSION CRITERION IN SSC CLINICAL TRIALS ON THE RATIO OF SKIN FIBROSIS PROGRESSION VS. IMPROVEMENT – AN ANALYSIS OF THE GENISOS COHORT
   AbstractNg Sue-Ann (Singapore)THU0396COMBINED POSITRON EMISSION TOMOGRAPHY AND MAGNETIC RESONANCE IMAGING FOR THE ASSESSMENT OF SYSTEMIC SCLEROSIS GASTROINTESTINAL INVOLVEMENT

Thursday 14.06.2018 12:00 - 13:30


 
Poster Tour - Poster Area
  
Poster Tour T15: PARE Poster Tour I
   ChairWiek Dieter (Germany)  
   ChairMateus Elsa (Portugal)  
   AbstractNordlund Kim (Sweden)PARE0001#DOESNTSHOWDOESNTEXIST / #SYNSINTEFINNSINTE – AN AWERNESS CAMPAIGN FOR PUBLIC TRANSPORT BY SWEDISH NATIONAL ORGANIZATION FOR YOUNG RHEUMATICS
   AbstractViora Ugo (Italy)PARE0002ADHERENCE TO THERAPY AND PATIENTS ENGAGEMENT IN ITALY: A CLOSE LINK
   AbstractWilson Jennifer (Canada)PARE0003PROVIDING PATIENT AND FAMILY EDUCATION AND SUPPORT FOR CHILDREN WITH RHEUMATIC DISEASES AND THEIR FAMILIES: CASSIE AND FRIENDS ANNUAL FAMILY DAY IN BC
   AbstractBalazova Petra (Slovakia)PARE0004LET’S MOVE WITH ARTHRITIS! - NORDIC WALKING FOR PEOPLE WITH RMDS
   AbstractRichards Dawn (Canada)PARE0005DEVELOPMENT & DISSEMINATION OF A RESOURCE ABOUT METHOTREXATE USE FOR AND BY PATIENTS WITH INFLAMMATORY ARTHRITIS
   AbstractHammitt Katherine (United States)PARE0006A SUMMARY OF KEY FINDINGS FROM THE SJÖGREN'S SYNDROME FOUNDATION'S NATIONAL PATIENT SURVEY RELATED TO TREATMENTS AND MEDICATIONS USED
   AbstractRoffler Martina (Switzerland)PARE0007FAMILY DAY BY THE SWISS LEAGUE AGAINST RHEUMATISM: A NETWORKING EVENT FOR CHILDREN AFFECTED BY JIA AND THEIR FAMILIES
   AbstractUnesi Nina (Sweden)PARE0008SURVEY RESULTS FROM A NATIONWIDE ONLINE AWARENESS CAMPAIGN SUGGEST A CLEAR DIFFERENCE IN TREATMENT AND PERCEPTION OF QUALITY OF HEALTHCARE FOR PATIENTS DIAGNOSED WITH PSORIASIS ARTHRITIS, PSA, VERSUS PATIENTS WITH SYMPTOMS SIMILAR TO PSORIASIS ARTHRITIS I.E. PSORIASIS AND JOINT PAIN.

Thursday 14.06.2018 13:30 - 15:00


 
WIN & HOT Session - Hall 7.1
  
WIN & HOT Session 4
   SpeakerChinoy Hector (United Kingdom)SP0041WIN Session: What is new in the treatment of myositis?
   Speakervan Laar Jacob M. (Netherlands)SP0042HOT Session: Recent advances in the treatment of systemic sclerosis

 
Clinical Science Session - Hall 3
  
Can we halt progression of structural damage in axial SpA?
   ChairSepriano Alexandre (Portugal)  
   ChairGensler Lianne (United States)  
   Speakervan der Heijde Désirée (Netherlands)SP0043How to capture clinically relevant structural progression in axSpA
   SpeakerBaraliakos Xenofon (Germany)SP0044What do we learn from RCTs on the treatment effect on structural progression in axSpA?
   SpeakerLandewé Robert B.M. (Netherlands) Do observational studies give us the answer on the treatment effect on structural progression in axSpA?
   AbstractGensler Lianne (United States)OP0198COMBINED EFFECTS OF TUMOR NECROSIS FACTOR INHIBITORS AND NSAIDS ON RADIOGRAPHIC PROGRESSION IN ANKYLOSING SPONDYLITIS
   AbstractDougados Maxime (Canada)OP0199SUSTAINED REMISSION OF INFLAMMATION IS ASSOCIATED WITH REDUCED STRUCTURAL DAMAGE ON SACROILIAC JOINT MAGNETIC RESONANCE IMAGING IN PATIENTS WITH EARLY AXIAL SPONDYLOARTHRITIS: EVIDENCE TO SUPPORT THE CONCEPT OF TREAT-TO-TARGET

 
Clinical Science Session - Auditorium / Balcony
  
Reproductive issues in Rheumatology
   ChairDolhain Radboud (Netherlands)  
   ChairSchreiber Karen (United Kingdom)  
   SpeakerCutolo Maurizio (Italy)SP0045Oestrogens, immune response and autoimmune diseases
   SpeakerFörger Frauke (Switzerland) Hormonal treatment in patients with different autoimmune rheumatic diseases
   SpeakerØstensen Monika (Norway)SP0046What we need to consider in physician-patient communication on sexual problems in different rheumatic conditions
   SpeakerFischer-Betz Rebecca (Germany)SP0047Challenges in the management of different rheumatologic disorders during pregnancy: lessons from the registries
   AbstractClowse Megan (United States)OP0200CHARACTERISTICS AND OUTCOMES OF PROSPECTIVELY REPORTED PREGNANCIES EXPOSED TO CERTOLIZUMAB PEGOL FROM A SAFETY DATABASE

 
Challenges in Clinical Practice Session - Elicium 2
  
Clinical Challenges in Giant Cell Arteritis in 2018
   ChairMolloy Eamonn S. (Ireland)  
   Chairnot confimed yet  
   PresenterMuratore Francesco (Italy)SP0048Case 1 presentation: A case of pulseless stroke
   DiscussantSalvarani Carlo (Italy) Case 1 discussion: Visual loss and strokes in GCA: clinical manifestations, diagnosis and management
   PresenterMatza Mark A. (United States)SP0049Case 2 presentation: Head Games with GCA and GCS
   DiscussantStone John H. (United States) Case 2 discussion: Advances in therapy of GCA: the role of biologics

 
Clinical Science Session - Hall 7.2
  
Do we still need biopsies to diagnose Sjögren‘s and autoimmune myostitis?
   ChairBootsma Hendrika (Netherlands)  
   ChairFeist Eugen (Germany)  
   SpeakerJousse-Joulin Sandrine (France)SP0050Opportunities and challenges of imaging in Sjögren’s
   SpeakerDiederichsen Louise (Denmark) Value of imaging in myositis in 2018
   SpeakerBootsma Hendrika (Netherlands) The value of histologic confirmation in Sjögren‘s and myositis
   AbstractSciascia Savino (Italy)OP0201CLINICAL OUTCOMES AND RESPONSE TO ANTI-THROMBOTIC TREATMENT AMONG PATIENTS WITH CONCOMITANT LUPUS NEPHRITIS AND THROMBOTIC MICROANGIOPATHY: A MULTICENTER COHORT STUDY
   AbstractVitali Claudio (Italy)OP0202GENE EXPRESSION PROFILES IN PRIMARY SJÖGREN’S SYNDROME WITH AND WITHOUT SYSTEMIC MANIFESTATIONS

 
Paediatric Rheumatology Session - Forum
  
How monogenetic autoinflammatory diseases help to understand and treat rheumatic diseases
   ChairHissink-Mueller Petra (Netherlands)  
   ChairAvcin Tadej (Slovenia)  
   SpeakerFoell Dirk (Germany) Pathogenesis of autoinflammatory diseases mimicking adult-onset rheumatic conditions
   SpeakerOzen Seza (Turkey)SP0051Clinical presentation of Autoinflammatory diseases in children and adults: how not to miss these patients
   SpeakerGattorno Marco (Italy) New therapeutic options: IL-1 and beyond
   AbstractSwart Joost (Netherlands)OP0203SAFETY AND EFFICACY OF INTRAVENOUS ADMINISTRATION OF BONE-MARROW DERIVED MESENCHYMAL STROMAL CELLS IN THERAPY REFRACTORY JUVENILE IDIOPATHIC ARTHRITIS PATIENTS, A PHASE IB/IIA PILOT-STUDY

 
Basic and Translational Science Session - Elicium 1
  
Joint EULAR - EFIS session: I’ve got a B in my bonnet
   ChairMariette Xavier (France)  
   ChairRadbruch Andreas (Germany)  
   SpeakerTrouw Leendert (Netherlands)SP0052Posttranslational modification of autoantibodies in RA
   AbstractMusters Anne (Netherlands)OP0204DOMINANT B CELL RECEPTOR CLONES IN PERIPHERAL BLOOD PREDICT ONSET OF ARTHRITIS IN INDIVIDUALS AT RISK FOR RHEUMATOID ARTHRITIS – A VALIDATION COHORT
   SpeakerRadbruch Andreas (Germany)SP0053Memory plasma cells in systemic auto-immune diseases – a roadblock to tolerance induction
   AbstractFehres Cynthia (Netherlands)OP0205APRIL INDUCES A NOVEL SUBSET OF IGA+ REGULATORY B CELLS THAT SUPPRESS INFLAMMATION THROUGH THE EXPRESSION OF IL-10 AND PD-L1
   SpeakerMauri Claudia (United Kingdom)SP0054Regulatory B cells in rheumatic disease (or in systemic auto-immune diseases)

 
Health Professionals Session - Amtrium
  
Sustainable Healthcare in Rheumatology and the Role of Health Professionals
   Chairde Thurah Annette (Denmark)  
   ChairMintz Sandra (United States)  
   SpeakerVrijhoef Hubertus J.M. (Netherlands)SP0055How can Integrated Healthcare Contribute to Sustainable Healthcare in Rheumatology?
   Speakervan Eijk-Hustings Yvonne (Netherlands) Sustainable Healthcare, and the Role of the Nurses
   SpeakerSlusher Barbara (United States)SP0056Sustainable Healthcare – It Takes a Village
   AbstractSweeney Anne-Marie (Denmark)OP0206-HPROUTPATIENT FOLLOW UP ON DEMAND FOR PATIENTS WITH RHEUMATOID ARTHRITIS - A TWO-YEAR RANDOMIZED CONTROLLED TRIAL

 
Clinical Science Session - Emerald
  
SSc: From registries to trials – do we have sufficient data and the appropriate design?
   ChairKowal-Bielecka Otylia (Poland)  
   ChairSantiago Tania (Portugal)  
   SpeakerMatucci-Cerinic Marco (Italy)SP0057The course of SSc: What can we learn from registries?
   SpeakerRiemekasten Gabriela (Germany) Outcome of organ dysfunction: what can be predicted?
   SpeakerDistler Oliver (Switzerland) Future trial designs to predict and improve outcome
   AbstractFrantz Camelia (France)OP0207THE OUTCOMES OF LIMITED CUTANEOUS SYSTEMIC SCLEROSIS PATIENTS: A EUSTAR DATABASE STUDY.
   AbstractLow Andrea Hsiu Ling (Singapore)OP0208A PROOF-OF-CONCEPT DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL OF PROBIOTICS IN SYSTEMIC SCLEROSIS ASSOCIATED GASTROINTESTINAL DISEASE

 
PARE Session - PARE Room
  
Patient involvement in research: The future of collaborative research. Lessons from the field of rheumatology and beyond
   ChairClausen Jürgen (Germany)  
   ChairGossec Laure (France)  
   SpeakerColeman Courtney (United Kingdom)SP0058Patient involvement in research in pneumology
   SpeakerMcInnes Iain (United Kingdom) EULAR’s RheumaMap – research to transform the lives of people with RMDs
   SpeakerZabalan Codruta (Romania)SP0059EULAR`s patient research partner network – patients future involvement in research
   AbstractDorris Emma (Ireland)OP0209-PARETHE PATIENT VOICE IN ARTHRITIS RESEARCH: A COLLABORATIVE APPROACH TO EMBEDDING PPI INTO RESEARCH STRATEGY
   AbstractSchoemaker Casper (Netherlands)OP0210-PAREDUTCH JUVENILE IDIOPATHIC ARTHRITIS PATIENTS, CARERS AND CLINICIANS CREATING A RESEARCH AGENDA TOGETHER FOLLOWING THE JAMES LIND ALLIANCE METHOD

 
EULAR Projects in Musculoskeletal Imaging - E106 / E107
  
EULAR Projects in Musculoskeletal Imaging
   ChairTerslev Lene (Denmark)  
   ChairNaredo Esperanza (Spain)  
   SpeakerMandl Peter (Austria) Implementation and role of modern musculoskeletal imaging in rheumatological practice in Europe
   SpeakerFournier Gilles (Denmark)SP0060First step in producing EULAR Recommendations for the use of imaging in patient with mechanical back pain
   Speakerd'Agostino Maria-Antonietta (France) EULAR Recommendations for the reporting of musculoskeletal ultrasound studies in rheumatology
   SpeakerGandjbakhch Frédérique (France) Preview on EULAR Recommendations /criteria for the appropriate use of musculoskeletal ultrasound in rheumatology clinical practice

 
Practical Skills Session - D201 / D202
  
Crystal II
   ChairPascual Eliseo (Spain)  
   ChairTausche Anne Kathrin (Germany)  
   TutorSivera Francisca (Spain)  
   TutorPimentao José (Portugal)  
   TutorOliviero Francesca (Italy)  
   TutorNorkuviene Eleonora (Lithuania)  

 
Practical Skills Session - D203 / D204
  
MRI
   ChairOstergaard Mikkel (Denmark)  
   ChairHermann Kay-Geert (Germany)  
   SpeakerOstergaard Mikkel (Denmark)SP0061How to use MRI in the diagnosis and management of psoriatic arthritis + clinical cases
   SpeakerConaghan Philip (United Kingdom)SP0062How to use MRI in the diagnosis and management of osteoarthritis + clinical cases
   SpeakerMoeller-Bisgaard Signe (Denmark) Should we use MRI in clinical remission to guide step-down or step-up of therapy? + clinical cases
   SpeakerHermann Kay-Geert (Germany) How to read full MRIs of axial and peripheral joints in RA and SpA – an introduction

Thursday 14.06.2018 15:30 - 17:00


 
WIN & HOT Session - Hall 7.1
  
WIN & HOT Session 6
   SpeakerNavarro-Compán Victoria (Spain)SP0063WIN Session: About diagnosis and classification of spondyloarthritis
   SpeakerRamiro Sofia (Netherlands)SP0064HOT Session: Recent advances in the management of spondyloarthritis

 
Challenges in Clinical Practice Session - Hall 3
  
To taper or not to taper in RA
   ChairBuch Maya (United Kingdom)  
   ChairMorel Jacques (France)  
   PresenterBaker Kenneth (United Kingdom)SP0065Case 1 presentation: "non biological DMARD case presentation"
   DiscussantIsaacs John D. (United Kingdom) Case 1 discussion: To taper or not to taper non biological DMARD
   PresenterKedra Joanna (France)SP0066Case 2 presentation: "biological DMARD case presentation"
   DiscussantFautrel Bruno (France)SP0067Case 2 discussion: To taper or not to taper biological DMARD

 
Clinical Science Session - Auditorium / Balcony
  
Can we improve the care of gout?
   ChairSo Alexander (Switzerland)  
   ChairPascual Eliseo (Spain)  
   SpeakerDalbeth Nicola (New Zealand)SP0068DECT imaging in gout – ready for prime time?
   SpeakerAbhishek Abhishek (United Kingdom)SP0069Improving adherence in gout therapy
   SpeakerBardin Thomas (France)SP0070What are gout guidelines good for?
   AbstractHammer Hilde (Norway)OP0211ULTRASOUND SHOWS RAPID REDUCTION OF URIC ACID LOAD DURING A TREAT-TO-TARGET APPROACH IN GOUT PATIENTS: RESULTS FROM A LONGITUDINAL STUDY (NOR-GOUT)
   AbstractNarongroeknawin Pongthorn (Thailand)OP0212MOBILE PHONE TEXT MESSAGES FOR IMPROVING ALLOPURINOL ADHERENCE: A RANDOMIZED CONTROLLED TRIAL OF TEXT MESSAGE REMINDERS

 
Clinical Science Session - Elicium 2
  
"Why does BMI matter?"
   ChairBykerk Vivian (United States)  
   ChairAlivernini Stefano (Italy)  
   SpeakerMcInnes Iain (United Kingdom) Fat and inflammation in RA – biological concepts
   SpeakerUhlig Till (Norway)SP0071Is obesity a risk for RA?
   SpeakerKiely Patrick (United Kingdom)SP0072Does obesity influence RA outcomes ?
   AbstractBaganz L (Germany)OP0213WHAT IS THE IMPACT OF POOR PROGNOSTIC FACTORS ON THE ACHIEVEMENT OF LOW DISEASE ACTIVITY OR REMISSION IN PATIENTS WITH RHEUMATOID ARTHRITIS?
   AbstractLinde Louise (Denmark)OP0214BASELINE COMORBIDITIES AND OVERWEIGHT PREDICT FUNCTIONAL STATUS AND HEALTH-RELATED QUALITY OF LIFE 9 YEARS LATER – A LONGITUDINAL COHORT STUDY OF 428 PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING STANDARD CARE.

 
Clinical Science Session - Hall 7.2
  
Musculoskeletal pain; feeding the opioid epidemic
   ChairBerenbaum Francis (France)  
   ChairMcCabe Candy (United Kingdom)  
   SpeakerSmith Blair (United Kingdom)SP0073Opioid prescribing; what’s the problem?
   SpeakerZhang Weiya (United Kingdom) Opioids; do they really work for arthritis pain, or is the benefit mainly placebo?
   SpeakerStein Christoph (Germany)SP0074Are all opioids the same?
   AbstractMuilu Paula (Finland)OP0215TIME-RELATED TRENDS IN OPIOID PURCHASES AMONG PATIENTS WITH EARLY INFLAMMATORY ARTHRITIDES
   AbstractVina Ernest (United States)OP0216EXAMINING MODIFIABLE PSYCHOLOGICAL & SOCIAL HEALTH FACTORS ASSOCIATED WITH USE OF OSTEOARTHRITIS ORAL ANALGESIC TREATMENT

 
From Bench to Bedside - Forum
  
What is lupus – Syndrome or different entities?
   ChairStojanovic Ljudmila (Serbia)  
   ChairDoria Andrea (Italy)  
   SpeakerDaikh David (United States) Pathogenic mechanisms of SLE – what we know in 2018?
   SpeakerMeroni Pier Luigi (Italy)SP0075Autoantibodies - not always what they seem
   SpeakerMosca Marta (Italy) Early SLE versus mimickers – what should we consider in 2018?
   SpeakerJohnson Sindhu (Canada) Presentation of the new SLE classification criteria
   AbstractLauvsnes Maria (Norway)OP0217A PERMEABLE BLOOD-BRAIN BARRIER IS NOT REQUIRED FOR NEUROPSYCHATRIC MANIFESTATIONS IN SLE AND PSS

 
Basic and Translational Science Session - Elicium 1
  
Genetics, epigenetics and disease: is it all in the genes?
   ChairBarton Anne (United Kingdom)  
   Chairvan der Woude Diane (Netherlands)  
   SpeakerSmith Kenneth G.C. (United Kingdom)SP0076Applying genomic approaches and insights to the clinical management of rheumatological disease
   SpeakerKnight Julian (United Kingdom) Functional genomics to understand disease mechanisms
   SpeakerEyre Stephen (United Kingdom) The potential of genetic engineering, in the form of CRISPR/Cas9, in the research and treatment of rheumatological disease
   AbstractVecellio Matteo (United Kingdom)OP0218INVESTIGATING THE REGULATORY SNPS AT THE RUNX3 LOCUS ASSOCIATED WITH ANKYLOSING SPONDYLITIS

 
Health Professionals Session - Amtrium
  
It’s your move: Promoting Physical Activity in people with RMD’s
   Chairvan den Ende Els (Netherlands)  
   ChairDavergne Thomas (France)  
   SpeakerKnittle Keegan (Finland)SP0077New Insights into strategies to effectively promote physical activity
   SpeakerYankov Zhivko (Bulgaria) Patient’s perspective on physical activity: good reasons for being active
   SpeakerHambly Karen (United Kingdom)SP0078The patients perspective on physical activity and work participation in RMDs
   SpeakerIversen Maura D. (United States)SP0079Major achievements and future challenges in physical activity
   AbstractThomsen Tanja (Denmark)OP0219-HPRTHE EFFICACY OF MOTIVATIONAL COUNSELLING AND SMS-REMINDERS ON DAILY SITTING TIME IN PATIENTS WITH RHEUMATOID ARTHRITIS: 22 MONTHS FOLLOW-UP OF A RANDOMISED, PARALLEL-GROUP TRIAL

 
Practical Skills Session - Emerald
  
Data visualization: tables and graphs for publication and presentation I
   SpeakerBoers Maarten (Netherlands)SP0080Data visualisation: tables and graphs for publication and presentation

 
PARE Session - PARE Room
  
Challenges of patient organisations’ in the 21st century
   ChairBetteridge Neil (United Kingdom)  
   ChairElling-Audersch Corinna (Germany)  
   SpeakerKösters Winfried (Germany)SP0081Patient organisations’ challenges in a world that is getting older – less – more colorful
   SpeakerMateus Elsa (Portugal)SP0082How a user-led organisation for RMDs enables citizen participation in Portugal
   SpeakerKoutsogianni Katerina (Greece)SP0083Gaps in patient treatment – What patient organisations can do
   AbstractKrafft Valerie (Switzerland)OP0220-PAREDEVELOPMENT OF THE SWISS NATIONAL STRATEGY “MUSCULOSKELETAL DISEASES” 2017-2022 BY THE SWISS LEAGUE AGAINST RHEUMATISM
   AbstractNgcozana Tanaka (United Kingdom)OP0221-PAREKNOW THEIR NUMBERS: WHAT DO RA PATIENTS KNOW ABOUT THEIR OWN BIOMEDICAL DATA?

 
EULAR Projects in Health Professionals - E106 / E107
  
The EULAR exercise recommendations for physical activity in people with inflammatory arthritis and osteoarthritis
   ChairAppel Esbensen Bente (Denmark)  
   ChairSwinnen Thijs (Belgium)  
   SpeakerIversen Maura D. (United States)SP0084Why physical activity and exercise works
   SpeakerRausch Osthoff Anne-Kathrin (Switzerland)SP0085The evidence for physical activity in inflammatory arthritis and osteoarthritis
   SpeakerNiedermann Karin (Switzerland)SP0086The development and purpose of the Eular recommendations for physical activity in people with inflammatory arthritis and osteoarthritis
   SpeakerNurmohamed Michael (Netherlands)SP0087How to deal with cardiovascular risk factors for physical activity and implement the PA recommendations in the rheumatologic practice
   AbstractPettersson Susanne (Sweden)OP0222-HPRPHYSICAL CAPACITY CONTRIBUTES MARGINALLY IN EXPLAINING VARIATIONS OF FATIGUE IN PERSONS MODERATELY AFFECTED BY RHEUMATOID ARTHRITIS

 
Practical Skills Session - D201 / D202
  
Capillaroscopy I
   ChairCutolo Maurizio (Italy)  
   ChairSmith Vanessa (Belgium)  
   SpeakerSmith Vanessa (Belgium)SP0088The importance to differentiate normal from abnormal capillaroscopic images for an early diagnosis of disease
   SpeakerSulli Alberto (Italy) Scoring the capillaroscopic images
   SpeakerHerrick Ariane L. (United Kingdom)SP0089How to distinguish the major capillaroscopic patterns
   SpeakerCutolo Maurizio (Italy) How capillaroscopy can predict disease severity and prognosis

 
Practical Skills Session - D203 / D204
  
Ultrasound Advanced I
   ChairAmmitzboll Mads (Denmark)  
   ChairKortekaas Marion (Netherlands)  
   SpeakerMöller Ingrid (Spain)SP0090US for pulley lesions – clinical relevance + demo
   SpeakerBong David (Spain)SP0091US for peripheral nerve entrapments + demo
   SpeakerJousse-Joulin Sandrine (France)SP0092US for scoring Sjögren disease
   SpeakerDamjanov Nemanja (Serbia) US for impingement syndromes + demo
   TutorNysom Sara (Denmark)  

Thursday 14.06.2018 17:30 - 19:00


 
Basic and Translational Science Session - Elicium 1
  
Immune senescence and ageing
   Chairvan Wijk Femke (Netherlands)  
   ChairLubberts Erik (Netherlands)  
   SpeakerAkbar Arne (United Kingdom) Cellular senescence and inflammation
   SpeakerGibbons Deena (United Kingdom) The neonatal immune system and inflammation
   AbstractVarela-Eirín Marta (Spain)OP0223TARGETING CHONDROCYTE PLASTICITY VIA CONNEXIN43 MODULATION ATTENUATES CELLULAR SENESCENCE IN OSTEOARTHRITIS
   Speakervan Wijk Femke (Netherlands)SP0093Rejuvenation of the immune system following haematopoietic stem cell transplantation

Friday 15.06.2018 08:15 - 09:45


 
Basic and Translational Science Session - Elicium 1
  
Special delivery: Intercellular communication
   ChairTaams Leonie (United Kingdom)  
   ChairApparailly Florence (France)  
   SpeakerDavis Daniel (United Kingdom)SP0094Membrane nanotubes: reaching out to other cells
   AbstractFu Wenyu (United States)OP0224ADAMTS-12 PROTECTS AGAINST INFLAMMATORY ARTHRITIS THROUGH INTERACTING WITH PROINFLAMMATORY CTGF
   SpeakerWauben Marca H.M. (Netherlands) Extracellular vesicles as couriers of the immune system
   AbstractVan Den Bosch Martijn (Netherlands)OP0225S100A9 MEDIATES ACUTE NOCICEPTIVE PAIN IN EXPERIMENTAL SYNOVITIS
   SpeakerKoenders Marije (Netherlands)SP0095Inflammatory cytokines as key messengers of the immune system

Friday 15.06.2018 10:15 - 11:45


 
WIN & HOT Session - Hall 7.1
  
WIN & HOT Session 8
   SpeakerLortholary Olivier (France) WIN Session: Infectious complications of rheumatic disease (treatment)
   SpeakerRoux Christian (France)SP0096HOT Session: Advances in the management of osteoporosis

 
Abstract Session - Hall 3
  
Abstract Session: Biologics in RA. More, more and more about safety
   ChairCombe Bernard (France)  
   ChairDe Cock Diederik (United Kingdom)  
   AbstractChen Sarah (United States)OP0226RISK OF HOSPITALIZED INFECTION AND INITIATION OF ABATACEPT VERSUS TNF INHIBITORS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS: A PROPENSITY SCORE-MATCHED COHORT STUDY
   AbstractGeorge Michael (United States)OP0227TIMING OF ABATACEPT BEFORE ELECTIVE ARTHROPLASTY AND POST-OPERATIVE OUTCOMES
   AbstractGeorge Michael (United States)OP0228COMPARATIVE RISK OF BIOLOGIC THERAPIES AND RISK OF GLUCOCORTICOIDS IN PATIENTS WITH RHEUMATOID ARTHRITIS UNDERGOING ELECTIVE ARTHROPLASTY
   AbstractJani Meghna (United Kingdom)OP0229THE ASSOCIATION OF BIOLOGIC DRUG-LEVELS WITH INFECTION RISK: RESULTS FROM THE BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER FOR RHEUMATOID ARTHRITIS
   AbstractBoleto Gonçalo (France)OP0230PREDICTORS OF HYPOGAMMAGLOBULINEMIA DURING RITUXIMAB MAINTENANCE THERAPY IN RHEUMATOID ARTHRITIS: A 12-YEAR LONGITUDINAL MULTI-CENTER STUDY
   AbstractBarbulescu Andrei (Sweden)OP0231GASTRO-INTESTINAL PERFORATIONS AMONG RHEUMATOID ARTHRITIS PATIENTS TREATED WITH BIOLOGIC DMARDS: A NATIONWIDE SWEDISH COHORT STUDY
   AbstractHambardzumyan Karen (Sweden)OP0232FEMALE GENDER AND POSITIVE RHEUMATOID FACTOR PREDICT LOW SERUM INFLIXIMAB LEVELS AND POSITIVE ANTI-DRUG ANTIBODIES, WHICH ASSOCIATE WITH TREATMENT FAILURE ON INFLIXIMAB IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS. REPORT FROM THE SWEFOT TRIAL POPULATION
   AbstractBurmester G.R. (Germany)OP0233LONG-TERM SAFETY OF ADALIMUMAB IN ADULT PATIENTS FROM GLOBAL CLINICAL TRIALS ACROSS MULTIPLE INDICATIONS: AN UPDATED ANALYSIS IN 29,987 PATIENTS REPRESENTING 56,951 PATIENT-YEARS

 
Abstract Session - Auditorium / Balcony
  
Abstract Session: Clinical and therapeutic aspects of vasculitis
   ChairMuratore Francesco (Italy)  
   ChairVassilopoulos Dimitrios (Greece)  
   AbstractPark Eun Hye (Korea, Republic Of)OP0234INFLIXIMAB THERAPY IN PATIENTS WITH TAKAYASU ARTERITIS
   AbstractSaadoun David (France)OP0235INTERFERON-FREE ANTIVIRALS FOR HEPATITIS C VIRUS-ASSOCIATED CRYOGLOBULINEMIA VASCULITIS: A LONG-TERM FOLLOW-UP STUDY
   AbstractBerti Alvise (Italy)OP0236RISK OF CARDIOVASCULAR DISEASE AND VENOUS THROMBOEMBOLISM AMONG PATIENTS WITH INCIDENT ANCA-ASSOCIATED VASCULITIS: A 20 YEAR POPULATION-BASED COHORT STUDY
   AbstractMallalieu Navita L (United States)OP0237A COMPARISON OF PK AND PD OUTCOMES OF TOCILIZUMAB IN GIANT CELL ARTERITIS AFTER SC AND IV DOSING
   AbstractMonti Sara (Italy)OP0238ASSOCIATION BETWEEN AGE AT DIAGNOSIS AND CLINICAL PRESENTATION AND OUTCOMES OF ANCA-ASSOCIATED VASCULITIS. ANALYSIS FROM THE DCVAS STUDY
   AbstractNossent Johannes (Australia)OP0239PREGNANCY OUTCOMES IN PATIENTS WITH IGA VASCULITIS.
   AbstractRubbert-Roth Andrea (Switzerland)OP0240FAVOURABLE LONGTERM OUTCOME IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB. REAL LIFE DATA FROM A SWISS CENTER
   AbstractMekinian Arsene (France)OP0241EFFICACY OF TOCILIZUMAB IN TAKAYASU ARTERITIS: MULTICENTER FRENCH RETROSPECTIVE STUDY OF 46 PATIENTS.

 
Abstract Session - Elicium 2
  
Abstract Session: Axial spondyloarthritis: On the interface between healthy and diseased
   ChairPoddubnyy Denis (Germany)  
   Chairde Hooge Manouk (Belgium)  
   AbstractBaraliakos Xenophon (Germany)OP0242FATTY LESIONS DETECTED ON MRI SCANS IN PATIENTS WITH ANKYLOSING SPONDYLITIS ARE BASED ON THE DEPOSITION OF FAT IN THE VERTEBRAL BONE MARROW
   AbstractBaraliakos Xenofon (Germany)OP0243PREVALENCE OF INFLAMMATORY AND CHRONIC CHANGES SUGGESTIVE OF AXIAL SPONDYLOARTHRITIS IN MAGNETIC RESONANCE IMAGES OF THE AXIAL SKELETON IN INDIVIDUALS < 45 YEARS IN THE GENERAL POPULATION AS PART OF A LARGE COMMUNITY STUDY (SHIP)
   Abstractde Winter Janneke (Netherlands)OP0244AN ASAS-POSITIVE MRI OF THE SACROILIAC JOINTS CAN ALSO OCCUR IN HEALTHY INDIVIDUALS, RUNNERS AND WOMEN WITH POSTPARTUM BACK PAIN
   AbstractSeven Sengül (Denmark)OP0245ABILITY OF MRI OF THE SACROILIAC JOINTS TO DIFFERENTIATE PATIENTS WITH AXIAL SPONDYLOARTHRITIS FROM WOMEN, WHO HAVE GIVEN BIRTH, PATIENTS WITH DISC HERNIATION, PERSONS WITH HARD PHYSICAL WORK, LONG-DISTANCE RUNNERS AND HEALTHY MALES.
   AbstractSepriano Alexandre (Netherlands)OP0246INFLAMMATION ON MRI OF SPINE AND SACROILIAC JOINTS IS HIGHLY PREDICTIVE OF STRUCTURAL DAMAGE IN AXIAL SPONDYLOARTHRITIS: THE 5 YEARS DATA OF THE DESIR COHORT
   AbstractSepriano Alexandre (Portugal)OP0247PERFORMANCE OF REFERRAL STRATEGIES FOR SPONDYLOARTHRITIS: A POPULATION-BASED NATIONWIDE STUDY
   AbstractLandewé R. (Netherlands)OP0248POTENTIAL DIFFERENCES IN AXIAL SPONDYLOARTHRITIS DISEASE ACTIVITY CATEGORIZATION USING DIFFERENT MINIMUM VALUES FOR HIGH-SENSITIVITY CRP IN ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE CALCULATION AND DIFFERENT DEFINITIONS OF DISEASE FLARE
   AbstractLambert Robert (Canada)OP0249THE CONTRIBUTION OF STRUCTURAL MRI LESIONS TO DETECTION OF SACROILIITIS IN PATIENTS IN THE ASSESSMENTS IN SPONDYLOARTHRITIS INTERNATIONAL SOCIETY (ASAS) CLASSIFICATION COHORT

 
Abstract Session - Hall 7.2
  
Abstract Session: Present and future treatments for SLE, Sjogren and APS
   ChairIsenberg David (United Kingdom)  
   ChairAlunno Alessia (Italy)  
   AbstractDörner Thomas (Germany)OP0250A RANDOMIZED, DOUBLE-BLIND STUDY TO ASSESS THE SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF LENIOLISIB (CDZ173) IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME
   AbstractMorand Eric (Australia)OP0251ATTAINMENT OF LOW DISEASE ACTIVITY AND REMISSION IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH HIGH DISEASE ACTIVITY IN THE ATACICEPT PHASE IIB ADDRESS II STUDY AND ITS LONG-TERM EXTENSION
   AbstractVan Vollenhoven Ronald (Netherlands)OP0252ORGAN DAMAGE PROGRESSION AND LONG-TERM SAFETY OF BELIMUMAB (BEL) IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): AN EXTENSION OF PIVOTAL PHASE 3 BLISS STUDIES
   AbstractFurie R (United States)OP0253A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT OR PLACEBO ON STANDARD OF CARE IN PATIENTS WITH ACTIVE CLASS III OR IV LUPUS NEPHRITIS
   AbstractUrowitz Murray (Canada)OP0254A PROPENSITY SCORE-MATCHED (PSM) ANALYSIS OF ORGAN DAMAGE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) FROM THE POOLED BLISS LONG-TERM EXTENSION (LTE) TRIALS VERSUS THE TORONTO LUPUS COHORT (TLC)
   AbstractSánchez Pérez Hiurma (Spain)OP0255IDENTIFICATION OF CLINICAL AND SEROLOGICAL PREDICTIVE FACTORS OF RESPONSE TO RITUXIMAB TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS.
   AbstractChen Wei-Sheng (Taiwan, Province of China)OP0256HYDROXYCHLOROQUINE REDUCES RISK OF INCIDENT DIABETES MELLITUS IN PRIMARY SJÖGREN SYNDROME PATIENTS: A PROPENSITY SCORE MATCHED POPULATION-BASED COHORT STUDY
   AbstractColasanti Tania (Italy)OP0257DECREASE OF AUTOPHAGY IN PERIPHERAL BLOOD MONONUCLEAR CELLS FROM SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS TREATED WITH BELIMUMAB

 
Abstract Session - Forum
  
Abstract Session: From cartilage to bone
   ChairSchett Georg (Germany)  
   ChairBlüml Stephan (Austria)  
   AbstractAmantini David (France)OP0258EFFICACY OF THE HIGHLY SELECTIVE ADAMTS-5 INHIBITOR GLPG1972 IN THE RAT MENISCECTOMY MODEL
   AbstractHaqqi Tariq (United States)OP0259ZCCHC5, A LTR RETROTRANSPOSON-DERIVED NEOFUNCTIONALIZED GENE, IS ESSENTIAL FOR THE TRANSCRIPTIONAL ACTIVITY OF SOX9 AND THE EXPRESSION OF COL2A1 IN CHONDROCYTES AND IS DOWNREGULATED IN OA CARTILAGE
   AbstractTopping Louise (United Kingdom)OP0260TARGETING NEUTROPHIL MICROVESICLES TO DAMAGED CARTILAGE USING ANTIBODIES TO POST-TRANSLATIONALLY MODIFIED COLLAGEN II
   AbstractZhu Linyi (United Kingdom)OP0261RETINOIC ACID IS REGULATED BY CARTILAGE INJURY AND IS ANTI-INFLAMMATORY IN HAND OSTEOARTHRITIS
   AbstractVan Helvoort Eefje (Netherlands)OP0262DISEASE MODIFYING EFFECTS OF THE CANINE IL4-10 FUSION PROTEIN IN THE CANINE GROOVE MODEL OF OSTEOARTHRITIS
   AbstractLee Chang-Hoon (Korea, Republic Of)OP0263CLAUDIN-11 REGULATES BONE HOMEOSTASIS VIA BIDIRECTIONAL EPHB4-EPHRINB2 SIGNALING
   AbstractHenrotin Yves (Belgium)OP0264GLUCOSEPANE : A NEW BIOMARKER OF THE SEVERITY OF OSTEOARTHRITIS
   AbstractFenton Chloe (United Kingdom)OP0265LOCAL REACTIVATION OF GLUCOCORTICOIDS BY 11Β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 MEDIATES THE DEVELOPMENT OF GLUCOCORTICOID-INDUCED BONE LOSS

 
Abstract Session - Elicium 1
  
Abstract Session: Seeking the pathophysiology of rheumatoid arthritis and spondylarthritis
   ChairFonseca Joao Eurico (Portugal)  
   ChairElewaut Dirk (Belgium)  
   AbstractVan Baarsen Lisa (Netherlands)OP0266SYNOVIAL TISSUE PROFILING IN AUTOANTIBODY POSITIVE AT RISK INDIVIDUALS REVEALS GENE SIGNATURES ASSOCIATED WITH LATER DEVELOPMENT OF RHEUMATOID ARTHRITIS
   AbstractKolarz Bogdan (Poland)OP0267THE PADI4 GENE PROMOTER METHYLATION LEVEL IS ASSOCIATED WITH ANTI-PADI4 ANTIBODIES LEVEL AND RA ACTIVITY
   AbstractWang Chrong-Reen (-)OP0268APOPTOSIS OF SYNOVIAL FIBROBLASTS INDUCED BY P53-DERIVED HYBRID PEPTIDES THROUGH DISSOCIATING THE BINDING OF P73 WITH IASPP TO INCREASE PUMA AND BAX EXPRESSION
   AbstractFinlay Sam (United Kingdom)OP0269ACTIVATION OF MERTK+CD206+ SUBPOPULATION OF HUMAN SYNOVIAL TISSUE-RESIDENT MACROPHAGES LIMITS INFLAMMATORY RESPONSE.
   AbstractMankia Kulveer (United Kingdom)OP0270IGA ANTI-CCP ANTIBODIES ARE DETECTABLE IN THE SALIVA BUT NOT SPUTUM OF INDIVIDUALS AT-RISK OF DEVELOPING RHEUMATOID ARTHRITIS
   AbstractBenfaremo Devis (Italy)OP0271GASTROINTESTINAL DAMAGE AND MICROBIAL TRANSLOCATION ARE INVOLVED IN THE DEVELOPMENT OF IMMUNE SYSTEM ACTIVATION IN INFLAMMATORY BOWEL DISEASE-ASSOCIATED SPONDYLOARTHRITIS
   AbstractGulino Giulia (Belgium)OP0272INFLAMMATION AT BARRIER TISSUES SUCH AS SKIN AND GUT TRIGGERS MILD JOINT INFLAMMATION AND IS INFLUENCED BY BIOMECHANICAL STRESS INDUCED BY FORCED-RUNNING.
   AbstractVan Duivenvoorde Leonie (Netherlands)OP0273TRANSMEMBRANE TNF SIGNALING THROUGH TNF-RI INDUCES SPA-LIKE INFLAMMATION, WHEREAS SIGNALING THROUGH TNF-RII IS CRUCIAL FOR NEW BONE FORMATION.

 
Abstract Session - Amtrium
  
HPR Abstract Session: Supporting self-management
   ChairNdosi Mwidimi (United Kingdom)  
   ChairEstévez-López Fernando (Spain)  
   AbstractFernandes Giovana (Brazil)OP0274-HPRA FUNCTIONAL EXERCISE PROGRAM IMPROVES PAIN AND HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH FIBROMYALGIA: A RANDOMIZED CONTROLLED TRIAL.
   AbstractMckenna Sean (Ireland)OP0275-HPRTHE EFFECTS OF EXERCISE ON DEPRESSIVE AND ANXIETY SYMPTOMS IN RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
   AbstractAhlstrand Inger (Sweden)OP0276-HPROCCUPATIONAL BALANCE AND ITS RELATION TO PERFORMANCE OF VALUED LIFE ACTIVITIES IN PERSONS WITH RHEUMATOID ARTHRITIS IN WORKING AGE
   AbstractVassalli Mariana (Brazil)OP0277-HPREVALUATION OF THE EFFECTIVENESS OF A PROGRESSIVE RESISTANCE TRAINING PROGRAM FOR PATIENTS WITH FIBROMYALGIA: A RANDOMIZED CONTROLLED TRIAL
   AbstractJust Søren (Denmark)OP0278-HPRPATIENT REPORTED OUTCOMES AND SAFETY IN PATIENTS UNDERGOING SYNOVIAL BIOPSY: COMPARISON OF ARTHROSCOPIC, ULTRASOUND-GUIDED PORTAL-FORCEPS AND ULTRASOUND-GUIDED NEEDLE BIOPSY TECHNIQUES, IN FIVE CENTERS ACROSS EUROPE
   AbstractMartin Melanie (United Kingdom)OP0279-HPRA NATIONAL SURVEY OF THE UTILISATION AND EXPERIENCE OF HYDROTHERAPY IN THE MANAGEMENT OF AXIAL SPONDYLOARTHRITIS: THE PATIENTS' PERSPECTIVE
   AbstractBremander Ann (Sweden)OP0280-HPRPHYSICAL ACTIVITY IN ESTABLISHED RA AND VARIABLES ASSOCIATED WITH PHYSICAL ACTIVITY MAINTENANCE OVER A SEVEN YEAR PERIOD
   AbstractVan Heuckelum Milou (Netherlands)OP0281-HPRPREFERENCES OF PATIENTS WITH RHEUMATOID ARTHRITIS REGARDING DISEASE MODIFYING ANTI-RHEUMATIC DRUGS: A DISCRETE CHOICE EXPERIMENT

 
Abstract Session - Emerald
  
Abstract Session: From Gene to Function
   ChairPadyukov Leonid (Sweden)  
   Chairvan der Helm - van Mil Annette (Netherlands)  
   AbstractLópez-Isac Elena (Spain)OP0282NEW SYSTEMIC SCLEROSIS RISK LOCI IDENTIFIED THROUGH A META-GWAS STRATEGY
   AbstractAcosta-Herrera Marialbert (Spain)OP0283CROSS-DISEASE META-ANALYSIS IN FOUR SYSTEMIC AUTOIMMUNE DISEASES TO IDENTIFY SHARED GENETIC ETIOLOGIES
   AbstractJuge Pierre-Antoine (France)OP0284MUC5B PROMOTER VARIANT RS35705950 IS A RISK FACTOR FOR RHEUMATOID ARTHRITIS - INTERSTITIAL LUNG DISEASE
   AbstractCavalli Giulio (Italy)OP0285IDENTIFICATION OF RARE CODING VARIANTS IN IL-1-RELATED PATHWAYS IN PATIENTS WITH ADULT-ONSET STILL’S DISEASE.
   AbstractAl-Mossawi Mohammad (United Kingdom)OP0286GENOTYPIC EFFECTS OF ANKYLOSING SPONDYLITIS ASSOCIATED IL7R POLYMORPHISMS ARE MEDIATED THROUGH MONOCYTES IN INFLAMMATION
   AbstractYarwood Annie (United Kingdom)OP0287GENE ENHANCERS ASSOCIATED WITH AN INCREASED RISK OF DEVELOPING JIA FAIL TO DOWN REGULATE RUNX1 AFTER CELL STIMULATION
   AbstractEyre Stephen (United Kingdom)OP0288TRANSCRIPTIONAL PERTURBATION OF RA-RISK ENHANCER BY CRISPR-DEADCAS9 REGULATES LONG RANGE GENE TARGETS
   AbstractNagpal Sunil (United States)OP0289INTEGRATION OF CHROMATIN CONFORMATION, TRANSCRIPTOME AND GENOME-WIDE LANDSCAPE OF BRD2 AND BRD4 BINDING MOTIFS IDENTIFIES MECHANISMS OF BET INHIBITOR ACTION IN RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS

 
Abstract Session - PARE Room
  
PARE Abstract Session
   ChairBetteridge Kate (United Kingdom)  
   ChairPchelnikova Polina (Russian Federation)  
   SpeakerMisuno Magdalena (Poland) Edgar Stene Prize 2018: My personal champion – supporting my everyday life with a rheumatic and musculoskeletal disease (RMD)
   AbstractZiegler Connie (Denmark)OP0290-PAREKEEP AN EYE OUT FOR INVISIBLE PAINS - A DANISH CAMPAIGN
   AbstractHolla Jasmijn (Netherlands)OP0291-PARERUNNING WITH RHEUMATISM: A 7-WEEK TRAINING PROGRAMME FOR NOVICE RUNNERS WITH INFLAMMATORY RHEUMATIC DISEASE
   AbstractIacovou Andreas (Cyprus)OP0292-PARETHE CREATION OF THE “AQUA RE-ACTION”.A METHODOLOGICALLY BASED AQUATIC PHYSICAL INTERVENTION / REHABILITATION PROGRAM FOR PEOPLE WITH RMD’S
   AbstractWegscheider Petra (Austria)OP0293-PAREPROBLEMS, GOALS AND URGENT WISHES OF YOUNG AUSTRIANS DIAGNOSED WITH RHEUMATIC DISORDERS: A REPORT
   AbstractHigginbottom Adele (United Kingdom)OP0294-PAREADDRESSING KEY CHALLENGES OF LAY INVOLVEMENT IN MUSCULOSKELETAL RESEARCH: CO-APPLICANTS AND TRIAL STEERING COMMITTEES
   AbstractDe Jong Sija (Netherlands)OP0295-PARE'KWEEK BEGRIP': THE LAUNCH OF OUR CREATIVE CAMPAIGN ACROSS THE NETHERLANDS ON WORLDARTHRITISDAY AIMS TO INCREASE AWARENESS ABOUT RMDS IN GENERAL AND PEOPLE LIVING WITH RMDS IN PARTICULAR.
   AbstractHaroon Nigil (Canada)OP0296THE RISK OF DELIBERATE SELF-HARM IN RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS: A POPULATION-BASED COHORT STUDY

 
Abstract Session - E106 / E107
  
Abstract Session: More money or more education and collaboration?
   ChairFautrel Bruno (France)  
   ChairStocker Juliane (Netherlands)  
   AbstractBergstra Sytske Anne (Netherlands)OP0297DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS PATIENTS IS INFLUENCED BY COUNTRIES’ SOCIOECONOMICS: RESULTS FROM THE METEOR REGISTRY.
   AbstractLopez-Olivo Maria (United States)OP0298THE COMPARATIVE EFFECTIVENESS OF CYCLING TUMOR NECROSIS FACTOR INHIBITOR (TNFI) VERSUS SWAPPING TO A NONTNFI ON PATIENT-REPORTED FUNCTIONAL ABILITY OF PATIENTS WITH RHEUMATOID ARTHRITIS.
   Abstractvan Mulligen Elise (Netherlands)OP0299COST-EFFECTIVENESS OF TAPERING TNF BLOCKERS VERSUS CONVENTIONAL SYNTHETIC DMARDS IN RHEUMATOID ARTHRITIS: FIRST YEAR RESULTS OF THE RANDOMISED CONTROLLED TARA-STUDY
   AbstractBarr Andrew (United Kingdom)OP0300REDUCING AVOIDABLE BIOLOGIC DRUG WASTAGE THROUGH COLLABORATION BETWEEN PATIENTS AND CARE PROVIDERS: THE LEEDS SPONDYLOARTHRITIS SERVICE EXPERIENCE.
   AbstractPazmino Sofia (Belgium)OP0301TWO YEAR COST-EFFECTIVENESS ANALYSIS OF THE CARERA TRIAL IN EARLY RA: A PIGGY BACK STUDY
   AbstractAhrari Azin (Canada)OP0302AN EVALUATION OF UTILIZATION PATTERNS AND APPROPRIATENESS OF LABORATORY TESTS AMONG NEW REFERRALS TO RHEUMATOLOGISTS: CHOOSING UNWISELY!
   AbstractMoltó Anna (France)OP0303SYSTEMATIC SCREENING OF COMORBIDITIES IMPROVES VACCINATION RATES, SKIN CANCER SCREENING AND VITAMIN D SUPPLEMENTATION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS OF THE COMEDSPA PROSPECTIVE, CONTROLLED ,ONE YEAR RANDOMISED TRIAL.
   AbstractKostine Marie (France)OP0304MULTIDISCIPLINARY COLLABORATION AMONG YOUNG SPECIALISTS: RESULTS OF AN ONGOING INTERNATIONAL SURVEY BY YOUNG ORGANISATIONS.

 
Abstract Session - D201 / D202
  
Abstract Session: The changing therapeutic landscape of PsA
   ChairVeale Douglas (Ireland)  
   Chairde Vlam Kurt (Belgium)  
   AbstractKampylafka Eleni (Germany)OP0305DISEASE INTERCEPTION IN PSORIASIS PATIENTS WITH SUBCLINICAL JOINT INFLAMMATION BY INTERLEUKIN 17 INHIBITION WITH SECUKINUMAB – DATA FROM A PROSPECTIVE OPEN LABEL STUDY
   Abstractvan der Heijde D. (Netherlands)OP0306SUBCUTANEOUS SECUKINUMAB INHIBITS RADIOGRAPHIC PROGRESSION IN PSORIATIC ARTHRITIS: ANALYSIS BY PRIOR ANTI-TNF THERAPY AND CONCOMITANT METHOTREXATE USE
   AbstractMease Philip (United States)OP0307EFFICACY AND SAFETY OF RISANKIZUMAB, A SELECTIVE IL-23P19 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS OVER 24 WEEKS: RESULTS FROM A PHASE 2 TRIAL
   AbstractDeodhar Atul (United States)OP0308EFFICACY AND SAFETY RESULTS OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS OVER 56 WEEKS FROM A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
   AbstractMease Philip (United States)OP0309CHARACTERIZATION OF CLINICAL BENEFITS IN SUBJECTS CLASSIFIED AS ACR20 NON-RESPONDERS AT WEEK 104 OF APREMILAST TREATMENT: SUBANALYSIS OF 3 LONG-TERM, PHASE III TRIALS
   AbstractPinto-Tasende Jose (Spain)OP0310PREVALENCE OF RISK FACTORS AND CARDIOVASCULAR EVENTS ACROSS PSORIATIC ARTHRITIS PATIENTS TREATED WITH BIOLOGICAL THERAPY.
   AbstractVandendorpe Ann-Sophie (Belgium)OP0311NOTABLE EVOLUTIONS IN THE CHARACTERISTICS OF PSORIATIC ARTHRITIS CLINICAL TRIALS POPULATIONS IN THE ERA OF BIOLOGICAL TREATMENTS
   AbstractElmamoun Musaab (Canada)OP0312INTERNATIONAL LEAGUE OF ASSOCIATIONS FOR RHEUMATOLOGY (ILAR) TREATMENT RECOMMENDATIONS FOR PSORIATIC ARTHRITIS IN RESOURCE-POOR COUNTRIES

 
Abstract Session - D203 / D204
  
Abstract Session: T/B be or not T/B: adaptive or innate immunity – that is the question
   ChairSchulze-Koops Hendrik (Germany)  
   ChairKoenders Marije (Netherlands)  
   AbstractVergroesen Rochelle (Netherlands)OP0313MOLECULAR ANALYSIS OF ANTI-CITRULLINATED PROTEIN ANTIBODY VARIABLE REGIONS INDICATES ABERRANT SELECTION PROCESSES DURING ACPA B-CELL DEVELOPMENT
   AbstractFloudas Achilleas (Ireland)OP0314B CELL PHENOTYPE AND FUNCTION IN THE SYNOVIUM OF ACPA+ AND ACPA- RHEUMATOID ARTHRITIS PATIENTS.
   AbstractLeong Jing Yao (Singapore)OP0315JUVENILE IDIOPATHIC ARTHRITIS PATIENTS EXHIBIT PERSISTENCE IN CD4 MEMORY T CELLS AND DISTINCT TRANSCRIPTOMIC SIGNATURE DESPITE BIOLOGICS THERAPY
   AbstractDekkema Gerjan (Netherlands)OP0316INCREASED EXPRESSION OF MICRORNA-142-3P IS ASSOCIATED WITH THE FUNCTIONAL DEFECT OF REGULATORY T CELLS IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY ASSOCIATED VASCULITIS.
   AbstractCamacho Encina Maria (Spain)OP0317SCREENING OF AN AUTOANTIBODY SIGNATURE OF EARLY KNEE OSTEOARTHRITIS: DATA FROM THE OSTEOARTHRITIS INITIATIVE.
   AbstractChirivi Renato (Netherlands)OP0318NETOSIS-INHIBITING T-ACPA THERAPY FOR USE IN DIFFERENT NET-DRIVEN HUMAN AUTOIMMUNE DISEASES
   AbstractJablonski Kyle (United States)OP0319LOW AND MODERATE PHYSICAL ACTIVITY REDUCES LOCALIZED IL-1Β IN AN ACUTE MOUSE MODEL OF GOUT BY DOWN-REGULATING TLR2 EXPRESSION ON CIRCULATING NEUTROPHILS
   AbstractVan Den Bosch Martijn (Netherlands)OP0320S100A9 HAMPERS OSTEOCLAST DIFFERENTIATION FROM CIRCULATING PRECURSORS BY REDUCING THE EXPRESSION OF RANK.

Friday 15.06.2018 11:45 - 13:30


 
Poster Tour - Poster Area
  
Poster Tour F10: Clinical and Therapeutic Advances in Vasculitis
   ChairCalabrese Leonard (United States)  
   ChairSchäfer Valentin (Germany)  
   AbstractMuñoz-Vahos Carlos (Colombia)FRI0474CLASSIFICATION OF SKIN INVOLVEMENT IN LEVAMISOLE-ADULTERATED COCAINE INDUCED VASCULOPATHY
   AbstractShchegoleva Elena (Russian Federation)FRI0475LUNG DAMAGE IN PATIENTS WITH MICROSCOPIC POLYANGIITIS
   AbstractMunoz Carlos (Colombia)FRI0476THE MYRIAD OF NEPHRITIS IN LEVAMISOLE-ADULTERATED COCAINE VASCULOPATHY
   AbstractEsatoglu Sinem Nihal (Turkey)FRI0477IMMUNOGENICITY OF INFLIXIMAB AMONG PATIENTS WITH BEHCET’S SYNDROME: A CONTROLLED STUDY
   AbstractMoiseev Sergey (Russian Federation)FRI0478OCCURRENCE OF GENUINE VASCULITIS IN PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
   AbstractSalvarani Carlo (Italy)FRI0479PRIMARY CENTRAL NERVOUS SYSTEM VASCULITIS WITH TUMOR-LIKE PRESENTATION
   AbstractAmano Koichi (Japan)FRI0480TOCILIZUMAB MONO-THERAPY FOR POLYMYALGIA RHEUMATICA ~ RESULTS OF 104-WEEK TREATMENT OF A PROSPECTIVE, SINGLE-CENTER, OPEN TRIAL.
   AbstractYavne Yarden (Israel)FRI0481GIANT CELL ARTERITIS AND INFLAMMATORY BOWEL DISEASE – IS THERE A CONNECTION? RESULTS FROM A POPULATION-BASED STUDY
   AbstractPalm Øyvind (Norway)FRI0482CAUSES OF DEATH IN CONNECTIVE TISSUE DISEASE (CTD’S) AND VASCULITIDES; DATA FROM THE NORWEGIAN CONNECTIVE TISSUE DISEASES AND VASCULITIS REGISTRY (NOSVAR)
   AbstractGiliaev Sergei (Russian Federation)FRI0483SULFASALAZINE AS A POTENTIAL TREATMENT FOR IGA-VASCULITIS (HENOCH-SCHÖNLEIN PURPURA) IN ADULTS.
  
Poster Tour F11: Novelties in osteoarthritis: clinical aspects
   ChairBerenbaum Francis (France)  
   ChairKroon Féline (Netherlands)  
   AbstractCamacho Encina Maria (Spain)FRI0520DISCOVERY OF POTENTIAL BIOMARKERS FOR THE DIAGNOSIS OF EROSIVE AND NODAL HAND OSTEOARTHRITIS.
   AbstractLjuhar Richard (Austria)FRI0521COMBINING FRACTAL- AND ENTROPY-BASED BONE TEXTURE ANALYSIS FOR THE PREDICTION OF OSTEOARTHRITIS: DATA FROM THE MULTICENTER OSTEOARTHRITIS STUDY (MOST)
   AbstractZheng Shuang (Australia)FRI0522VITAMIN D SUPPLEMENTATION IMPROVES DEPRESSION IN KNEE OSTEOARTHRITIS PATIENTS OVER 24 MONTHS
   AbstractCai Guoqi (Australia)FRI0523ZOLEDRONIC ACID PLUS PREDNISOLONE VERSUS ZOLEDRONIC ACID ALONE OR PLACEBO IN THE TREATMENT OF KNEE OSTEOARTHRITIS: A RANDOMISED TRIAL
   AbstractSteen Pettersen Pernille (Norway)FRI0524CENTRAL SENSITIZATION IN HAND OSTEOARTHRITIS AND ASSOCIATIONS WITH RADIOGRAPHIC SEVERITY, SYNOVITIS ON ULTRASOUND AND SYMPTOM DURATION
   AbstractLiao Zetao (China)FRI0525ASSOCIATION BETWEEN DIETARY VITAMIN K INTAKE WITH KNEE SYMPTOMS AND BACK PAIN IN PATIENTS WITH KNEE OSTEOARTHRITIS
   AbstractCallhoff Johanna (Germany)FRI0526THE IMPACT OF DISEASE CHARACTERISTICS IN KNEE AND HIP OSTEOARTHRITIS ON RECOMMENDATIONS FOR JOINT REPLACEMENT
   AbstractHenrotin Yves (Belgium)FRI0527EFFICACY OF BIO-OPTIMIZED CURCUMA EXTRACT (FLEXOFYTOL®) FOR PAINFUL KNEE OSTEOARTHRITIS: DATA FROM COPRA, A MULTICENTER RANDOMIZED CONTROLLED STUDY
   AbstractEathakkattu Antony Benny Samuel (Australia)FRI0528LONG-TERM EFFECTS OF VITAMIN D SUPPLEMENTATION AND MAINTAINING VITAMIN D SUFFICIENCY ON KNEE OSTEOARTHRITIS OVER 5 YEARS.
   AbstractGademan Maaike (Netherlands)FRI0529PREOPERATIVE PAIN SEEMS TO MODIFY THE EFFECT OF RADIOGRAPHIC OSTEOARTHIRITIS SEVERITY ON POSTOPERATIVE PAIN AND FUNCTION 1 YEAR AFTER TOTAL KNEE ARTHROPLASTY.
  
Poster Tour F12: You can do better studies if you know how
   ChairCarmona Loreto (Spain)  
   ChairFanouriakis Antonis (Greece)  
   AbstractHartman Linda (Netherlands)FRI0600METHODS FOR THE ANALYSIS OF ADHERENCE DATA FROM A MEDICATION EVENT MONITORING SYSTEM (MEMS): A SYSTEMATIC REVIEW
   AbstractMeissner Yvette (Germany)FRI0601THE NATURE AND EXTENT OF DATA ITEMS COLLECTED ACROSS EUROPEAN PREGNANCY REGISTERS – FIRST RESULTS OF THE EUROPEAN NETWORK OF PREGNANCY REGISTERS IN RHEUMATOLOGY (EUNEP)
   AbstractDejaco Christian (Italy)FRI0602EULAR ‘POINTS TO CONSIDER’ FOR THE CONDUCTION OF WORKFORCE REQUIREMENT STUDIES IN RHEUMATOLOGY
   AbstractGallardo-Castro Antonio (Mexico)FRI0603THE POTENTIAL USES OF AN INFODEMIOLOGY APPROACH FOR HEALTH-CARE SERVICES IN RHEUMATOLOGY.
   AbstractMeza-Lopez Ana (Mexico)FRI0604TRENDS OF INFORMED CONSENT FORMS FOR INDUSTRY-SPONSORED CLINICAL TRIALS IN RHEUMATOLOGY OVER A 17-YEAR PERIOD: READABILITY, AND ASSESSMENT OF PATIENTS’ HEALTH LITERACY AND PERCEPTIONS.
   AbstractNajm Aurelie (France)FRI0605THE DEVELOPMENT PROCESS OF MOBILE HEALTH APPLICATIONS FOR SELF-MANAGEMENT IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES IS HETEROGENEOUS AND OFTEN INCOMPLETE: RESULTS OF A SYSTEMATIC LITERATURE REVIEW.
   AbstractTerbrueggen Robert (United States)FRI0606THE LIFT STUDY’S DIRECT-TO-PATIENT DESIGN PROVIDES RELIABLE SELF-REPORTED DATA FROM LUPUS PATIENTS
   AbstractBansback Nick (Canada)FRI0607HOW TO DESIGN CLINICAL TRIALS TO BE MORE PATIENT ORIENTED: AN EXAMPLE FROM PREVENTATIVE TREATMENTS FOR RHEUMATOID ARTHRITIS.
   AbstractGavan Sean (United Kingdom)FRI0608A SYSTEMATIC REVIEW AND CRITICAL APPRAISAL OF ECONOMIC EVALUATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS
   AbstractDa Silva Daniela (United Kingdom)FRI0609EUROPEAN MEDICINES AGENCY'S GUIDELINE ON THE CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
  
Poster Tour F13: Searching for outcome measures
   ChairFonseca Joao Eurico (Portugal)  
   ChairRodrigues Ana (Portugal)  
   AbstractVandormael Patrick (Belgium)FRI0640AUTOANTIBODIES TO TWO NOVEL PEPTIDES IN SERONEGATIVE AND EARLY RHEUMATOID ARTHRITIS IN THREE LARGE INDEPENDENT COHORTS
   AbstractJesus Diogo (Portugal)FRI0641DETECTION OF CHANGES IN SLE DISEASE ACTIVITY IS HIGHLY IMPROVED WITH SLE-DAS AS COMPARED TO SLEDAI: DERIVATION AND PRELIMINARY VALIDATION OF THE SLE DISEASE ACTIVITY SCORE (SLE-DAS)
   AbstractALBERT Jean-David (France)FRI0642SEPTIC ARTHRITIS SCREENING WITH A FAST DIAGNOSTIC TOOL USING MID INFRARED SPECTROSCOPY: A MULTI-CENTRIC STUDY
   AbstractDekkers Jacqueline (Netherlands)FRI0643AUTOANTIBODY STATUS IS NOT ASSOCIATED WITH EARLY TREATMENT RESPONSE TO FIRST-LINE METHOTREXATE IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS
   AbstractBoer Aleid (Netherlands)FRI0644THE USE OF MRI-DETECTED SYNOVITIS TO DETERMINE THE NUMBER OF INVOLVED JOINTS FOR THE 2010 ACR/EULAR CLASSIFICATION CRITERIA FOR RHEUMATOID ARTHRITIS – IS IT OF ADDITIONAL BENEFIT?
   AbstractGehin Johanna Elin (Norway)FRI0645ANTI-DRUG ANTIBODIES TO CERTOLIZUMAB PEGOL ARE ASSOCIATED WITH LOW DRUG LEVELS AND REDUCED CLINICAL RESPONSE AT 3 MONTHS IN PATIENTS WITH INFLAMMATORY JOINT DISEASES. DATA FROM THE NOR-DMARD STUDY.
   AbstractGalant Christine (Belgium)FRI0646SYNOVIAL TISSUE HISTOPATHOLOGY FINDINGS IN EARLY RA. IS IT USEFULL? ANALYSIS OF THE BELGIAN CAP48 COHORT.
   AbstractSurendran Sandeep (India)FRI0647ESTIMATION OF MINIMUM CLINICALLY IMPORTANT DIFFERENCE IN FIBROMYALGIA FOR FIQR USING BPI AS THE ANCHOR MEASURE
   AbstractShoop-Worrall Stephanie (United Kingdom)FRI0648DIRECTLY COMPARING LATENT FUNCTIONAL ABILITY IN ADOLESCENTS WITH JIA USING THE CHAQ AND HAQ: AN ITEM RESPONSE THEORY ANALYSIS
   AbstractThudium Christian (Denmark)FRI0649SYSTEMIC LEVELS OF TYPE VI COLLAGEN METABOLITES ARE ELEVATED IN RA PATIENTS AND MODULATED BY TREATMENT WITH ANTI-IL6R THERAPY
  
Poster Tour F14: Education for better patients care
   ChairDamjanov Nemanja (Serbia)  
   ChairBukilica Mirjana (Serbia)  
   AbstractMora Alfonso Sergio (Colombia)FRI0691EFFECT OF AN EDUCATIONAL INTERVENTION BASED ON CLINICAL SIMULATION IN THE DIAGNOSIS OF PSORIATIC ARTHRITIS IN LATIN AMERICAN DERMATOLOGISTS
   AbstractTincani Angela (Italy)FRI0692ANTI-TNF TREATMENTS FOR WOMEN WITH CHRONIC INFLAMMATORY DISEASES: COMPARING ATTITUDES AND PERCEPTIONS OF PHYSICIANS IN EUROPE AND THE US
   AbstractTincani Angela (Italy)FRI0693FEARS AND MISCONCEPTIONS OF WOMEN WITH CHRONIC RHEUMATIC DISEASES ON THEIR JOURNEY TO MOTHERHOOD
   AbstractMohameden Mosaab (United States)FRI0694TWITTER: A NEW PLATFORM FOR PUBLIC HEALTH CAMPAIGNS: SYSTEMIC LUPUS ERYTHEMATOSUS AND RHEUMATOID ARTHRITIS AS EXAMPLES
   AbstractNisar Muhammad (United Kingdom)FRI0695DMARD MONITORING GUIDELINES AND SHARED PRESCRIBING IN PRIMARY CARE - IS MORE EDUCATION REQUIRED?
   AbstractSendra-García Ana (Spain)FRI0696PATIENT ACTIVATION AND ADHERENCE TO BIOLOGICAL THERAPY: PRELIMINARY RESULTS
   AbstractMucke Johanna (Germany)FRI0697EXPECTATIONS, MOTIVATING FACTORS AND BARRIERS TO BASIC RESEARCH AMONG YOUNG RHEUMATOLOGISTS IN GERMANY– RESULTS OF A NATIONAL ONLINE SURVEY
   AbstractAllanore Yannick (France)FRI0698SURVEY OF 1,318 PATIENTS ON THEIR KNOWLEDGE OF THE PULMONARY MANIFESTATIONS OF RHEUMATOID ARTHRITIS AND THEIR NEEDS IN TERMS OF INFORMATION AND FOLLOW-UP
   AbstractChinchilla Sandra (Spain)FRI0699RHEUMATOLOGY TALKS TO THE COMMUNITY: RESULTS OF AN EDUCATIONAL INTERVENTION
   AbstractRat Anne-Christine (France)FRI0700PATIENTS AND RELATIVES COPING WITH INFLAMMATORY ARTHRITIS: A TEAM WORK
  
Poster Tour F15: Bread and butter for clinicians
   Chairde Thurah Annette (Denmark)  
   ChairMarques Andrea (Portugal)  
   AbstractAili Katarina (Sweden)FRI0737-HPRWOMEN’S EXPERIENCES OF COPING WITH CHRONIC WIDESPREAD PAIN – A QUALITATIVE STUDY
   AbstractPrimdahl Jette (Denmark)FRI0738-HPRNURSE-LED SCREENING: CHANGES IN CARDIOVASCULAR RISK PROFILE AND ASSOCIATION TO SOCIO-ECONOMIC STATUS IN OUTPATIENTS WITH INFLAMMATORY ARTHRITIS
   AbstractLeón Leticia (Spain)FRI0739-HPREXPERT RECOMMENDATIONS ON PSYCHOLOGICAL NEEDS OF PATIENTS WITH RHEUMATOID ARTHRITIS
   AbstractShaw Y (United States)FRI0740-HPRRESPONDING RESILIENTLY TO CHRONIC DISEASE: RHEUMATOID ARTHRITIS PATIENTS' DISCOURSE ON COPING STRATEGIES AND CHALLENGES
   AbstractMalm Karina (Sweden)FRI0741-HPRDISCUSSIONS OF LIFESTYLE HABITS AS AN INTEGRAL PART OF CARE MANAGEMENT IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS.
   AbstractBech Bianca (Denmark)FRI0742-HPREULAR RECOMMENDATIONS FOR THE ROLE OF THE NURSE IN THE MANAGEMENT OF CHRONIC INFLAMMATORY ARTHRITIS: 2018 UPDATE
   AbstractPoder Maria Teisner (Denmark)FRI0743-HPRNURSE-LED OUTPATIENT MANAGEMENT FOR IMPROVED TREATMENT OF GIANT CELL ARTERITIS (GCA) AND POLYMYALGIA RHEUMATIC (PMR) IN A RHEUMATOLOGY OUTPATIENT CLINIC
   AbstractKonings-Pijnappels Anouk (Netherlands)FRI0744-HPRTHE ASSOCIATION OF LOCAL DISEASE ACTIVITY AND FOREFOOT DEFORMITIES WITH PLANTAR PRESSURE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND FOREFOOT SYMPTOMS: A CROSS-SECTIONAL STUDY IN THE AMSTERDAM FOOT COHORT
   AbstractVan Heuckelum Milou (Netherlands)FRI0745-HPRIMPLICIT AND EXPLICIT ATTITUDES AND ASSOCIATIONS OF RHEUMATOID ARTHRITIS PATIENTS TOWARDS CONVENTIONAL DISEASE MODIFYING ANTI-RHEUMATIC DRUGS AS POSSIBLE TARGETS FOR IMPROVING MEDICATION ADHERENCE
   AbstractKwok Gladys (Hong Kong)FRI0746NURSING CONSULTATION VERSUS RHEUMATOLOGIST FOLLOW UP FOR PATIENTS WITH STABLE RHEUMATOID ARTHRITIS: A RANDOMIZED CONTROLLED TRIAL
  
Poster Tour F1: Digging deep : basic and translational science in pediatric rheumatology
   ChairPrakken Berent J. (Netherlands)  
   ChairTenbrock Klaus (Germany)  
   AbstractMoura Rita A. (Portugal)FRI0001EXTENDED OLIGOARTICULAR AND POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS PATIENTS HAVE A SIMILAR B CELL PHENOTYPE WHEN COMPARED TO ESTABLISHED RHEUMATOID ARTHRITIS
   AbstractDi Sante Gabriele (Italy)FRI0002ANALYSIS OF B CELLS AND T CELLS SUBPOPULATIONS AND COLLAGEN SPECIFIC T CELL REPERTOIRE IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS
   AbstractLamot Lovro (Croatia)FRI0003EPIGENETIC ALTERATIONS LEADING TO SPECIFIC EXPRESSION PATTERNS OF IMMUNE RESPONSE REGULATING GENE MIGHT BE RESPONSIBLE FOR DISTINCTIVE MICROBIOTA COMPOSITION AND DISEASE DEVELOPMENT IN JUVENILE SPONDYLOARTHRITIS PATIENTS
   AbstractFisher Corinne (United Kingdom)FRI0004GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR IS SECRETED AT HIGHER LEVELS FROM STIMULATED MONOCYTE-DERIVED MACROPHAGES FROM PATIENTS WITH ENTHESITIS RELATED ARTHRITIS AND IS SIGNIFICANTLY ENHANCED BY THE UNFOLDED PROTEIN RESPONSE
   AbstractKasapcopur Ozgur (Turkey)FRI0005THE RELATIONSHIP BETWEEN JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS AND THE TRANSCRIPTION FACTORS NF-KAPPAB AND PPAR-GAMMA
   AbstractJung Jae Hyun (Korea, Republic Of)FRI0006ASSOCIATION BETWEEN INTERLEUKIN-10 POLYMORPHISMS AND JUVENILE IDIOPATHIC ARTHRITIS: A META-ANALYSIS
  
Poster Tour F2: Let’s discuss RA outcomes
   ChairIsaacs John D. (United Kingdom)  
   ChairBaker Kenneth (United Kingdom)  
   AbstractHammer Hilde Berner (Norway)FRI0042TENDER JOINTS HAVE LOW AGREEMENT WITH PATIENT’S EVALUATION OF SPONTANEOUS JOINT PAIN, JOINT SWELLING AND ULTRASOUND VERIFIED SYNOVITIS IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS
   AbstractProvan Sella (Norway)FRI0043TRENDS IN ALL-CAUSE AND CARDIOVASCULAR MORTALITY IN PATIENTS WITH RHEUMATOID ARTHRITIS. A 10- TO 20-YEAR FOLLOW-UP STUDY IN 3 CONSECUTIVE INCIDENCE COHORTS.
   AbstractAhmad H (United States)FRI0044EXCEEDING PREDEFINED THRESHOLDS FOR MRI BONE OEDEMA AND EROSION AND HAQ-DI CAN PREDICT RELAPSE AFTER WITHDRAWAL OF ALL TREATMENT IN MTX-NAÏVE PATIENTS WITH RA IN REMISSION AFTER 12 MONTHS OF ABATACEPT THERAPY IN THE AVERT TRIAL
   AbstractHambardzumyan Karen (Sweden)FRI0045EVALUATION OF SERUM PROTEIN LEVELS AT BASELINE AS PREDICTORS OF RESPONSE TO METHOTREXATE IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: RESULTS FROM SWEFOT TRIAL POPULATION
   AbstractPentony Peta (United Kingdom)FRI0046PATIENTS PRESENTING WITH NEW MUSCULOSKELETAL SYMPTOMS IN THE WRISTS, HANDS AND FEET ENRICHES DETECTION OF ANTI-CCP ANTIBODIES IN PRIMARY CARE – A NATIONAL COHORT STUDY.
   AbstractMankia Kulveer (United Kingdom)FRI0047MRI INTEROSSEOUS TENDON INFLAMMATION OCCURS IN ANTI-CCP POSITIVE AT-RISK INDIVIDUALS AND MAY PRECEDE THE DEVELOPMENT OF SYNOVITIS
   AbstractShimoyama Shuhei (Japan)FRI0048MORTALITY AND MORBIDITY OF RHEUMATOID ARTHRITIS-ASSOCIATED LUNG DISEASE DURING A 10-YEAR PERIOD: A LONGITUDINAL COHORT STUDY OF 103 JAPANESE PATIENTS.
   AbstractYang Jing (China)FRI0049SIGNIFICANT IMPROVEMENT OF RHEUMATOID ARTHRITIS (RA) OUTCOME WITH REPEATED SELF-ASSESSMENT APPLYING SMART SYSTEM OF DISEASE MANAGEMENT (SSDM) MOBILES TOOLS: A COHORT STUDY OF RA PATIENTS EMPOWERING
   AbstractSchett Georg (Germany)FRI0050TOCILIZUMAB ACHIEVES BETTER REPAIR OF FOCAL BONE EROSIONS THAN TUMOR NECROSIS FACTOR INHIBITION IN RA PATIENTS - DATA FROM THE PROSPECTIVE REBONE STUDY ON EROSION REPAIR
   AbstractBöhler Christoph (Austria)FRI0051THE RISK OF ASEPTIC ARTHROPLASTY LOOSENING IN PATIENTS WITH RHEUMATOID ARTHRITIS
  
Poster Tour F3: The Hydra Beast in RA: a multifaceted disease
   ChairNikiphorou Elena (United Kingdom)  
   ChairTaylor Peter C. (United Kingdom)  
   AbstractSon Kyeong Min (Korea, Republic Of)FRI0090ASSOCIATION OF BODY COMPOSITION WITH DISEASE ACTIVITY AND DISABILITY IN RHEUMATOID ARTHRITIS
   AbstractRocha Teresa (Portugal)FRI0091SOMATOSENSORY DYSFUNCTION IN RHEUMATOID ARTHRITIS – A QUANTITATIVE SENSORY TESTING ASSESSMENT
   AbstractBoer Aleid (Netherlands)FRI0092THE ASSOCIATION OF PSYCHOLOGICAL STRESS WITH INFLAMMATION IN PATIENTS WITH CLINICALLY SUSPECT ARTHRALGIA - A STUDY DURING RHEUMATOID ARTHRITIS DEVELOPMENT
   AbstractAlbrecht Katinka (Germany)FRI0093DON’T MISS THE DEPRESSION! COMORBIDITIES IN PATIENTS WITH RHEUMATOID ARTHRITIS AND THEIR IMPACT ON PATIENT-REPORTED OUTCOMES: RESULTS OF CLAIMS DATA LINKED TO A QUESTIONNAIRE SURVEY
   AbstractBurgers Leonie (Netherlands)FRI0094DOES SUBCLINICAL INFLAMMATION EXPLAIN JOINT PAIN IN PATIENTS WITH ARTHRALGIA SUSPICIOUS FOR PROGRESSION TO RHEUMATOID ARTHRITIS? - RESULTS OF A CROSS-SECTIONAL MRI-STUDY.
   AbstractDomínguez Casas Lucía Cristina (Spain)FRI0095ANTI-TNFΑ VERSUS RITUXIMAB IN REFRACTORY PERIPHERAL ULCERATIVE KERATITIS ASSOCIATED TO RHEUMATIC DISEASES. MULTICENTER STUDY OF 24 PATIENTS
   AbstractPedersen Kathrine (Denmark)FRI0096IS SIDE EFFECTS AND TREATMENT RESPONSE TO METHOTREXATE ASSOCIATED TO COMORBIDITY IN EARLY RHEUMATOID ARTHRITIS
   AbstractLyngfelt Lovisa (Sweden)FRI0097EXPRESSION OF UNCOUPLING PROTEIN-1 IN SUBCUTANEOUS FAT REDUCES THE TOTAL CHOLESTEROL LEVEL AND CARDIOVASCULAR RISK IN FEMALE RA PATEINTS
   AbstractHsieh Tsu-Yi (Taiwan, Province of China)FRI0098HEPATIC SAFETY IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO RECEIVED ISONIAZID FOR LATENT TUBERCULOSIS: POST-HOC ANALYSIS FROM PHASE 3 BARICITINIB STUDIES
   AbstractSoriano Enrique (Argentina)FRI0099LIVER ENZYME ABNORMALITIES AFTER TOFACITINIB TREATMENT IN PATIENTS WITH HEPATIC STEATOSIS FROM THE RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND PSORIASIS CLINICAL PROGRAMMES
  
Poster Tour F4: SpA Pathophysiology: of mice and men...
   ChairElewaut Dirk (Belgium)  
   Chairvan den Bosch Filip (Belgium)  
   AbstractAsquith Mark (United States)FRI0148A STUDY OF MICROBIAL TRANSLOCATION IN AN ANIMAL MODEL OF SPONDYLOARTHRITIS
   AbstractLiu Hui (China)FRI0149INFLAMMATION INTENSITY-DEPENDENT EXPRESSION OF OSTEOINDUCTIVE WNT PROTEINS IS CRITICAL FOR ECTOPIC NEW BONE FORMATION IN ANKYLOSING SPONDYLITIS
   Abstractvan Duivenvoorde Leonie (Netherlands)FRI0150MTOR BLOCKADE BY RAPAMYCIN DECREASES ARTHRITIS AND SPONDYLITIS DEVELOPMENT AND SEVERITY IN HLA-B27 TRANSGENIC RATS.
   AbstractKwon Euijong (Korea, Republic Of)FRI0151PROTEIN INHIBITOR OF ACTIVATED STAT3 PREVENTS PERIPHERAL ARTHRITIS AND GUT INFLAMMATION BY REGULATING TH17/TREG CELL IMBALANCE VIA STAT3 SIGNALING IN MICE MODEL OF SPONDYLOARTHRITIS
   AbstractCiccia Francesco (Italy)FRI0152INFLAMMASOMES ACTIVATION OCCURS IN THE INFLAMED TISSUES OF AS PATIENTS AND DRIVES IL-23 EXPRESSION
   AbstractHoyt Kathleen (United States)FRI0153ROLE OF ROR GAMMA T INHIBITION IN THE IL-23 MINICIRCLE MODEL AND SPA PATIENT TISSUE CULTURES
   AbstractRademacher Judith (Germany)FRI0154ADDED VALUE OF BIOMARKERS COMPARED TO ROUTINE CLINICAL PARAMETERS FOR THE PREDICTION OF RADIOGRAPHIC SPINAL PROGRESSION IN AXIAL SPONDYLOARTHRITIS
   AbstractStavre Zheni (United States)FRI0155GENES REGULATING BONE HOMEOSTASIS ARE DIFFERENTIALLY EXPRESSED AT PERIPHERAL VERSUS AXIAL ENTHESIAL SITES IN AN ANIMAL MODEL OF SPONDYLOARTHRITIS
   AbstractRuiz-Limon Patricia (Spain)FRI0156AN ANTIMICROBIAL MECHANISM, NETOSIS, IS POTENTIALLY INVOLVED IN ANKYLOSING SPONDYLITIS PATHOGENESIS
   AbstractLadehesa Lourdes (Spain)FRI0157ALTERED EXPRESSION OF THE SPLICEOSOME COMPONENTS IN LEUKOCYTES SUBSETS FROM PATIENTS WITH ANKYLOSING SPONDYLITIS: ASSOCIATION TO DISEASE PATHOGENESIS AND THERAPEUTIC RESPONSE
  
Poster Tour F5: Spondyloarthritis: It looks as if it is only imaging that matters
   ChairLandewé Robert B.M. (Netherlands)  
   ChairMoltó Anna (France)  
   AbstractMaksymowych Walter (Canada)FRI0169FIRST VALIDATION OF CONSENSUS DEFINITIONS FOR MRI LESIONS IN THE SACROILIAC JOINT BY THE ASSESSMENTS IN SPONDYLOARTHRITIS INTERNATIONAL SOCIETY (ASAS) MRI GROUP
   AbstractMaksymowych Walter (Canada)FRI0170CONSENSUS DEFINITIONS FOR MRI LESIONS IN THE SACROILIAC JOINTS OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: FIRST ANALYSIS FROM THE ASSESSMENTS IN SPONDYLOARTHRITIS INTERNATIONAL SOCIETY (ASAS) CLASSIFICATION COHORT
   AbstractSepriano Alexandre (Netherlands)FRI0171WHICH IMAGING OUTCOMES FOR AXSPA ARE MOST SENSITIVE TO CHANGE? A 5-YEAR ANALYSIS OF THE DESIR COHORT
   AbstractSepriano Alexandre (Netherlands)FRI0172INFLAMMATION ON MRI OF THE SACROILIAC JOINTS IS HIGHLY PREDICTIVE OF STRUCTURAL DAMAGE IN AXIAL SPONDYLOARTHRITIS PATIENTS IN CLINICAL PRACTICE: DATA FROM THE ASAS AND DESIR COHORTS
   AbstractPoddubnyy Denis (Germany)FRI0173IDENTIFICATION OF A TYPICAL PATTERN OF MRI LESIONS OF SACROILIAC JOINTS IN PATIENTS WITH OSTEITIS CONDENSANS ILII AS COMPARED TO AXIAL SPONDYLOARTHRITIS
   AbstractRamiro Sofia (Netherlands)FRI0174SPINAL RADIOGRAPHIC PROGRESSION IN EARLY AXIAL SPA: 5-YEAR DATA FROM THE DESIR COHORT
   AbstractProtopopov Mikhail (Germany)FRI0175RATES AND PREDICTORS OF RADIOGRAPHIC SACROILIITIS PROGRESSION AFTER CENTRAL READING IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS FROM THE ASAS COHORT: A 5-YEAR FOLLOW-UP STUDY.
   AbstractLee Seunghun (Korea, Republic Of)FRI0176PERFORMANCE OF SPINAL AND SACROILIAC JOINT MRI FINDINGS IN PATIENTS WITH AXSPA
   AbstractRenson Thomas (Belgium)FRI0177ASSESSING THE VALUE OF WHOLE BODY MAGNETIC RESONANCE IMAGING AS TO CLINICAL EXAMINATION TO PREDICT REMISSION AND RELAPSE IN EARLY PERIPHERAL SPONDYLOARTHRITIS.
  
Poster Tour F6: Gout epidemiology and therapy
   ChairSo Alexander (Switzerland)  
   ChairAbhishek Abhishek (United Kingdom)  
   AbstractNorkuviene Eleonora (Lithuania)FRI0220ULTRASOUND IN ASSESSMENT OF DISEASE COURSE IN GOUT: THE 24 MONTH SINGLE-CENTRE PROSPECTIVE OBSERVATIONAL STUDY
   AbstractZobbe Kristian (Denmark)FRI0221GOUT IS ASSOCIATED WITH AN INCREASED RISK OF CANCER - A NATIONWIDE COHORT STUDY INCLUDING OVER 70,000 GOUT PATIENTS
   AbstractTsoi Man Fung (Hong Kong)FRI0222ASSOCIATION BETWEEN BLOOD LEAD LEVELS AND GOUT: THE UNITED STATES NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY 2007-2014.
   AbstractUghi Nicola (Italy)FRI0223IS PERFORMANCE OF THE 2015 ACR/EULAR GOUT CLASSIFICATION CRITERIA AFFECTED BY DISEASE DURATION AND GENDER? RESULTS FROM AN ITALIAN MULTICENTRE STUDY FOCUSED ON THE MANAGEMENT OF CRYSTAL-INDUCED ARTHRITIDES (ATTACK STUDY).
   AbstractYu Jinquan (China)FRI0224MANAGEMENT TO REDUCING LIVER FUNCTION IMPAIRMENT WHEN INITIATING FEBUXOSTAT FOR GOUT BASED ON THE PREDICTION NOMOGRAM
   AbstractChang Juliana (United States)FRI0225ELECTRONIC CONSULTATION UTILITY IN THE MANAGEMENT OF GOUT
   AbstractElisеev Maxim (Russian Federation)FRI0226ASSESSMENT OF THERAPY ADHERENCE AND TREATMENT RESULTS IN GOUT PATIENTS WHO ATTENDED SCHOOLS FOR PATIENTS AND IN THOSE WHO DID NOT.
   AbstractBardin Thomas (Viet Nam)FRI0227RISK FACTORS FOR SKIN REACTIONS TO ALLOPURINOL IN THE KINH POPULATION OF VIETNAM
   AbstractDehlin Mats (Sweden)FRI0228URATE CORRELATES TO CORONARY ARTERY CALCIFICATION BUT NOT TO INTIMA MEDIA THICKNESS
   AbstractChristiansen Sara (Denmark)FRI0229THE VALIDITY OF THE OMERACT ULTRASOUND DEFINITIONS OF GOUT ELEMENTARY LESIONS IN THE DIAGNOSIS OF GOUT.
  
Poster Tour F7: The enemy in us
   ChairHerrmann Martin (Germany)  
   ChairZhao Yi (China, People's Republic of)  
   AbstractZhou Ying-Bo (China)FRI0255INJECTION OF CD40 DNA VACCINE AMELIORATES THE AUTOIMMUNE PATHOLOGY OF NON-OBESE DIABETIC MICE WITH SJOGREN’S SYNDROME
   AbstractGuo Xiang (United States)FRI0256EFFECTS OF ANIFROLUMAB ON OXIDATIVE STRESS AND MACROPHAGE ACTIVATION: NOVEL BIOMARKERS AND IMPACT OF TYPE I INTERFERON BLOCKADE IN SYSTEMIC LUPUS ERYTHEMATOSUS
   AbstractHagberg Niklas (Sweden)FRI0257THE STAT4 SLE RISK ALLELE RS7574865[T] IS ASSOCIATED WITH INCREASED IL-12-INDUCED IFN-GAMMA PRODUCTION IN T CELLS FROM SLE PATIENTS
   AbstractSmith Eve (United Kingdom)FRI0258COMPARISON OF ELISA AND MULTIPLEX TECHNIQUES FOR QUANTIFYING A URINE BIOMARKERS PANEL FOR LUPUS NEPHRITIS IN CHILDREN
   AbstractJacobs Barbara (United States)FRI0259IN VITRO INDUCED REGULATORY T-CELLS CAN AMELIORATE SEVERITY OF PRISTANE INDUCED LUPUS (PIL)
   AbstractPerricone Carlo (Italy)FRI0260POLYMORPHISMS OF STAT4 AND MIR146A PREDICT THE ACHIEVEMENT OF 5 YEARS REMISSION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
   AbstractHamada Ahmed (Egypt)FRI0261ASSESSMENT OF AUTOPHAGE FUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS IN RESPECT OF HYPERLIPIDEMIA AND IMMUNOSUPPRESSIVE DRUGS
   AbstractMouries-Martin Suzanne (France)FRI0262MONITORING DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS WITH DIGITAL ELISA QUANTIFICATION OF SERUM INTERFERON-Α
   AbstractVerstappen Gwenny (Netherlands)FRI0263CHARACTERIZATION OF EPITHELIUM-ASSOCIATED FCRL4+ B CELLS FROM PAROTID GLANDS OF PATIENTS WITH SJÖGREN’S SYNDROME USING SINGLE CELL RNA SEQUENCING
  
Poster Tour F8: Back to the future: how to mix the old and new treatments for SLE, Sjogren and APS
   ChairTincani Angela (Italy)  
   ChairFredi Micaela (Italy)  
   AbstractCouture Priscille (France)FRI0302SYSTEMIC LUPUS ERYTHEMATOSUS-ASSOCIATED THROMBOTIC MICROANGIOPATHIES IN 60 PATIENTS: CLINICAL FEATURES, PROGNOSIS AND TREATMENT IN A FRENCH MULTICENTRIC COHORT.
   Abstractvan Vollenhoven Ronald (Netherlands)FRI0303EFFICACY AND SAFETY OF USTEKINUMAB IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A PHASE 2, RANDOMIZED PLACEBO-CONTROLLED STUDY
   AbstractMiao Miao (China)FRI0304LONG-TERM AND LOW-DOSE IL-2 THERAPY MAINTAINS THE TH17/TREG BALANCE IN PERIPHERAL BLOOD OF PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME
   AbstractAranow Cynthia (United States)FRI0305PHASE 2 TRIAL OF INDUCTION THERAPY WITH ANTI-CD20 (RITUXIMAB) FOLLOWED BY MAINTENANCE THERAPY WITH ANTI-BAFF (BELIMUMAB) IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS
   AbstractHsu Hailing (United States)FRI0306DEVELOPMENT OF BAFF AND ICOSL BISPECIFIC INHIBITOR AMG 570 FOR SLE TREATMENT
   AbstractBodewes Iris (Netherlands)FRI0307TBK1 INHIBITION DOWNREGULATES EXPRESSION OF INTERFERON TYPE I AND THE UPREGULATED EXPRESSION OF RIG-LIKE RECEPTORS AND DNA-SENSING RECEPTORS IN INTERFERON POSITIVE PRIMARY SJÖGREN’S SYNDROME PATIENTS
   AbstractLiu Bo (China)FRI0308CORTICOSTEROIDS COMBINED WITH DOUBLET OR SINGLE-AGENT IMMUNOSUPPRESSIVE THERAPY FOR ACTIVE PROLIFERATIVE LUPUS NEPHRITIS
   AbstractParodis Ioannis (Sweden)FRI0309THE IMPACT OF BELIMUMAB AND RITUXIMAB ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
   AbstractAdamichou Christina (Greece)FRI0310ACHIEVEMENT OF LOW DISEASE ACTIVITY IN LUPUS PATIENTS TREATED WITH BELIMUMAB IS INDEPENDENT OF SEROLOGIC STATUS AT BASELINE: A REAL-LIFE OBSERVATIONAL STUDY
   AbstractVan Dam Laura (Netherlands)FRI0311THE EFFECT OF B CELL TARGETED THERAPIES ON AUTOANTIBODIES AND EXCESSIVE NEUTROPHIL EXTRACELLULAR TRAP FORMATION IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
  
Poster Tour F9: Shaping Pathophysiology: New Molecules – New Views on Pathways in SSc, Myositis and Related Syndromes
   ChairMüller-Ladner Ulf (Germany)  
   Chairde Vries Jeska (Netherlands)  
   AbstractXu Shiwen (United Kingdom)FRI0396THE ATM KINASE AND PTEN, DRIVE MYOFIBROBLASTS DIFFERENTIATION BY ACTIVATING THE TGFΒ AUTOCRINE LOOP
   AbstractGiannini Margherita (Italy)FRI0397PECULIAR EXPRESSION OF AUTOPHAGY BIOMARKERS IN NECROTIZING AUTOIMMUNE MYOPATHY MUSCLE
   AbstractLindsay Ross (United States)FRI0398SL-401, A NOVEL TARGETED THERAPY DIRECTED TO THE INTERLEUKIN-3 RECEPTOR (CD123), KILLS PLASMACYTOID DENDRITIC CELLS FROM SYSTEMIC SCLEROSIS PATIENTS.
   AbstractCorallo Claudio (Netherlands)FRI0399RNAI-BASED IDENTIFICATION OF NOVEL DRUG TARGETS TO REDUCE ENDOTHELIAL TO MESENCHYMAL TRANSITION (ENDOMT) IN HUMAN DERMAL MICROVASCULAR ENDOTHELIAL CELLS: A TARGET DISCOVERY APPROACH FOR SCLERODERMA.
   AbstractMerlevede Benita (Germany)FRI0400THE AP1 TRANSCRIPTION FACTOR CJUN AMPLIFIES HEDGEHOG-INDUCED FIBROBLAST ACTIVATION AND TISSUE FIBROSIS
   AbstractZehender Ariella (Germany)FRI0401THE TYROSINE PHOSPHATASE SHP2 CONTROLS TGFΒ-INDUCED STAT3 SIGNALING TO REGULATE FIBROBLAST ACTIVATION AND FIBROSIS
   AbstractKozlova Anastasiia (Switzerland)FRI0402MICRORNA-125B REGULATES APOPTOSIS IN SYSTEMIC SCLEROSIS
   AbstractBoyer Olivier (France)FRI0403MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS IN MYOSITIS: A CENTRAL PATHOGENIC PATHWAY FROM MOUSE TO MAN.
   AbstractSoldano Stefano (Italy)FRI0404CHARACTERIZATION OF A MONOCYTES/MACROPHAGES CELL SUBSET CO-EXPRESSING BOTH M1 AND M2 PHENOTYPE MARKERS IN SYSTEMIC SCLEROSIS PATIENTS
   AbstractYue Xiaoyang (Germany)FRI0405A NOVEL ANIMAL MODEL FOR SYSTEMIC SCLEROSIS INDUCED BY IMMUNIZATION OF ANGIOTENSIN II RECEPTOR 1
   AbstractTam Angela (United Kingdom)FRI0406INCREASED FREQUENCY OF CIRCULATING CD163+ NON-CLASSICAL MONOCYTES IN SCLERODERMA AND ENHANCED DUAL POLARISATION TOWARDS M1 AND M2-LIKE PHENOTYPES IN MONOCYTE-DERIVED MACROPHAGES

Friday 15.06.2018 12:00 - 13:30


 
Poster Tour - Poster Area
  
Poster Tour F16: PARE Poster Tour II
   ChairCaeyers Nele (Belgium)  
   ChairBoteva Boryana (Bulgaria)  
   AbstractRobertson Nathalie (Canada)PARE0009CANADIAN ARTHRITIS PATIENT ALLIANCE: UNDERSTANDING MEMBER PROFILES AND NEEDS
   AbstractPhoka Charalambous Androulla (Cyprus)PARE0010NATURALLY HEALING THE CHRONIC PAIN AND HEALTH MAINTENANCE
   AbstractDiao Tidiane (Sweden)PARE0011FUNKA UTAN SKAM TO FUNCTION WITHOUT SHAME
   AbstractGrange Laurent (France)PARE0012THE FRENCH PATIENT'S ASSOCIATION AFLAR: HAS GENERATED THE FRENCH NATIONAL ALLIANCE AGAINST OSTEOPOROSIS AND THE FIRST GENERAL CONVENTION FOR OSTEOPOROSIS , THAT IS A CAMPAIGN TO CREATE A NATIONAL PROMOTING TOOL TO IMPROVE THE MANAGEMENT OF OSTEOPOROSIS.: 7 PRIORITIES TO BETTER TREAT PATIENTS I
   AbstractGrygielska Jolanta (Poland)PARE0013SOURCES OF INFORMATION AND KNOWLEDGE ABOUT RHEUMATIC DISEASES AMONG PEOPLE WITH RHEUMATIC DISEASES IN POLAND AND IN OTHER EUROPEAN COUNTRIES
   AbstractProulx Laurie (Canada)PARE0014GETTING THE PULSE ON WORKPLACE EXPERIENCES AND ACCOMMODATIONS
   AbstractDe Jong Sija (Netherlands)PARE0015LARGE-SCALE SURVEY OFFERS GENERAL INSIGHT AND BASIS FOR POLICY DRAFTING
   AbstractCelano Antonella (Italy)PARE0016THE ROLE OF EMPATHY QUOTIENT IN PATIENT-PHYSICIAN COMMUNICATION: A TOOL TO IMPROVE MEDICATION ADHERENCE
   AbstractOlsder Wendy (Netherlands)PARE0017SUPPORTING YOUNG PEOPLE WITH RMDS IN MANAGING ISSUES AROUND RELATIONSHIPS, PREGNANCY AND SEXUALITY

Friday 15.06.2018 13:30 - 15:00


 
WIN & HOT Session - Hall 7.1
  
WIN & HOT Session 7
   SpeakerKapiteijn Ellen (Netherlands)SP0097WIN Session: Check-point inhibitors: What are they used for?
   SpeakerCalabrese Leonard (United States)SP0098HOT Session: Immune related adverse events upon check-point inhibitors

 
Challenges in Clinical Practice Session - Hall 3
  
Challenges in systemic lupus diagnosis
   ChairMeroni Pier Luigi (Italy)  
   ChairPons-Estel Guillermo (Argentina)  
   PresenterZen Margherita (Italy)SP0099Case 1 presentation: Painful dyspnea
   DiscussantDoria Andrea (Italy) Case 1 discussion: Shrinking lung
   PresenterFanouriakis Antonis (Greece)SP0100Case 2 presentation: NEUROPSYCHIATRIC LUPUS OR NOT?
   DiscussantBoumpas Dimitrios (Greece) Case 2 discussion: Diagnosis of neuropsychiatric SLE: the problem of attribution

 
From Bench to Bedside - Auditorium / Balcony
  
Pathophysiology and biomarkers in PsA: what impact?
   ChairVeale Douglas (Ireland)  
   ChairElewaut Dirk (Belgium)  
   SpeakerLories Rik (Belgium) Pathophysiology of PsA: what is the role of cells and cytokines?
   SpeakerLauwerys Bernard (Belgium) Synovial markers in inflammatory arthritis: is this the new holy grail?
   SpeakerRitchlin Christopher T. (United States) Serum biomarkers in PsA: a novel tool in diagnosis and therapeutic monitoring?
   SpeakerSchett Georg (Germany) Does it matter to the clinician: can pathophysiological knowledge lead to better patient care?
   AbstractMiyagawa Ippei (Japan)OP0321PRECISION MEDICINE USING DIFFERENT BIOLOGICAL DMARDS BASED ON CHARACTERISTIC PHENOTYPES OF PERIPHERAL T HELPER CELLS IN PSORIATIC ARTHRITIS

 
Clinical Science Session - Elicium 2
  
The art of diagnosis of axial SpA
   ChairNavarro-Compán Victoria (Spain)  
   ChairDeodhar Atul (United States)  
   SpeakerRudwaleit Martin (Germany) What is early axial SpA? Challenges for an early diagnosis
   SpeakerMoltó Anna (France) The symptom of back pain – disentangle between inflammatory, degenerative or both?
   Speakervan den Bosch Filip (Belgium) Clinical impact of an early diagnosis in axial SpA
   AbstractNavarro-Compán Victoria (Spain)OP0322ARE WE TREATING WITH BIOLOGICAL THERAPIES WOMEN PATIENTS WITH REAL NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS?
   AbstractOrtolan Augusta (Italy)OP0323ARE GENDER-SPECIFIC APPROACHES NEEDED IN DIAGNOSING EARLY AXIAL SPONDYLOARTHRITIS? DATA FROM THE SPONDYLOARTHRITIS CAUGHT EARLY COHORT

 
The Young Rheumatologist - Hall 7.2
  
Understanding the language of basic research, epidemiology and health services articles
   ChairMcInnes Iain (United Kingdom)  
   ChairCarmona Loreto (Spain)  
   SpeakerMcInnes Iain (United Kingdom) Understanding the language of basic research articles
   SpeakerDixon William G. (United Kingdom)SP0101Understanding the language of epidemiology articles
   SpeakerCarmona Loreto (Spain)SP0102Understanding the language of health services articles
   AbstractGrøn Kathrine (Denmark)OP0324RISK OF SERIOUS INFECTIONS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ABATACEPT, RITUXIMAB AND TOCILIZUMAB IN DENMARK AND SWEDEN
   AbstractGandrup Julie (United States)OP0325EFFECT OF THREE HEALTH IT INTERVENTIONS ON RA DISEASE ACTIVITY SCORE DOCUMENTATION IN AN ACADEMIC RHEUMATOLOGY CLINIC

 
Clinical Science Session - Forum
  
Joint EULAR - ESSR Session on: The role of MR imaging in rheumatic diseases and its clinical implications
   ChairSieper Joachim (Germany)  
   ChairReijnierse Monique (Netherlands)  
   SpeakerOstendorf Benedikt (Germany)SP0103Indications and clinical implications of MR imaging in RA
   SpeakerFaculty (-) Q&A
   SpeakerGrainger Andrew (United Kingdom) MRI in early and established RA - what is the added value
   SpeakerFaculty (-) Q&A
   SpeakerOstergaard Mikkel (Denmark)SP0104Indications and clinical implications of MR imaging in SpA
   SpeakerFaculty (-) Q&A
   SpeakerEshed Iris (Israel)SP0105MRI in early and established SpA - what is the added value
   SpeakerFaculty (-) Q&A

 
Basic and Translational Science Session - Elicium 1
  
The stromal link to inflammation
   ChairGay Steffen (Switzerland)  
   ChairKlein Kerstin (Switzerland)  
   SpeakerBuckley Chris (United Kingdom) Stromal inflammatory memory: Cellular priming and alterations
   AbstractStratton Richard (United Kingdom)OP0326MODELLING THE INTERACTION BETWEEN DISEASE MICROENVIRONMENT AND MESENCHYMAL STEM CELLS IN SCLERODERMA
   SpeakerPitzalis Costantino (United Kingdom) Treatment resistance: A role of fibroblasts and stromal cells?
   AbstractMarut Wioleta (Netherlands)OP0327CXCL4 DRIVES FIBROSIS BY PROMOTING SEVERAL KEY CELLULAR AND MOLECULAR PROCESSES
   SpeakerDistler Jörg (Germany)SP0106Fibroblasts: their roles in matrix and vessels

 
Health Professionals Session - Amtrium
  
New approaches in measuring what matters to patients
   ChairRedmond Anthony (United Kingdom)  
   ChairRitschl Valentin (Austria)  
   SpeakerRitschl Valentin (Austria)SP0107What can Bayes statistics contribute to measuring patient perspectives?
   SpeakerBekker Hilary (United Kingdom)SP0108Decision aid tools
   SpeakerKaldeweide Mara (Germany) Patient's view on measuring what matters to patients
   AbstractPrimdahl Jette (Denmark)OP0328-HPRPATIENTS’ VIEWS ON ROUTINE COLLECTION OF PATIENT-REPORTED OUTCOMES IN RHEUMATOLOGY CARE - A DANBIO FOCUS GROUP STUDY
   AbstractOude Voshaar Martijn (Netherlands)OP0329-HPROUTCOMES THAT MATTER TO PEOPLE LIVING WITH INFLAMMATORY ARTHRITIS; A GLOBAL STANDARD SET, DEVELOPED BY THE INTERNATIONAL CONSORTIUM FOR HEALTH OUTCOME MEASUREMENT (ICHOM) WORKING GROUP FOR INFLAMMATORY ARTHRITIS

 
Practical Skills Session - Emerald
  
Data visualization: tables and graphs for publication and presentation II
   SpeakerBoers Maarten (Netherlands)SP0080Data visualisation: tables and graphs for publication and presentation

 
Joint Session PARE / Clinical - PARE Room
  
Innovative treatments for a better quality of life
   Chairda Silva José Antonio P. (Portugal)  
   ChairTzigounaki - Kritza Eva (Greece)  
   SpeakerBijlsma Johannes W.J. (Netherlands) Why JAK inhibitors can make a difference?
   SpeakerClausen Jürgen (Germany)SP0109Involvement of a patient organisation in Health Technology Assessment
   SpeakerBosworth Ailsa (United Kingdom) Patient rights and safety concerns in an era of innovative therapies
   AbstractBosworth Ailsa (United Kingdom)OP0330-PARELOVE YOUR HEART, AN ONLINE, INTERACTIVE CARDIOVASCULAR RISK ASSESSMENT PROGRAMME FOR PEOPLE WITH RA/IA
   AbstractAlemo Munters Li (Sweden)OP0331-PAREBEHAVIOR CHANGE EXPERIENCES AND NEEDS OF PERSONS WITH RHEUMATIC DISEASE

 
EULAR Projects in Investigative Rheumatology - E106 / E107
  
EULAR Projects in Investigative Rheumatology
   ChairMariette Xavier (France)  
   ChairRadstake Timothy R. (Netherlands)  
   SpeakerRonnelid Johan (Sweden)SP0110Autoantibody standardization in autoimmune diseases
   SpeakerBarone Francesca (United Kingdom) From pathophysiology of Sjögren’s syndrome to new clinical trials
   SpeakerCutolo Maurizio (Italy)SP0111How neuro endocrine Immunology impact rheumatic diseases?
   SpeakerSmith Vanessa (Belgium)SP0112Microcirculation in rheumatic diseases

 
Practical Skills Session - D201 / D202
  
Laboratory course - from the clinic to the lab and back
   ChairBurmester Gerd Rüdiger (Germany)  
   ChairDörner Thomas (Germany)  
   SpeakerDörner Thomas (Germany) ANA diagnostic and antiphospholipid syndrome (APS) as inherited coagulation disorder
   SpeakerMiossec Pierre (France) Vasculitis, systemic autoimmunity
   SpeakerFeist Eugen (Germany)SP0113New trends in biomarkers in inflammatory joint disease

 
Practical Skills Session - D203 / D204
  
New assessments in clinical practice
   ChairIagnocco Annamaria (Italy)  
   ChairDoherty Michael (United Kingdom)  
   SpeakerDoherty Michael (United Kingdom)SP0114How to perform quick and reliable physical examination in rheumatology
   SpeakerSefik-Bukilica Miriana (Serbia)SP0115Value of inflammatory biomarkers in clinical decision making
   SpeakerTerslev Lene (Denmark)SP0116Value of ultrasound in clinical decision making
   SpeakerIagnocco Annamaria (Italy)SP0117Ultrasound scanning of RA patients in remission

Friday 15.06.2018 15:30 - 17:00


 
WIN & HOT Session - Hall 7.1
  
WIN & HOT Session 1
   SpeakerRaza Karim (United Kingdom) WIN Session: How to diagnose rheumatoid arthritis early?
   SpeakerBuch Maya (United Kingdom)SP0118HOT Session: Recent advances in the treatment of rheumatoid arthritis

 
Clinical Science Session - Hall 3
  
Advances in Biologic Therapy of Small Vessel Vasculitis
   ChairSaadoun David (France)  
   ChairCalabrese Leonard (United States)  
   SpeakerJayne David (United Kingdom) Complement inhibition in AAV
   SpeakerMoosig Frank (Germany)SP0119The evolving role of mepolizumab in EGPA
   SpeakerTerrier Benjamin (France)SP0120Current controversies in the use of rituximab for induction and maintenance of AAV disease
   AbstractBrogan Paul (United Kingdom)OP0332PEDIATRIC OPEN-LABEL CLINICAL STUDY OF RITUXIMAB FOR THE TREATMENT OF GRANULOMATOSIS WITH POLYANGIITIS (GPA) AND MICROSCOPIC POLYANGIITIS (MPA)
   AbstractFelicetti Mara (Italy)OP0333SURVIVAL IN ANCA ASSOCIATED VASCULITIDES: A RETROSPECTIVE MULTICENTRIC ANALYSIS IN NORTHERN ITALY

 
Clinical Science Session - Auditorium / Balcony
  
Tapering and flaring in PsA and SpA
   ChairCarron Philippe (Belgium)  
   ChairKiltz Uta (Germany)  
   SpeakerCoates Laura (United Kingdom)SP0121Tapering in PsA – to do or not to do?
   SpeakerPoddubnyy Denis (Germany)SP0122Tapering in axial disease – to do or not to do?
   SpeakerMarzo-Ortega Helena (United Kingdom) The concept of flare and how to deal with it
   AbstractLandewé R. (Netherlands)OP0334EFFICACY AND SAFETY OF CONTINUING VERSUS WITHDRAWING ADALIMUMAB (ADA) IN MAINTAINING REMISSION IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA)
   AbstractCarron Philippe (Belgium)OP0335HIGH NEED FOR ANTI-TNF THERAPY AFTER WITHDRAWAL STRATEGY IN EARLY PERIPHERAL SPONDYLOARTHRITIS.

 
Clinical Science Session - Elicium 2
  
Prevention of OA: Yes we can!
   ChairBerenbaum Francis (France)  
   ChairHaugen Ida Kristin (Norway)  
   SpeakerFelson David (United States)SP0123Why has the prevalence of knee OA doubled in recent years?
   SpeakerEnglund Martin (Sweden)SP0124Physical activity and exercise: opportunities and challenges
   SpeakerSellam Jeremie (France) We are what we eat!
   AbstractCook Michael (United Kingdom)OP0336THE EFFECT OF TIMING AND DURATION OF STATIN EXPOSURE ON THE RISK OF REVISION FOLLOWING TOTAL HIP OR KNEE ARTHROPLASTY: A POPULATION-BASED COHORT STUDY
   AbstractPan Feng (Australia)OP0337ASSOCIATION BETWEEN METABOLIC SYNDROME AND TRAJECTORIES OF KNEE PAIN: A 10.7-YEAR FOLLOW-UP STUDY

 
Clinical Science Session - Hall 7.2
  
Big Data for Musculoskeletal Research
   ChairPrieto-Alhambra Daniel (United Kingdom)  
   ChairDriessen Annemariek (Netherlands)  
   SpeakerKhalid Sara (United Kingdom)SP0125How Big Data and Machine Learning could Change the Game
   SpeakerWeinans Harrie (Netherlands) “Big Data and Machine Learning for Precision Medicine in OA”
   SpeakerSepriano Alexandre (Portugal) "Big Data for Treatment Effectiveness and Safety”
   AbstractMehta Bella (United States)OP0338RELATIONSHIP OF PROVIDER DENSITY ON TOTAL JOINT REPLACEMENT OUTCOMES
   AbstractRodriguez-Rodriguez Luis (Spain)OP0339DEVELOPMENT OF A PREDICTIVE MODEL OF RADIOLOGICAL DAMAGE IN PATIENTS WITH RHEUMATOID ARTHRITIS BASED ON ARTIFICIAL INTELLIGENCE

 
Paediatric Rheumatology Session - Forum
  
From big data to personalized medicine in pediatric rheumatic diseases
   ChairSmith Eve (United Kingdom)  
   ChairKimura Yukiko (United States)  
   SpeakerBelot Alexandre (France)SP0127The bumpy road from signaling pathways to personalized medicine in childhood SLE
   Speakervan Royen Annet (Netherlands)SP0128Finding the needle in the haystack and using it: Galectin 90 as a biomarker ofJuvenile Dermatomyositis
   SpeakerAlbani Salvatore (Singapore) How the human immunome revolutionizes personalized treatment of pediatric inflammatory diseases
   AbstractGiancane Gabriella (Italy)OP0340EVIDENCE BASED RECOMMENDATIONS FOR CORTICOSTEROID TAPERING/DISCONTINUATION IN NEW ONSET JUVENILE DERMATOMYOSITIS PATIENTS FROM THE PRINTO TRIAL

 
Basic and Translational Science Session - Elicium 1
  
Triple T: T cells, technologies and therapies
   ChairLubberts Erik (Netherlands)  
   ChairCope Andrew (United Kingdom)  
   SpeakerKoning Frits (Netherlands) Application of single cell technology to understand T cell heterogeneity
   AbstractFortea-Gordo Paula (Spain)OP0341INCREASED FREQUENCY OF CIRCULATING CD4+CXCR5-PD1HI PERIPHERAL HELPER T (CTPH) CELLS IN PATIENTS WITH SEROPOSITIVE EARLY RHEUMATOID ARTHRITIS (RA).
   SpeakerTaams Leonie (United Kingdom)SP0129Studying T cell function in RA and PsA
   AbstractPaleja Bhairav (Singapore)OP0342ALTERED FREQUENCY AND FUNCTION OF MAIT CELLS IN SYSTEMIC SCLEROSIS REVEALED BY HIGH DIMENSIONAL MASS CYTOMETRY AND TRANSCRIPTOME ANALYSIS
   SpeakerThomas Ranjeny (Australia)SP0130Towards T cell tolerance in RA

 
Health Professionals Session - Amtrium
  
Navigating the world of digital health
   ChairBremander Ann (Sweden)  
   ChairKlokkerud Mari (Norway)  
   SpeakerHeron Elizabeth (United Kingdom)SP0131Digital Health Literacy, State of the Art
   SpeakerDrossaert Constance (Netherlands)SP0132Measuring digital health literacy
   SpeakerSuarez-Almazor Maria (United States) Multi-media patient education based on Entertainment education delivered to patients with low HL
   SpeakerRaunsbaek - Knudsen Line (Denmark)SP0133Patient experiences from a tele-health intervention on disease activity in RA. The keen and the reluctant patient
   AbstractFerwerda Maaike (Netherlands)OP0343-HPRAN ECONOMIC EVALUATION OF A TAILORED GUIDED INTERNET-BASED COGNITIVE BEHAVIOURAL INTERVENTION FOR PATIENTS WITH RHEUMATOID ARTHRITIS AS AN ADDITION TO USUAL CARE.

 
Clinical Science Session - Emerald
  
The rheumatologist-orthopedic surgeon connection in secondary fracture prevention
   ChairChapurlat Roland D. (France)  
   ChairGeusens Piet (Netherlands)  
   SpeakerDreinhöfer Karsten (Germany) The care of fracture
   SpeakerÅkesson Kristina (Sweden)SP0134The connection between fracture care and secondary fracture prevention
   SpeakerLems Willem F. (Netherlands)SP0135The EULAR/EFORT recommendations for patients with recent fracture
   AbstractLibanati Cesar (United States)OP0344FRAME STUDY: THE FOUNDATION EFFECT OF REBUILDING BONE WITH ONE YEAR OF ROMOSOZUMAB LEADS TO CONTINUED LOWER FRACTURE RISK AFTER TRANSITION TO DENOSUMAB
   AbstractLems Willem F. (United States)OP0345DENOSUMAB COMPARED WITH RISEDRONATE IN GLUCOCORTICOID-TREATED SUBJECTS: RESULTS FROM THE FINAL 24-MONTH ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY

 
PARE Session - PARE Room
  
What`s new: Latest advances in treatment in JIA and osteoarthritis
   ChairConaghan Philip (United Kingdom)  
   ChairRomero Pazos Victoria (Spain)  
   SpeakerKloppenburg Margreet (Netherlands)SP0136Latest advances in treatment and management of OA
   AbstractCampbell Laura (United Kingdom)OP0346-PAREA PARTNERSHIP IN IMPLEMENTATION: ADAPTING AN OSTEOARTHRITIS GUIDEBOOK ACROSS EUROPEAN CULTURES - WITH PATIENTS, FOR PATIENTS
   SpeakerAvcin Tadej (Slovenia) Latest advances in treatment and management of JIA
   AbstractEl Miedany Yasser (United Kingdom)OP0347SHARE DECISION MAKING AID FOR JUVENILE IDIOPATHIC ARTHRITIS: MOVING FROM INFORMATIVE PATIENT EDUCATION TO INTERACTIVE CRITICAL THINKING

 
EULAR Projects in Epidemiology and Health Services - E106 / E107
  
Assessment and prevention of RMDs, what have we learned?
   ChairGossec Laure (France)  
   ChairFinckh Axel (Switzerland)  
   SpeakerAskling Johan (Sweden) What randomized trials and observational studies have taught us in rheumatoid arthritis
   SpeakerVerstappen Suzanne (United Kingdom)SP0137Prevention of RMDs – what have we learned?
   SpeakerGuillemin Francis (France)SP0138Why not all effective interventions are worthwhile

 
Practical Skills Session - D201 / D202
  
Capillaroscopy II
   ChairHerrick Ariane L. (United Kingdom)  
   ChairSulli Alberto (Italy)  
   SpeakerSmith Vanessa (Belgium)SP0088The importance to differentiate normal from abnormal capillaroscopic images for an early diagnosis of disease
   SpeakerSulli Alberto (Italy) Scoring the capillaroscopic images
   SpeakerHerrick Ariane L. (United Kingdom)SP0089How to distinguish the major capillaroscopic patterns
   SpeakerCutolo Maurizio (Italy) How capillaroscopy can predict disease severity and prognosis

 
Practical Skills Session - D203 / D204
  
Ultrasound Advanced II
   ChairKortekaas Marion (Netherlands)  
   ChairAmmitzboll Mads (Denmark)  
   SpeakerMöller Ingrid (Spain)SP0090US for pulley lesions – clinical relevance + demo
   SpeakerBong David (Spain)SP0091US for peripheral nerve entrapments + demo
   SpeakerJousse-Joulin Sandrine (France)SP0092US for scoring Sjögren disease
   SpeakerDamjanov Nemanja (Serbia) US for impingement syndromes + demo
   TutorNysom Sara (Denmark)  

Friday 15.06.2018 17:30 - 19:00


 
Basic and Translational Science Session - Elicium 1
  
High-end imaging: Looking for the invisible
   ChairFinzel Stephanie (Germany)  
   ChairHerrmann Martin (Germany)  
   SpeakerUderhardt Stefan (United States)SP0139The role of phagocytes at the inflammatory site
   SpeakerBrewer James (United Kingdom)SP0140Imaging the arthritic joint
   SpeakerChristiansen Silke (Germany)SP0141The ultra high resolution X ray microscope in the analysis of calcified tissues
   AbstractRocha Beatriz (Spain)OP0348MASS SPECTROMETRY IMAGING ANALYSIS OF SYNOVIUM DIFFERENTIATE PATIENTS WITH PSORIATIC AND RHEUMATOID ARTHRITIS

Saturday 16.06.2018 09:00 - 10:30


 
WIN & HOT Session - Auditorium / Balcony
  
WIN & HOT Lancet Session
   ChairBijlsma Johannes W.J. (Netherlands)  
   ChairSargent Jennifer (United States)  
   SpeakerVeale Douglas (Ireland)SP0142WIN Session: What can new insights in the pathogenesis of psoriasis and psoriatic arthritis teach the rheumatologist?
   Speakervan den Bosch Filip (Belgium) HOT Session: New approaches in the treatment of psoriatic arthritis

 
Challenges in Clinical Practice Session - Elicium 2
  
The GI tract in systemic sclerosis – is there light at both ends?
   ChairCutolo Maurizio (Italy)  
   ChairHasseli Rebecca (Germany)  
   PresenterFrantz Camelia (France)SP0143Case 1 presentation: Armful hidden telangiectasia
   DiscussantAllanore Yannick (France) Case 1 discussion: Light at the upper GI tract
   PresenterClark Kristina (United Kingdom)SP0144Case 2 presentation: The importance of maintaining control
   DiscussantDenton Christopher (United Kingdom)SP0145Case 2 discussion: Light at the lower GT tract

 
Clinical Science Session - Hall 7.2
  
RA: is it all in your head?
   ChairIsaacs John D. (United Kingdom)  
   ChairHuegle Thomas (Switzerland)  
   SpeakerHarrison Neil (United Kingdom)SP0146The link between Inflammation and Depression
   SpeakerApfelbacher Christian (Germany) Depression, social deprivation and RA: is it preventable and treatable?
   SpeakerCavanagh Jonathan (United Kingdom) Neuroimaging in RA
   AbstractBykerk Vivian (United States)OP0349REMAINING PAIN AND WIDESPREAD PAIN DISTRIBUTION DURING THE FIRST 12 MONTHS AFTER RA DIAGNOSIS
   AbstractFragoulis George (United Kingdom)OP0350DEPRESSION AND ANXIETY IN AN EARLY RHEUMATOID ARTHRITIS INCEPTION COHORT. ASSOCIATIONS WITH EPIDEMIOLOGICAL, SOCIOECONOMIC AND DISEASE FEATURES

 
Paediatric Rheumatology Session - Forum
  
Battling hyperinflammation in pediatric rheumatic diseases
   ChairLamot Lovro (Croatia)  
   ChairBeresford Michael (United Kingdom)  
   SpeakerVastert Sebastian (Netherlands) Understanding inflammation in systemic JIA; a bird eye’s view
   SpeakerRavelli Angelo (Italy) The clinical conundrum of diagnosing Macrophage Activation Syndrome
   Speakerde Benedetti Fabrizio (Italy) From pathogenic insight to novel therapeutic approaches of hyperinflammation
   AbstractDavies Rebecca (United Kingdom)OP0351FIRST DIAGNOSIS OF UVEITIS IS NOT HIGHER AMONG JUVENILE IDIOPATHIC ARTHRITIS (JIA) PATIENTS RECEIVING ETANERCEPT (ETN) COMPARED TO METHOTREXATE

 
Basic and Translational Science Session - Elicium 1
  
Gut bacteria: the boss of the immune system
   ChairRiemekasten Gabriela (Germany)  
   ChairZhao Yi (China, People's Republic of)  
   SpeakerVieira-Silva Sara (Belgium) The microbiota and inflammation
   SpeakerZaiss Mario (Germany)SP0147How the gut microbiota and its metabolites impact on bone homeostasis
   SpeakerSokol Harry (France) Microbiota in Crohn’s disease
   AbstractMankia Kulveer (United Kingdom)OP0352AN INCREASED PREVALENCE OF PERIODONTAL DISEASE, PORPHYROMONAS GINGIVALIS AND AGGREGATIBACTER ACTINOMYCETEMCOMITANS IN ANTI-CCP POSITIVE INDIVIDUALS AT-RISK OF INFLAMMATORY ARTHRITIS

 
Health Professionals Session - Amtrium
  
Multi-disciplinary management of complex persistent pain
   ChairDures Emma (United Kingdom)  
   ChairPrior Yeliz (United Kingdom)  
   SpeakerKnudsen Lone (Denmark)SP0148Pain: The Role of Psychology
   SpeakerBrunner Florian (Switzerland) CRPS – Early diagnosis and first therapeutic measures
   SpeakerConnett Robyn (United Kingdom)SP0149The patient’s perspective of living with Complex Regional Pain Syndrome
   SpeakerMcCabe Candy (United Kingdom)SP0150Functional rehabilitation for the relief of complex persistent pain
   AbstractHammond Alison (United Kingdom)OP0353-HPRTHE EFFECTS OF ARTHRITIS GLOVES ON HAND PAIN IN PEOPLE WITH RHEUMATOID OR INFLAMMATORY ARTHRITIS: A RANDOMISED CONTROLLED TRIAL (A-GLOVES TRIAL).

 
From Bench to Bedside - Emerald
  
Osteoarthritis: a vascular disease
   ChairGravallese Ellen M. (United States)  
   ChairBerenbaum Francis (France)  
   SpeakerLafage-Proust Marie-Hélène (France) OA and angiogenesis: what is special about blood vessels in bone?
   SpeakerConaghan Philip (United Kingdom)SP0151Does imaging support the vascular nature of OA?
   SpeakerFelson David (United States)SP0152Hypertension and OA
   AbstractMaugesten Øystein (Norway)OP0354RADIOGRAPHIC EROSIONS ARE ASSOCIATED WITH FLUORESCENCE OPTICAL IMAGING ENHANCEMENT IN HAND OSTEOARTHRITIS.

 
PARE Session - PARE Room
  
Workshop: Is there a diet for people with RMDs?
   ChairWiek Dieter (Germany)  
   ChairCaeyers Nele (Belgium)  
   SpeakerLinauskas Asta (Denmark)SP0153What evidence is there that diets help people with RMDs?
   SpeakerElling-Audersch Corinna (Germany)SP0154How to offer seminars on nutrition
   SpeakerKrafft Valerie (Switzerland)SP0155Nutrition - how to talk about it
   Speakernot confimed yet Group discussion and Q&A
   SpeakerWiek Dieter (Germany) Resume of the group discussions

 
EULAR Projects in Education and Training - E106 / E107
  
Challenging projects in education and training
   ChairIagnocco Annamaria (Italy)  
   Chairda Silva José Antonio P. (Portugal)  
   SpeakerBoers Maarten (Netherlands)SP0156Theory of poster design and presentation
   SpeakerIagnocco Annamaria (Italy)SP0157The EULAR School of Rheumatology. A challenging educational EULAR Project. Where are we now?
   Speakerda Silva José Antonio P. (Portugal) How to deliver a presentation?

Saturday 16.06.2018 10:30 - 12:00


 
Poster Tour - Poster Area
  
Poster Tour S10: SLE, Sjogren’s and APS - novel predictors of disease activity and long-term outcomes
   ChairMok Chi-Chiu (China, People's Republic of)  
   ChairWong Priscilla (China, People's Republic of)  
   AbstractLee Chan Hee (Korea, Republic Of)SAT0414DEVELOPMENT OF MALIGNANCY IN KOREAN SJOGREN’S SYNDROME PATIENTS; WHOLE NATIONAL HEALTH INSURANCE DATA BASED ANALYSIS
   AbstractVenhoff Nils (Germany)SAT0415THE MRZ REACTION HELPS TO DISTINGUISH RHEUMATOLOGIC DISORDERS WITH CENTRAL NERVOUS INVOLVEMENT FROM MULTIPLE SCLEROSIS
   AbstractRetamozo Soledad (Spain)SAT0416LIFE-THREATENING PRIMARY SJÖGREN SYNDROME: CLINICAL CHARACTERIZATION AND OUTCOMES IN 1535 PATIENTS (GEAS-SS REGISTRY)
   AbstractZhan Zhongping (China)SAT0417PREDICTIVE VALUE OF FETAL UMBILICAL ARTERY DOPPLER IN PRETERM BIRTH IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
   AbstractTouma Zahi (Canada)SAT0418CAN THE AUTOMATED NEUROPSYCHOLOGICAL ASSESSMENT METRICS (ANAM) PREDICT COGNITIVE IMPAIRMENT COMPARED TO A COMPREHENSIVE NEUROPSYCHOLOGICAL BATTERY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)?
   AbstractFarinha Filipa (United Kingdom)SAT0419RENAL AND OVERALL SURVIVAL ANALYSIS IN A COHORT OF PATIENTS WITH LUPUS NEPHRITIS WITH UP TO 40 YEARS OF FOLLOW UP
   AbstractChung Cecilia (United States)SAT0420INCREASED RESISTANT HYPERTENSION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A RETROSPECTIVE COHORT STUDY
   AbstractMok Chi Chiu (Hong Kong)SAT0421LONG-TERM IMMUNOGENICITY OF A QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
   AbstractFujii Takao (Japan)SAT0422INDIRECT PATHOGENIC ROLES OF CEREBROSPINAL FLUID ANTI-U1RNP ANTIBODIES IN THE PRESENCE OF ANTI-NR2 ANTIBODIES IN PATIENTS WITH NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS
   AbstractJames Judith (United States)SAT0423MOLECULAR PROFILES ASSOCIATE WITH CLINICAL DISEASE ACTIVITY AND INFORM PATIENT SUBSETTING IN ADULT SYSTEMIC LUPUS ERYTHEMATOSUS
  
Poster Tour S11: SSc, Myositis, Related Syndromes – Novel Ideas Take Place
   ChairMüller-Ladner Ulf (Germany)  
   ChairLundberg Ingrid (Sweden)  
   AbstractSharma Shefali (India)SAT0468SCLERODERMA -INTERSTITIAL LUNG DISEASE: DOES MAINTENANCE THERAPY MAKE A DIFFERENCE
   AbstractBarsotti Simone (Italy)SAT0469“INTERSTITIAL LUNG DISEASE IN IDIOPATHIC INFLAMMATORY MYOPATHIES: ULTRASOUND ASSESSMENT OF PLEURAL IRREGULARITIES AND COMPARISON WITH HIGH RESOLUTION COMPUTED TOMOGRAPHY”
   AbstractFELTEN Renaud (France)SAT0470MYOSITIS, OFTEN SUSPECTED, IS ACTUALLY RARE IN PRIMARY SJÖGREN'S SYNDROME: DATA FROM THE FRENCH COHORT ASSESS
   AbstractEman Abdulle Amaal (Netherlands)SAT0471ABNORMAL NAILFOLD CAPILLAROSCOPIC PATTERNS ARE COMMON IN UNDERWEIGHT SUBJECTS WITH RAYNAUD’S PHENOMENON
   AbstractYelnik Cécile (France)SAT0472ULNAR OCCLUSION IS A MARKER OF GLOBAL VASCULAR DAMAGE IN SYSTEMIC SCLEROSIS: RESULTS FROM A MONOCENTRIC PROSPECTIVE STUDY OF 99 PATIENTS.
   AbstractBoonstra Maaike (Netherlands)SAT0473CLINICAL AND ECHOCARDIOGRAPHIC ASSOCIATES OF ALL-CAUSE MORTALITY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH SYSTEMIC SCLEROSIS
   AbstractJaeger Veronika (Switzerland)SAT0474RACIAL DIFFERENCES IN SSC DISEASE PRESENTATION: A EUROPEAN SCLERODERMA TRIALS AND RESEARCH GROUP STUDY
   AbstractSelva-O'callaghan Albert (Spain)SAT0475ANTI-MDA5 (+) CLINICALLY AMYOPATHIC DERMATOMYOSITIS-ASSOCIATED RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE: ROLE OF HEMOPERFUSION WITH POLYMYXIN
   AbstractMakol Ashima (United States)SAT0476INCIDENCE, PREVALENCE, MORTALITY AND PERFORMANCE OF THE ACR/EULAR 2013 CLASSIFICATION CRITERIA IN PHYSICIAN DIAGNOSED SYSTEMIC SCLEROSIS: RESULTS FROM A POPULATION BASED US COHORT (1980-2016)
   AbstractCecchi Irene (Italy)SAT0477INTENSIFIED B-CELL DEPLETION THERAPY IN PROGRESSIVE SYSTEMIC SCLEROSIS PATIENTS: 24 MONTHS FOLLOW-UP.
  
Poster Tour S12: Be familiar with orphan diseases
   ChairDamjanov Nemanja (Serbia)  
   ChairOstojic Predrag (Serbia)  
   AbstractSokol Evgeniya (Russian Federation)SAT0587MAJOR SALIVARY GLANDS ULTRASONOGRAPHY IN DIFFERENTIAL DIAGNOSIS OF IGG4-RELATED DISEASE AND PRIMARY SJOGREN’S SYNDROME
   AbstractRichter Michael (United States)SAT0588RHEUMATOLOGIC IMMUNE-RELATED ADVERSE EFFECTS OF CHECKPOINT INHIBITOR THERAPY: A SINGLE CENTER COHORT OF 29 PATIENTS.
   AbstractEndo Yushiro (Japan)SAT0589MUSCULOSKELETAL MANIFESTATIONS OCCUR PREDOMINANTLY IN PATIENTS WITH OLDER ONSET FAMILIAL MEDITERRANEAN FEVER
   AbstractDouglas Kevin (United States)SAT0590LONG-TERM EFFICACY AND SAFETY OF ADALIMUMAB BY ETIOLOGY IN PATIENTS WITH NON-INFECTIOUS UVEITIS IN THE VISUAL III TRIAL.
   AbstractOzdemir Isik Ozlem (Turkey)SAT0591DEMOGRAPHIC AND CLINICAL FEATURES OF FAMILIAL MEDITERRANEAN FEVER PATIENTS
   AbstractChen Li (China)SAT0592HRCT PULMONARY MANIFESTATIONS IN PATIENTS WITH SYNOVITIS, ACNE, PUSTULOSIS, HYPEROSTOSIS, AND OSTEITIS (SAPHO)SYNDROME
   AbstractFischer Aryeh (United States)SAT0593PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE (PF-ILD) IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES
   AbstractBilgin Emre (Turkey)SAT0594WHICH ONE IS MORE VALUABLE FOR DIAGNOSIS OF ADULT ONSET STILL’S DISEASE? SOLELY NEUTROPHILIA OR LEUKOCYTOSIS WITH NEUTROPHILIA?
   AbstractUriarte Miren (Spain)SAT0595ANALYSIS OF RECURRENCES AFTER SUSPENSION OF IMMUNOSUPPRESSIVE TREATMENT IN NON-INFECTIOUS UVEITIS
   AbstractRetamozo Soledad (Spain)SAT0596THORACIC INVOLVEMENT AT DIAGNOSIS DRIVES A DIFFERENTIATED CLINICAL PRESENTATION OF SARCOIDOSIS: ANALYSIS OF 1245 PATIENTS (SARCOGEAS-SEMI)
  
Poster Tour S13: Imaging strategies in the management of arthritis
   ChairTerslev Lene (Denmark)  
   ChairAmmitzboll Mads (Denmark)  
   AbstractKuettel Dorota (Denmark)SAT0630AGREEMENT BETWEEN PATIENT-REPORTED SWOLLEN AND TENDER JOINTS, CLINICAL EXAMINATION AND SYNOVITIS DETECTED BY ULTRASONOGRAPHY IN RHEUMATOID ARTHRITIS PATIENTS AT THE TIME OF PATIENT-REPORTED FLARE.
   AbstractBaker Kenneth (United Kingdom)SAT0631LACK OF ASSOCIATION BETWEEN CLINICAL AND ULTRASOUND MEASURES OF DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS CLINICAL REMISSION: A CROSS-SECTIONAL ANALYSIS.
   AbstractBonfiglioli Karina (Brazil)SAT0632ULTRASOUND IN THE MANAGEMENT OF RHEUMATOID ARTHRITIS USING A NOVEL PRAGMATIC ALGORITHM: A MULTICENTRIC OBSERVATIONAL STUDY
   AbstractPeiteado Diana (Spain)SAT0633ULTRASOUND PREDICTIVE VALUE IN PREARTHRITIS. A PROSPECTIVE LONGITUDINAL STUDY.
   AbstractBurgers Leonie (Netherlands)SAT0634DOES THE PRESENCE OF MRI-DETECTED OSTEITIS AT DIAGNOSIS WITH RHEUMATOID ARTHRITIS LOWERS THE RISK FOR ACHIEVING DMARD-FREE SUSTAINED REMISSION? – RESULTS OF A LONGITUDINAL STUDY
   AbstractBaraliakos Xenofon (Germany)SAT0635MAGNETIC RESONANCE IMAGING OF THE CERVICAL SPINE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS PRESENTING WITH CHRONIC NECK PAIN - A SYSTEMATIC COMPARISON OF CLINICAL ASSESSMENTS
   AbstractMøller Jakob (Denmark)SAT0636REPEATABILITY OF MRI DIFFUSION WEIGHTED IMAGING OF SACROILIAC JOINTS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND HEALTHY SUBJECTS.
   AbstractCarvajal Alegria Guillermo (France)SAT0637RADIOGRAPHIC AND MRI DETECTED SACROILIITIS IS MORE OFTEN OBSERVED IN PATIENTS WITH LUMBOSACRAL TRANSITIONAL VERTEBRA IN THE DESIR COHORT
   AbstractOsipyants Rita (Russian Federation)SAT0638ULTRASONOGRAFHY THE PREVALENCE OF MONOSIDIUM URATE CRYSTAL DEPOSITION IN PATIENTS WITH CALCIUM PYROPHOSPHATE DEPOSITION DISEASE: ASSOCIATION WITH LABORATORY, RADIOGRAPHIC PARAMETERS AND MICROSCOPY OF SYNOVIAL FLUID
   AbstractZufferey Pascal (Switzerland)SAT0639INTEROBSERVER AGREEMENT OF THE OMERACT ULTRASONOGRAPHIC CRITERIA FOR THE DIAGNOSIS OF CALCIUM PYROPHOSPHATE DEPOSITION DISEASE AT THE WRIST, AMONG PANEL OF RADIOLOGISTS AND RHEUMATOLOGISTS
  
Poster Tour S14: This poster tour might be risky!
   ChairGossec Laure (France)  
   ChairStudenic Paul (Austria)  
   AbstractAlpizar-Rodriguez Deshire (Switzerland)SAT0677PREVOTELLA COPRI IN INDIVIDUALS AT RISK FOR RHEUMATOID ARTHRITIS
   AbstractKudaeva Fatima (Canada)SAT0678SEASONALITY OF NEW EARLY INFLAMMATORY ARTHRITIS CASES: PRELIMINARY RESULTS FROM THE CANADIAN EARLY ARTHRITIS COHORT
   AbstractKhabbazi Alireza (Iran, Islamic Republic Of)SAT0679CIGARETTE SMOKING AND RISK OF BEHCET’S DISEASE: A CASE-CONTROL STUDY
   AbstractReiseter Silje (Norway)SAT0680THE DEVELOPMENT AND VALIDATION OF INTERSTITIAL LUNG DISEASE PREDICTION MODELS IN THREE INTERNATIONAL MIXED CONNECTIVE TISSUE DISEASE COHORTS: THE NORWEGIAN MCTD COHORT, THE HUNGARIAN MCTD COHORT AND THE MCTD COHORT FROM MINNESOTA, US
   AbstractPrats-Uribe Albert (Spain)SAT0681THE CAUSAL ASSOCIATION BETWEEN CHILDHOOD AND ADULTHOOD BODY MASS INDEX AND OSTEOARTHRITIS: A MENDELIAN RANDOMIZATION STUDY.
   AbstractNygaard Allan (Denmark)SAT0682“INCIDENCE AND REGIONAL VARIATION OF ANKYLOSING SPONDYLITIS AND SPONDYLOARTHRITIS 2000-2013: A NATIONWIDE COHORT STUDY”
   AbstractRetamozo Soledad (Spain)SAT0683A NORTH-SOUTH WORLDWIDE GRADIENT IN SYSTEMIC ACTIVITY OF PRIMARY SJÖGREN SYNDROME: INCREASED SEVERE DISEASE IN PATIENTS FROM SOUTHERN COUNTRIES
   AbstractChen Hsin-Hua (Taiwan, Province of China)SAT0684APPENDICITIS AND THE RISK OF NEWLY DIAGNOSED SYSTEMIC SCLEROSIS: A NATIONWIDE, POPULATION-BASED, CASE-CONTROL STUDY IN TAIWAN
   AbstractStojan George (United States)SAT0685TEMPERATURE AND SMALL PARTICULATE MATTER POLLUTION ARE ASSOCIATED WITH ORGAN SPECIFIC LUPUS FLARES: A SPATIO -TEMPORAL ANALYSIS
   AbstractBoeters Debbie (Netherlands)SAT0686ARE MRI-DETECTED EROSIONS IN PATIENTS WITH UNDIFFERENTIATED ARTHRITIS PREDICTIVE FOR THE DEVELOPMENT OF RHEUMATOID ARTHRITIS? A LARGE LONGITUDINAL STUDY
  
Poster Tour S15: Theory of poster design and presentation
   ChairBoers Maarten (Netherlands)  
  
Poster Tour S1: Born to be wild
   ChairHerrmann Martin (Germany)  
   ChairZaiss Mario (Germany)  
   AbstractDan Liu (China)SAT0001MECHANISM AND SIGNIFICANCE OF COMPLEMENT C3 RECEPTOR IN COLLAGEN-INDUCED RHEUMATOID ARTHRITIS MICE MODEL
   AbstractNemeth Tamas (Hungary)SAT0002THE INTRACELLULAR ITAM TYROSINES OF FC RECEPTOR GAMMA-CHAIN ARE CRITICAL FOR EXPERIMENTAL AUTOIMMUNE ARTHRITIS
   AbstractKurowska-Stolarska Mariola (United Kingdom)SAT0003SYNOVIAL TISSUE CD1C+ DENDRITIC CELLS IN RHEUMATOID ARTHRITIS EXPRESS HIGH LEVELS OF THE EPIGENETIC REGULATOR OF INFLAMMATION, MICRORNA-155 AND INFLAMMATORY CYTOKINES
   Abstractvan Dalen Stephanie (Netherlands)SAT0004INTRA-ARTICULAR INJECTION OF ADIPOSE-DERIVED MESENCHYMAL STROMAL CELLS REDUCE EXPERIMENTAL OA PATHOLOGY VIA IL-1Β-MEDIATED REALLOCATION AND ENHANCED PHAGOCYTOSIS OF POLYMORPHONUCLEAR LEUCOCYTES
   AbstractMok Mo Yin (Hong Kong)SAT0005INTERLEUKIN-33 AMELIORATES MURINE LUPUS VIA INDUCTION OF REGULATORY T CELLS AND M2 MACROPHAGE POLARISATION
   AbstractFurini Federica (Italy)SAT0006P2X7 RECEPTOR IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). EXPLORING A NOVEL PATHOGENETIC PATHWAY IN LUPUS RELATED SEROSITIS.
   AbstractHanlon Megan (Ireland)SAT0007DISTINCT MACROPHAGE PHENOTYPE AND BIOENERGETIC PROFILES IN RHEUMATOID ARTHRITIS
  
Poster Tour S2: The good, the bad and the ugly: soluble mediators in inflammation
   ChairTaams Leonie (United Kingdom)  
   ChairBecker Mike O. (Switzerland)  
   AbstractYao Genhong (China)SAT0016IL-12 SUPPRESS TR1 CELLS IN THE SJÖGREN’S SYNDROME
   AbstractFalkenburg Willem (Netherlands)SAT0017THE RHEUMATOID FACTOR RESPONSE IS COMPOSED OF MULTIPLE REACTIVITIES AGAINST DIFFERENT EPITOPES
   AbstractSkacelova Martina (Czech Republic)SAT0018BLOOD CHEMOKINE SYSTEM PROFILE ASSOCIATED WITH DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS
   AbstractPsarras Antonios (United Kingdom)SAT0019TNF-Α REGULATES PLASMACYTOID DENDRITIC CELLS BY SUPPRESSING IFN-Α PRODUCTION AND ENHANCING TH1 AND TH17 CELL DIFFERENTIATION
   AbstractIvanova Mariana (Bulgaria)SAT0020IMPACT OF IL12B SINGLE NUCLEOTIDE POLYMORPHISMS ON CIRCULATING PRO-INFLAMMATORY CYTOKINES IL-12P40 AND IL-23 IN ANKYLOSING SPONDYLITIS
   AbstractYeremenko Nataliya (Netherlands)SAT0021INNATE LYMPHOID CELLS ARE NOT A MAIN SOURCE OF IL-17A IN THE INFLAMED SPONDYLOARTHRITIS JOINT
   AbstractTan Wenfeng (China)SAT0022MIR-15A/16 SUPPRESS INFLAMMATORY RESPONSE AND CELL INVASION AND MIGRATION IN FIBROBLAST-LIKE SYNOVIOCYTES IN RHEUMATOID ARTHRITIS VIA TARGETING SOX5
   AbstractAngiolilli Chiara (Netherlands)SAT0023CONTROL OF CYTOKINE MRNA DEGRADATION BY THE HISTONE DEACETYLASE INHIBITOR ITF2357 IN RHEUMATOID ARTHRITIS FIBROBLAST-LIKE SYNOVIOCYTES
   AbstractNerviani Alessandra (United Kingdom)SAT0024IL-36 AXIS IS AN EMERGING THERAPEUTIC TARGET IN PSORIATIC ARTHRITIS SYNOVIAL TISSUE
   Abstract R.D.J. Radstake Timothy (Netherlands)SAT0025CXCL4 ALTERS TRANSCRIPTOMIC AND EPIGENETIC IMPRINTING OF DENDRITIC CELLS THEREBY DRIVING FIBROSIS THROUGH EXTRACELLULAR MATRIX FORMATION
  
Poster Tour S3: The joint connection: Cartilage, bone and synovial tissue
   ChairNeumann Elena (Germany)  
   ChairKlein Kerstin (Switzerland)  
   AbstractMendez Diaz Lara (Spain)SAT0048ANALYSIS OF DIFFERENT THERAPEUTIC REGIMES IN PATIENTS WITH HEMOPHILIC ARTHROPATHY
   AbstractHardy Rowan (United Kingdom)SAT004911BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 REGULATES CHRONIC SYNOVITIS WITH LOCAL AND SYSTEMIC COMPLICATIONS
   AbstractNajm Aurelie (France)SAT0050STANDARDIZATION OF SYNOVIAL BIOPSIES ANALYSIS: A EULAR SYNOVITIS STUDY GROUP INITIATIVE USING A DELPHI SURVEY.
   AbstractSousa-Valente Joao (United Kingdom)SAT0051EXAMINING THE ROLE OF TRPC5 IN OSTEOARTHRITIS PAIN
   AbstractHenrotin Yves (Belgium)SAT0052THE COLL2-1 PEPTIDE OF COLLAGEN TYPE II: A NEW ACTOR OF SYNOVITIS IN OSTEOARTHRITIS
   AbstractNogueira-Recalde Uxia (Spain)SAT0053IDENTIFICATION OF NOVEL DRUGS WITH SENOLYTIC ACTIVITY AS OSTEOARTHRITIS THERAPEUTICS
   AbstractChatzidionysiou Katerina (Sweden)SAT0054SIGNIFICANT DECREASE OF T-CELLS BUT NOT MACROPHAGES IN THE SYNOVIUM OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AFTER TREATMENT WITH TOCILIZUMAB
   AbstractDamerau Alexandra (Germany)SAT0055SIMULATING THE PATHOGENESIS OF ARTHRITIS IN VITRO BY DEVELOPING A HUMAN-BASED MULTICOMPONENT 3D JOINT MODEL
   AbstractBurguera Elena (Spain)SAT0056OSTEOARTHRITIS SEVERITY IS REDUCED BY INTRA-ARTICULAR ADMINISTRATION OF HYDROGEN SULFIDE
   AbstractGu Zhifeng (China)SAT0057THE EFFECT OF EXOSOMES FROM BONE MARROW MESENCHYMAL STEM CELLS ON OSTEOARTHRITIS
  
Poster Tour S4: Predicting tomorrow today: Prognosis, predictors and outcomes of RA
   ChairIsaacs John D. (United Kingdom)  
   ChairJani Meghna (United Kingdom)  
   AbstractPope Janet (Canada)SAT0073ACPA AND RF AS PREDICTORS OF SUSTAINED CLINICAL REMISSION IN RHEUMATOID ARTHRITIS PATIENTS: RESULTS FROM THE ONTARIO BEST PRACTICES RESEARCH INITIATIVE (OBRI)
   AbstractRuiz-Romero Cristina (Spain)SAT0074IDENTIFICATION OF A PROTEIN PANEL USEFUL FOR THE PREDICTION OF RESPONSE TO METHOTREXATE IN RHEUMATOID ARTHRITIS PATIENTS
   AbstractDai Lie (China)SAT0075ADDITIONAL TARGET OF NORMAL SERUM MATRIX METALLOPROTEINASE-3 IS A POTENTIAL BIOMARKER FOR LESS ONE-YEAR RADIOGRAPHIC PROGRESSION IN RHEUMATOID ARTHRITIS
   AbstractRivellese Felice (United Kingdom)SAT0076SYNOVIAL MAST CELLS AND RESPONSES TO SYNTHETIC AND BIOLOGIC DMARDS IN EARLY AND ESTABLISHED RHEUMATOID ARTHRITIS
   AbstractHanly John (Canada)SAT0077CHANGE IN FREQUENCY OF ARTHROPLASTY SURGERY IN RHEUMATOID ARTHRITIS: A 13 YEAR POPULATION HEALTH STUDY
   AbstractLuurssen-Masurel Nathalie (Netherlands)SAT0078WHICH CDMARD STRATEGY IS MOST EFFECTIVE IN NEWLY DIAGNOSED SERONEGATIVE RHEUMATOID ARTHRITIS PATIENTS; POST-HOC ANALYSIS OF THE TREACH STUDY.
   AbstractMucke Johanna (Germany)SAT0079TREATMENT EXPECTATIONS INFLUENCE BOTH SUBJECTIVE AND OBJECTIVE OUTCOME PARAMETERS IN PATIENTS WITH RHEUMATOID ARTHRITIS- A PROSPECTIVE COHORT STUDY
   AbstractBykerk Vivian (United States)SAT0080SECULAR TRENDS PRIOR TO-AND AFTER DISSEMINATION OF BEST PRACTICE RECOMMENDATIONS SHOWED EARLIER INTENSIFIED MEDICATION STRATEGIES AND IMPROVED OUTCOMES IN CANADIANS WITH EARLY INFLAMMATORY ARTHRITIS
   AbstractCordtz René (Denmark)SAT0081CHANGES IN INCIDENCE OF SHOULDER, ELBOW, WRIST AND FINGER REPLACEMENT SURGERY AMONG RHEUMATOID ARTHRITIS PATIENTS FOLLOWING THE INTRODUCTION OF BIOLOGICAL DMARDS: AN INTERRUPTED TIME SERIES ANALYSIS USING DANISH HEALTH CARE REGISTERS
   AbstractSoliman Eiman (Egypt)SAT0082OSTEOPONTINE AND OSTEOPROTEGRINE AS MARKERS OF ALTERED PRECLINICAL BONE METABOLISM IN RHEUMATOID FIRST DEGREE RELATIVES
  
Poster Tour S5: Breakout news on non-TNF biologics in RA
   ChairMariette Xavier (France)  
   Chairvan der Woude Diane (Netherlands)  
   AbstractYoussef Peter (Australia)SAT0165REASONS FOR BDMARD CESSATION AND SUBSEQUENT PERSISTENCE OF SECOND LINE TREATMENT IN A LARGE REAL WORLD RHEUMATOID ARTHRITIS REGISTRY
   AbstractKatayama Kou (Japan)SAT0166WHICH BIOLOGIC AGENT IS MOST SUITABLE FOR AN EXTENDED-INTERVAL TREATMENT FOR RHEUMATOID ARTHRITIS ? RESULTS FROM A MULTICENTER STUDY
   AbstractLee Young Ho (Korea, Republic Of)SAT0167COMPARISON OF THE EFFICACY AND TOLERABILITY OF TOCILIZUMAB, SARILUMAB, AND SIRUKUMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: A BAYESIAN NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
   AbstractPeterfy Charles (United States)SAT0168MRI RESULTS FOLLOWING DISCONTINUATION OF METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH SUBCUTANEOUS TOCILIZUMAB: RESULTS FROM A RANDOMIZED CONTROLLED TRIAL
   AbstractSafy Mary (Netherlands)SAT0169NO EVIDENCE THAT CONCOMITANT GLUCOCORTICOID THERAPY AFFECTS EFFICACY AND SAFETY OF TOCILIZUMAB MONOTHERAPY IN RHEUMATOID ARTHRITIS CLINICAL TRIALS
   AbstractLópez-Mejías Raquel (Spain)SAT0170ANTI-IL-6 THERAPY MODULATES LEPTIN IN PATIENTS WITH RHEUMATOID ARTHRITIS
   AbstractCurtis Jeffrey R. (United States)SAT0171REVERSIBLE DECREASES IN ABSOLUTE NEUTROPHIL COUNT (ANC) IN RHEUMATOID ARTHRITIS (RA) PATIENTS (PTS) ON SARILUMAB: COMPARISON OF DOSE DELAY AND DOSE DECREASE VS CONTINUED TREATMENT
   AbstractBurmester G. R. (Germany)SAT0172LONG-TERM EFFICACY WITH 5-YEAR-RADIOGRAPHIC RESULTS AND SAFETY OF SARILUMAB IN COMBINATION WITH CSDMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS
   AbstractTakeuchi Tsutomu (Japan)SAT0173EFFECTS OF DENOSUMAB, A SUBCUTANEOUS RANKL INHIBITOR, ON THE PROGRESSION OF STRUCTURAL DAMAGE IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH CSDMARDS: RESULT FROM THE LONG-TERM TREATMENT OF PHASE 3, DESIRABLE STUDY
   AbstractIto Hiromu (Japan)SAT0174DOES ABATACEPT INCREASE PERIOPERATIVE ADVERSE EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS COMPARED WITH CONVENTIONAL SYNTHETIC DISEASE MODIFYING DRUGS? - A RETROSPECTIVE MULTICENTER NESTED CASE-CONTROL STUDY -
  
Poster Tour S6: Novel insights on non-biologics in RA
   ChairSo Alexander (Switzerland)  
   ChairKyburz Diego (Switzerland)  
   AbstractKurochkina Yuliya (Russian Federation)SAT0212THE SAFETY AND TOLERABILITY OF INTRA-ARTICULAR INJECTION OF TOLEROGENIC DENDRITIC CELLS IN PATIENTS WITH RHEUMATOID ARTHRITIS: THE PRELIMINARY RESULTS
   AbstractRaizada Sabrina (United Kingdom)SAT0213TIGHT TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS IN THE EARLY STAGES OF DISEASE LEADS TO HIGH LEVELS OF REMISSION AND REDUCED USE OF BIOLOGICS
   AbstractStouten Veerle (Belgium)SAT0214EFFECTIVENESS OF A RANDOMIZED STEP-DOWN TO METHOTREXATE OR LEFLUNOMIDE MAINTENANCE THERAPY IN PATIENTS WITH LOW DISEASE ACTIVITY, 40 WEEKS AFTER STARTING COMBINED METHOTREXATE-LEFLUNOMIDE REMISSION INDUCTION THERAPY IN EARLY RHEUMATOID ARTHRITIS: RESULTS FROM THE CARERA TRIAL
   AbstractMalley Tamir (United Kingdom)SAT0215LIVER BLOOD TEST ABNORMALITIES ARE RARE IN PATIENTS ON METHOTREXATE: EVIDENCE FROM A LARGE COHORT OF INFLAMMATORY ARTHRITIS PATIENTS
   AbstractRamos-Bello Dolores (Mexico)SAT0216THE ADDITION OF COLCHICINE TO METOTREXATE MIGHT HELP ACHIEVE LOW DISEASE ACTIVITY IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS BY DOWNREGULATING THE ACTIVITY OF CASPASE-1.
   AbstractKeystone Edward (Canada)SAT0217IDENTIFICATION OF DISTINCT DISEASE ACTIVITY TRAJECTORIES IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB OVER 12 MONTHS
   AbstractLi Zhanguo (China)SAT0218EFFICACY AND SAFETY OF BARICITINIB IN MTX-IR PATIENTS WITH RHEUMATOID ARTHRITIS: 52 WEEK RESULTS FROM A PHASE 3 STUDY (RA-BALANCE)
   AbstractGenovese M (United States)SAT0219UPADACITINIB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS: A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF A SELECTIVE JAK1 INHIBITOR
   AbstractCalabrese Leonard (United States)SAT0220EVALUATION OF LIVE ZOSTER VACCINE IN A SUBSET OF PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TOFACITINIB WITH OR WITHOUT METHOTREXATE, AND ADALIMUMAB WITH METHOTREXATE: RESULTS FROM A PHASE 3B/4 RANDOMISED TRIAL
  
Poster Tour S7: Treatment in SpA: does it matter?
   ChairRamiro Sofia (Netherlands)  
   ChairNavarro-Compán Victoria (Spain)  
   AbstractBraun J (Germany)SAT0259LOW RATE OF SPINAL RADIOGRAPHIC PROGRESSION OVER 2 YEARS IN ANKYLOSING SPONDYLITIS PATIENTS TREATED WITH SECUKINUMAB: A HISTORICAL COHORT COMPARISON
   AbstractMarona José (Portugal)SAT0260ELIGIBILITY CRITERIA FOR TNFI THERAPY IN AXSPA: GOING BEYOND BASDAI
   AbstractGehin Johanna Elin (Norway)SAT0261CERTOLIZUMAB PEGOL SERUM LEVELS ≥ 20 MG/L ARE ASSOCIATED WITH TREATMENT RESPONSE IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS. DATA FROM THE NOR-DMARD STUDY
   AbstractCastro Villegas Maria del Carmen (Spain)SAT02623-YEAR FOLLOW-UP OF A DOSE TAPERING PROTOCOL OF ANTI-TNF THERAPY IN A COHORT OF PATIENTS WITH SPONDYLOARTHRITIS (SPA) IN CLINICAL REMISSION UNDER CONDITIONS OF CLINICAL PRACTICE
   AbstractSieper J. (Germany)SAT0263PREDICTORS OF REMISSION MAINTENANCE AND SUCCESSFUL THERAPY DISCONTINUATION IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA) WHO ACHIEVED SUSTAINED REMISSION ON OPEN-LABEL ADALIMUMAB (ADA) TREATMENT
   AbstractMichelsen Brigitte (Norway)SAT0264DOES BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUG NAÏVE VERSUS NON-NAÏVE PATIENTS WITH INFLAMMATORY JOINT DISEASES HAVE SIMILAR GOLIMUMAB DRUG SURVIVAL AND EFFICACY? DATA FROM THE PROSPECTIVE OBSERVATIONAL NOR-DMARD STUDY
   AbstractVallier Marie (France)SAT0265THE RESPONSE TO TNF-BLOCKERS TREATMENT OF SPA PATIENTS IS INFLUENCED BY THE INTERPLAY BETWEEN HLA-B27 AND GUT MICROBIOTA COMPOSITION AT BASELINE.
   AbstractTriggianese Paola (Italy)SAT0266USE OF CONVENTIONAL SYNTHETIC DMARDS AND BIOLOGICAL DMARDS IN PATIENTS WITH ENTEROPATHIC SPONDYLOARTHRITIS: A COMBINED GASTRO-RHEUMATOLOGICAL APPROACH
   AbstractDenisov Lev (Russian Federation)SAT0267EFFICACY AND SAFETY OF BCD-055, PROPOSED INFLIXIMAB BIOSIMILAR, COMPARED TO INFLIXIMAB: 54-WEEK RESULTS FROM ASART-2 PHASE 3 CLINICAL STUDY.
   AbstractBaraliakos X (Germany)SAT0268SECUKINUMAB DEMONSTRATES LOW RADIOGRAPHIC PROGRESSION AND SUSTAINED EFFICACY THROUGH 4 YEARS IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS
  
Poster Tour S8: PsA: a whole range of (subclinical) (co)morbidities!
   Chairvan den Bosch Filip (Belgium)  
   ChairCarubbi Francesco (Italy)  
   Abstractadarsh m (India)SAT0302EVALUATION OF SUBCLINICAL GUT INFLAMMATION USING FECAL CALPROTECTIN LEVEL AND COLONIC MUCOSAL BIOPSY IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS
   AbstractKristensen Lars (Denmark)SAT0303PAIN MECHANISMS AND ULTRASONIC INFLAMMATORY ACTIVITY AS PROGNOSTIC FACTORS IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS OF A DANISH PROSPECTIVE, EXPLORATORY COHORT STUDY
   AbstractZabotti Alen (Italy)SAT0304PRECLINICAL PHASES OF PSORIATIC ARTHRITIS: A CROSS-SECTIONAL ULTRASONOGRAPHIC STUDY ON PSORIASIS AND PSORIATIC ARTHRALGIA PATIENTS.
   AbstractMondal Sumantro (India)SAT0305ASSESSMENT OF SUB CLINICAL HAND JOINT SYNOVITIS IN PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS BY ULTRASOUND AND ITS RELATIONSHIP WITH CLINICAL DISEASE ACTIVITY.
   AbstractTinazzi Ilaria (Italy)SAT0306FINGER FLEXOR TENDON PULLEY COMPLEX INVOLVEMENT IN PSA DACTYLITIS: AN ULTRASONOGRAPHY STUDY
   AbstractFornaro Marco (Italy)SAT0307IMPACT OF THE MODIFIED RHEUMATIC DISEASE COMORBIDITY INDEX (MRDCI) ON DRUG SURVIVAL OF FIRST LINE ANTI-TNFΑ DRUGS IN PATENTS AFFECTED WITH PSORIATIC ARTHRITIS IN REAL LIFE SETTING.
   AbstractCanofari Claudia (Italy)SAT0308PROSPECTIVE OBSERVATIONAL STUDY ON OCULAR INVOLVEMENT IN PATIENTS AFFECTED BY MODERATE TO SEVERE PSORIATIC ARTHRITIS
   AbstractLam Ho Man (Hong Kong)SAT0309UNDERESTIMATION OF CARDIOVASCULAR EVENTS BY CARDIOVASCULAR RISK SCORES IN PSORIATIC ARTHRITIS PATIENTS
   AbstractGluszko Piotr (Poland)SAT0310THE ASSOCIATIONS OF SERUM IL18 AND OSTEOPROTEGERIN (OPG) LEVELS WITH THE LIPID PROFILE IN PSORIATIC ARTHRITIS (PSA) PATIENTS
   AbstractGiollo Alessandro (Italy)SAT0311PREVALENCE AND FACTORS RELATED TO INAPPROPRIATELY HIGH LEFT VENTRICULAR MASS IN PATIENTS WITH PSORIATIC ARTHRITIS WITHOUT OVERT CARDIAC DISEASE
  
Poster Tour S9: Beware the bug!
   ChairNikiphorou Elena (United Kingdom)  
   ChairGalloway James (United Kingdom)  
   AbstractMonge Pablo (Costa Rica)SAT0380PANLAR-ACCAR RECOMMENDATIONS ON DIAGNOSIS AND TREATMENT OF CHIKUNGUNYA-RELATED INFLAMMATORY ARTHROPATHIES IN LATIN AMERICA
   AbstractBaillet Athan (France)SAT0381NEUTROPHIL-RELATED BIOMARKERS DISCRIMINATE SEPTIC ARTHRITIS FROM OTHER INFLAMMATORY ARTHRITIDES : DATA FROM THE BOSSA TRIAL
   AbstractAjmani Sajal (India)SAT0382UTILITY OF NEUTROPHIL CD64 & SERUM TREM-1 IN DISTINGUISHING BACTERIAL INFECTION FROM DISEASE FLARE IN SLE AND ANCA ASSOCIATED VASCULITIS
   AbstractGupta Nikhil (India)SAT0383RHEUMATOLOGICAL DISORDERS FOLLOWING CHIKUNGUNYA INFECTION – A RETROSPECTIVE STUDY OF 882 CASES FROM NEW DELHI
   AbstractHayes Kaitlyn (Canada)SAT0384EVOLVING PATTERNS OF REACTIVE ARTHRITIS
   AbstractRetamozo Soledad (Spain)SAT0385MULTIPLE INFECTION IS INDEPENDENTLY RELATED TO DEATH IN ADULT PATIENTS WITH HEMOPHAGOCYTIC SYNDROME: ETIOPATHOGENICALLY-DRIVEN MULTIVARIATE ANALYSIS IN 151 PATIENTS
   AbstractGiancane Gabriella (Italy)SAT0386ADJUDICATION OF INFECTIONS FROM THE PHARMACOVIGILANCE IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS (PHARMACHILD) TREATED WITH BIOLOGIC AGENTS AND/OR METHOTREXATE: UPDATE ON RESULTS WITH A FOCUS ON OPPORTUNISTIC INFECTIONS
   AbstractAhijado Guzmán María Pilar (Spain)SAT0387DESCRIPTIVE ANALYSIS OF LEISHMANIASIS CASES IN THE FUENLABRADA OUTBREAK (SPAIN) ASSOCIATED WITH THE USE OF BILOGICAL THERAPY
   AbstractMarques Claudia (Brazil)SAT0388FACTORS ASSOCIATED WITH THE PERSISTENCE OF ARTICULAR SYMPTOMS IN PATIENTS WITH CHIKUNGUNYA FEVER - CHIKBRASIL COHORT
   AbstractChotard Emilie (France)SAT0389MRI PREDICTIVE FACTORS FOR POSITIVE CT-GUIDED BIOPSY IN SUSPECTED SEPTIC SPONDYLODISCITIS

Saturday 16.06.2018 12:00 - 13:30


 
EULAR Projects in Clinical Affairs - Auditorium / Balcony
  
Recommendation Session ESSCA
   ChairMüller-Ladner Ulf (Germany)  
   Chairvan der Heijde Désirée (Netherlands)  
   SpeakerElkayam Ori (Israel)SP01582018 EULAR Recommendations for vaccinations
   SpeakerRetamozo Soledad (Argentina)SP01592018 EULAR Recommendations for Sjögren´s syndrome
   SpeakerButtgereit Frank (Germany)SP01602018 EULAR Recommendations for the use of glucocorticoid therapy
   SpeakerKroon Féline (Netherlands)SP01612018 EULAR Recoommendations for management of hand osteoarthritis

 
Challenges in Clinical Practice Session - Elicium 2
  
Fractures: more than bone alone
   ChairLems Willem F. (Netherlands)  
   ChairChapurlat Roland D. (France)  
   PresenterBriot Karine (France)SP0162Case 1 presenter: Look at the cascade
   DiscussantRoux Christian (France) Case 1 discussant: Frail patients with a fracture: how to handle?
   PresenterWeerasinghe Gayani (United Kingdom)SP0163Case 2 presenter: A case of severe osteoporosis and ischaemic heart disease; what will be the future cardiovascular risk?
   DiscussantPrieto-Alhambra Daniel (United Kingdom) Case 2 discussant: Cardiovascular disease after a recent fracture

 
Clinical Science Session - Hall 7.2
  
Emerging topics in the management of the antiphospholipid syndrome
   ChairConti Fabrizio (Italy)  
   ChairLimper Maarten (Netherlands)  
   SpeakerAndreoli Laura (Italy)SP0164How to manage asymptomatic carriers of antiphospholipid antibodies
   SpeakerSvenungsson Elisabet (Sweden)SP0165The complex interplay between systemic lupus erythematosus and antiphospholipid syndrome
   SpeakerTektonidou Maria (Greece)SP0166All you need to know about kidney disease in Antiphospholipid Syndrome
   AbstractLi Can (China)OP0355PULMONARY THROMBOENDARTERECTOMY IS A CURATIVE RESOLUTION FOR CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION ASSOCIATED WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME: A RETROSPECTIVE COHORT STUDY
   AbstractHisada Ryo (Japan)OP0356PLASMABLAST PROLIFERATION IS ASSOCIATED WITH TOLL LIKE RECEPTOR 7 POLYMORPHISMS AND UPREGULATION OF TYPE I INTERFERON, CONTRIBUTING TO THE ANTIBODY PRODUCTION IN ANTIPHOSPHOLIPID SYNDROME

 
From Bench to Bedside - Forum
  
The links between gout and kidney function
   ChairSo Alexander (Switzerland)  
   ChairDalbeth Nicola (New Zealand)  
   SpeakerKoettgen Anna (Germany) Genetics of Hyperuricemia
   SpeakerPerez-Ruiz Fernando (Spain)SP0167Renal urate transporters
   SpeakerDalbeth Nicola (New Zealand)SP0168The use of XO inhibitors in CKD – pros and cons
   AbstractBardin Thomas (Viet Nam)OP0357HYPERECHOIC DEPOSITS IN THE RENAL MEDULLA ARE ASSOCIATED WITH SEVERE GOUT AND DECREASED EGFR: A TRANSVERSAL STUDY IN 503 VIETNAMESE PATIENTS.
   AbstractMa Qiuyue (Germany)OP0358WHY DO NOT ALL CHRONIC KIDNEY DISEASE PATIENTS GET GOUT? IMPAIRED NEUTROPHIL CHEMOTAXIS IN HYPERURICEMIA-RELATED CKD.

 
Basic and Translational Science Session - Elicium 1
  
Big Data in pre-clinical research
   ChairPitzalis Costantino (United Kingdom)  
   ChairFrank Bertoncelj Mojca (Slovenia)  
   SpeakerLipsky Peter (United States) Have bioinformatic studies in rheumatic diseases informed us about changes of clinical studies and practice?
   AbstractMartin Paul (United Kingdom)OP0359EXPLORATION OF T-CELL SIGNATURES FOLLOWING TCR STIMULATION USING SINGLE CELL RNA-SEQ TO INFORM TREATMENT RESPONSE STUDIES IN RHEUMATOID ARTHRITIS
   SpeakerColes Mark (United Kingdom) Combining systems modelling with experimentation to identify novel therapeutic targets
   AbstractBabaei Sepideh (Germany)OP0360RNA-SEQUENCING OF 800 HUMAN BLOOD SAMPLES REVEALS SHARED AND UNIQUE EXPRESSION PROFILES ACROSS SEVEN SYSTEMIC AUTOIMMUNE DISEASES
   SpeakerPadyukov Leonid (Sweden)SP0169Integration of Omics data for predicting response to anti TNF

 
Health Professionals Session - Amtrium
  
How do you sleep?
   ChairVriezekolk Joke (Netherlands)  
   ChairBarbosa Lurdes (Portugal)  
   SpeakerAppel Esbensen Bente (Denmark)SP0170Re-evaluate life when broken sleep has a negative effect on inflammatory arthritis
   SpeakerHackett Katie (United Kingdom)SP0171Sleep disturbances in primary Sjögren's syndrome: Evidence from the literature, patient sleep diaries and a qualitative focus group study
   SpeakerMcKenna Sean.G. (Ireland)SP0172What effect does exercise have on sleep in RMD?
   SpeakerJennum Poul Joergen (Denmark) How did you sleep last night?
   AbstractMalmborg Julia S (Sweden)OP0361-HPRSLEEPING PROBLEMS AND ANXIETY IS ASSOCIATED TO CHRONIC MULTISITE MUSCULOSKELETAL PAIN IN SWEDISH HIGH SCHOOL STUDENTS

 
From Bench to Bedside - Emerald
  
Stratifying Connective Tissue Diseases
   ChairIsaacs John D. (United Kingdom)  
   ChairAringer Martin (Germany)  
   SpeakerNg Wan-Fai (United Kingdom)SP0173Stratifying primary Sjögren‘s
   SpeakerRönnblom Lars (Sweden)SP0174The value of type I IFN signature to stratify patients
   SpeakerVencovsky Jiri (Czech Republic)SP0175Heterogeneity of myositis and therapeutic consequences
   AbstractLeonard Dag (Sweden)OP0362NOVEL GENE VARIANTS ASSOCIATED WITH CARDIOVASCULAR DISEASE IN SYSTEMIC LUPUS ERYTHEMATOSUS AND RHEUMATOID ARTHRITIS
   AbstractKnevel Rachel (Netherlands)OP0363OPTIMIZING PRECISION MEDICINE BY USING GENETICS TO ASSIGN DIAGNOSTIC PRIOR PROBABILITIES TO PATIENTS WITH SYNOVITIS - PROOF OF PRINCIPLE.

 
Joint Session PARE / HPR - PARE Room
  
Work and rehabilitation – key priorities for people with RMDs
   ChairStamm Tanja (Austria)  
   ChairMateus Elsa (Portugal)  
   SpeakerBendzuck Gerlinde (Germany)SP0176It works?! Employment support for people with RMDs
   SpeakerMosor Erika (Austria)SP0177Quality of life at the workplace - How early interventions of health professionals can support people with RMDs
   SpeakerCopsey Sarah (Spain)SP0178The contribution of occupational safety and health to working with RMDs
   AbstractKlokkerud Mari (Norway)OP0364-PAREWORK STATUS AND WORK BARRIERS IN PATIENTS RECEIVING BDMARDS AS INFUSIONS IN RHEUMATOLOGY HOSPITAL CLINICS IN NORWAY. A CROSS-SECTIONAL STUDY
   AbstractBezzant Matthew (United Kingdom)OP0365-PAREWORK MATTERS: A UK WIDE SURVEY OF ADULTS WITH RHEUMATOID ARTHRITIS AND JUVENILE IDIOPATHIC ARTHRITIS ON THE IMPACT OF THEIR DISEASE ON WORK

 
The Young Rheumatologist - E106 / E107
  
The challenges of Rheumatology Trainees in the Clinical Learning Environment
   Chairvan Onna Marloes (Netherlands)  
   ChairAlunno Alessia (Italy)  
   SpeakerBoyd Peter (Ireland)SP0179Patient perspective: what could clinicians do better in clinical communication?
   SpeakerGorter Simone (Netherlands)SP0180Communication skills, an essential competency in daily practice
   SpeakerNikiphorou Elena (United Kingdom) The use of social media: weighing the risks and benefits.
   AbstractStebbings Simon (New Zealand)OP0366AMBULATORY RHEUMATOLOGY TEACHING DAY – A 360-DEGREE EVALUATION OF STAKEHOLDER EXPERIENCES.
   AbstractSengewein Ruben (Germany)OP0367USING YOUTUBE TO TEACH THE FUNDAMENTALS OF RHEUMATOLOGY: A TWO-YEAR RETROSPECTIVE ANALYSIS OF FOUR ONLINE LECTURES

Saturday 16.06.2018 13:45 - 14:45


 
Highlight Session - Auditorium / Balcony
  
Clinical Basic Translational Highlight Session
   ChairDörner Thomas (Germany)  
   ChairLandewé Robert B.M. (Netherlands)  
   SpeakerTaams Leonie (United Kingdom) Basic and Translational Highlights
   SpeakerIsaacs John D. (United Kingdom) Clinical Highlights

 
Highlight Session - Amtrium
  
HPR Highlight Session
   ChairPrior Yeliz (United Kingdom)  
   ChairMoe Rikke Helene (Norway)  
   SpeakerEstévez-López Fernando (Spain)SP0181Highlights from the Health Professionals in Rheumatology Sessions
   SpeakerMcInnes Iain (United Kingdom) Highlights from the Scientific Programme
   SpeakerHaugmark Trond (Norway)SP0182Highlights from the PARE Programme

 
Highlight Session - PARE Room
  
PARE Highlight Session
   ChairWiek Dieter (Germany)  
   ChairCaeyers Nele (Belgium)  
   SpeakerNikiphorou Elena (United Kingdom) Highlights from the Scientific Programme
   Speakervan Eijk-Hustings Yvonne (Netherlands) Highlights from the HPR Programme
Logged in as Anonymous